### AD NUMBER

ADB282196

### NEW LIMITATION CHANGE

**TO**

Approved for public release, distribution unlimited

**FROM**

Distribution authorized to U.S. Gov't. agencies only; Proprietary Information; Aug 2001. Other requests shall be referred to US Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, MD 21702

### AUTHORITY

USAMRMC ltr, 21 Feb 2003

---

THIS PAGE IS UNCLASSIFIED
Award Number: DAMD17-99-1-9349

TITLE: Role of Hunk and Punc in Breast Cancer and Mammary Development

PRINCIPAL INVESTIGATOR: Lewis A. Chodosh, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246

REPORT DATE: August 2001

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government agencies only (proprietary information, Aug 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-99-1-9349
Organization: University of Pennsylvania

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure, or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor asserting the restriction is notified of such release, disclosure, or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

Carol C. Christian

6/14/02
Role of Hunk and Pnck in Breast Cancer and Mammary Development

Lewis A. Chodosh, M.D., Ph.D.

University of Pennsylvania
Philadelphia, Pennsylvania 19104-3246
E-mail: chodosh@mail.med.upenn.edu

U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

Report contains color

Distribution authorized to U.S. Government agencies only (proprietary information, Aug 01). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

Major insights into the molecular mechanisms of cancer have been obtained by studies of a family of regulatory molecules known as protein kinases. Many protein kinases serve as relays for signals in the cell that regulate normal growth and cellular function. In addition, several members of this family of molecules have previously been shown to be involved in the development of breast cancer in humans. We have cloned two novel protein kinases, Hunk and Pnck, that are turned on in the breast during specific stages of pregnancy, and that appear to be turned on to different degrees in different subgroups of breast cancer. Our studies have demonstrated that HUNK and PNCK are expressed in subsets of human breast cancers, that HUNK expression is downregulated in a large subset of human primary breast cancers, and that PNCK expression is upregulated in a large subset of human primary breast cancers. Our findings represent the first data implicating either a SNF1-related kinase or a CaM kinase in mammary carcinogenesis.
FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

X For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

[Signature] 11/30/07
PI - Signature Date
## Table of Contents

Cover........................................................................................................ 1

SF 298........................................................................................................ 2

Foreword.................................................................................................... 3

Table of Contents.................................................................................. 4

Introduction............................................................................................ 5

Body........................................................................................................ 5

Key Research Accomplishments.......................................................... 16

Reportable Outcomes.......................................................................... 16

Conclusions............................................................................................ 16

References.............................................................................................. 17

Appendices.............................................................................................. 18


INTRODUCTION

Major insights into the molecular mechanisms of cancer have been obtained by studies of the protein kinase family of regulatory molecules. Many protein kinases serve as relays for signals in the cell that regulate normal growth and cellular function. In addition, several members of this family of molecules have previously been shown to be involved in the development of breast cancer in humans. Indeed, the increased activity of some of these molecules has been shown to correlate with aggressive tumor behavior and poor clinical outcome in women with breast cancer. We have cloned two novel protein kinases, Hunk and Pnck (formerly called Punc), that are turned on in the breast during specific stages of pregnancy, and that appear to be turned on to different degrees in different subgroups of breast cancer. Our observations suggest that these genes may represent valuable biological markers in diagnosing cancer, in predicting the biological behavior of breast cancer, or in understanding the causes of breast cancer in humans. As such, we believe that continued study of these molecules may yield novel insights into those cell types in the breast that are most susceptible to carcinogenesis, and into those pathways in the cell that regulate growth.

BODY

SPECIFIC AIMS

I. Determine the Basis for Differential Hunk and Pnck Expression in neu- and c-Myc-initiated Breast Cancers.

Different oncogenes may give rise to different tumor types either because: (1) distinct cell types exist within the breast that are preferentially susceptible to particular types of initiating events (i.e. neu vs. c-myc); (2) there is one shared target cell type for transformation in the breast that is driven into distinct pathways by the action of different oncogenes.

II. Determine Whether HUNK and PNCK are Amplified, Overexpressed or Mutated in Human Breast Cancers

Protein kinases function as oncogenes in a variety of human cancers. The finding that HUNK and/or PNCK are overexpressed or mutated in human breast cancers would imply that these molecules play an important role in human carcinogenesis. Therefore, we will examine the status of the human HUNK and PNCK genes in a panel of human breast cancer cell lines, and in a series of primary human breast cancers.

TECHNICAL OBJECTIVES

Technical Objective I: Investigate the mechanism for the differential expression of Hunk and Pnck in neu and c-myc-initiated breast cancers.

Task 1: Months 1-12: Generate antisera specific for Hunk and Pnck.

Task 2: Months 1-24: Determine the basis for differential expression of Hunk and Pnck in transgenic mice.

Task 3: Months 1-24: Determine the basis for differential expression of Hunk and Pnck in transgenic breast cancer cell lines.
Technical Objective II: Determine whether \textit{HUNK} and \textit{PNCK} are amplified, overexpressed or mutated in human breast cancers.

\textbf{Task 1:} Months 6-24: Determine whether \textit{HUNK} or \textit{PNCK} are amplified, overexpressed or mutated in human breast cancer cell lines.

\textbf{Task 2:} Months 6-24: Determine whether \textit{HUNK} or \textit{PNCK} are amplified, overexpressed or mutated in primary human breast cancers.

Please note that the results from this study are described in detail in the five accompanying manuscripts that have been supported by this grant. These manuscripts are:


Please refer to these manuscripts for details not included in the present report.

Technical Objective I: Investigate the mechanism for the differential expression of \textit{Hunk} and \textit{Pnck} in \textit{neu} and \textit{c-myc}-initiated breast cancers.

\textbf{Task 1:} Months 1-12: Generate antiseral specific for \textit{Hunk} and \textit{Pnck}.

This task has been completed on schedule. Since understanding the function of \textit{Hunk} and \textit{Pnck} will require the ability to reliably detect the proteins encoded by these genes and the activities associated with them, we generated antiseras specific for mouse \textit{Hunk} and \textit{Pnck}. For each kinase, glutathione-S-transferase (GST) fusion protein constructs were generated that encode three non-overlapping regions of each molecule. Recombinant GST fusion proteins were produced in protease-deficient \textit{E. coli}, purified over glutathione-sepharose columns, and cleaved into separate GST and kinase polypeptide domains. Each purified polypeptide was injected into two rabbits. All injections, prebleeds and bleeds were performed by an off-site vendor (Colcalico, Inc) using standard methods. The specificity of affinity-
purified antisera was assessed by immunoblotting against endogenous as well as exogenously overexpressed Hunk and Pnck from unlabeled whole-cell lysates followed by immunoblotting using

antisera raised against different regions of these molecules. As an example, studies with Hunk are shown. We initially demonstrated that anti-Hunk antibodies would recognize exogenously expressed Hunk either in SMF cells (a mammary epithelial cell line isolated from an MMTV-neu transgenic mouse mammary tumor) or in HC11 mammary epithelial cells that we engineered to inducibly express Hunk when treated with doxycycline (Fig. 1).

Next, we demonstrated that anti-Hunk antibodies raised against distinct regions of the Hunk molecule could identify Hunk that was constitutively overexpressed in the mammary glands of MMTV-Hunk transgenic mice (MHK3). Hunk was immunoprecipitated from mammary gland extracts of either wild-type (Wt) or MHK3 transgenic animals (Tg) using an antibody directed against the carboxyl-terminus of Hunk, and then was detected by western immunoblotting using anti-Hunk antibodies (Fig. 2A). These results revealed detection of Hunk only in the mammary glands of Hunk-overexpressing transgenic animals. Immunoprecipitated Hunk was shown to have kinase activity by incubating anti-Hunk immunoprecipitates with $^{32}$P-ATP and histone as substrate (Fig. 2B). These antibodies were then shown to specifically recognize Hunk in the mammary glands of MHK3 transgenic animals by performing immunohistochemical studies using these anti-Hunk antibodies (Fig. 2C).

To demonstrate that the anti-Hunk antibodies that we raised were able to detect endogenously expressed Hunk, we performed immunoblotting of immunoprecipitates from protein extracts of lung tissue harvested either from wild-type animals, or animals in which we have deleted the Hunk locus by homologous recombination. These studies clearly show Hunk protein of the expected size in wild-type animals but not in animals in which the Hunk locus has been deleted (Fig. 3). Interestingly, heterozygous animals exhibit steady-state levels of Hunk protein expression that are approximately half of that observed in wild-type mice, indicating that there is no dosage-compensation for loss of one Hunk allele.

Finally, to determine whether the developmental pattern of Hunk expression that we previously identified based on RNA expression data correctly predicted protein expression profiles, we performed IP/Westerns on mammary gland lysates to measure Hunk protein expression levels during postnatal mammary development (Fig. 4). These studies clearly demonstrated the specific upregulation of Hunk protein expression during early pregnancy that we previously described at the mRNA level.

In summary, our ability to use multiple antisera to detect the same protein, our ability to demonstrate that the proteins detected by these antisera are upregulated in cells and tissues
overexpressing these kinases, and our ability to demonstrate that the proteins detected by these antisera are absent in tissues harvested from animals in which Hunk has been deleted, provide strong evidence that the antisera that we have generated are able to identify the protein products of the \textit{Hunk} and \textit{Pnck} genes.

\textbf{Task 2: Months 1-24: Determine the basis for differential expression of \textit{Hunk} and \textit{Pnck} in transgenic mice.}

This task has been completed on schedule. The differential expression of \textit{Hunk} and \textit{Pnck} in mammary epithelial cell lines derived from tumors arising in \textit{neu} and \textit{myc} transgenic mice may be a direct result of the differential induction of these kinases by the overexpression of \textit{neu-} or \textit{c-myc} in the non-transformed mammary epithelium. Alternately, this pattern of differential expression could result if the overexpression of \textit{Hunk} (or \textit{Pnck}) in \textit{neu}-induced (or \textit{c-myc}-induced) tumors reflects the selection and outgrowth of a \textit{Hunk}+ (or \textit{Pnck}+) epithelial cell subtype that otherwise represents a minor fraction of cells in the mammary epithelium. In this case, differential patterns of \textit{Hunk} and \textit{Pnck} expression would only expect to be seen in mammary tumors and not in intact mammary glands. To distinguish...
between these possibilities, nontransformed mammary gland tissue was harvested from MMTV-neu and MMTV-c-myc transgenic mice prior to the appearance of tumors and RNA was prepared from snap-frozen mammary glands. Mammary gland whole mounts and representative H&E sections were also analyzed to confirm the absence of tumors. Hunk and Pnck mRNA expression levels were determined by RNase protection in nontransformed neu and c-myc transgenic breast tissue, as well as in breast tissue from nontransgenic littermates. In addition, breast tissue was also harvested from virgin animals and from animals during early and late stages of pregnancy (when c-myc and neu transgene expression is highest) and was also assayed for Hunk and Pnck expression.

This analysis revealed that Hunk and Pnck mRNA expression levels in MMTV-neu and MMTV-c-myc transgenic animals are indistinguishable from those of wild-type animals during virgin development and during pregnancy and lactation. This finding suggests either: 1) that Hunk and Pnck expression are not induced either directly or indirectly by neu or c-myc expression in the mammary gland; 2) that MMTV-driven transgene expression of neu and c-myc in the non-tumorigenic mammary gland does not occur in cells that are capable of expressing Hunk or Pnck; or 3) that neu and c-myc are able to induce Hunk and/or Pnck expression in tumorigenic cells, but not in non-transformed cells.

To distinguish between these possibilities, we harvested mammary tumors arising in MMTV-neu and MMTV-c-myc transgenic animals. RNA was subsequently prepared from snap-frozen tumors and Hunk and Pnck mRNA expression levels were determined by RNase protection analysis. Surprisingly, these studies demonstrated that, unlike the cell lines derived from MMTV-neu and MMTV-c-myc mammary tumors, the tumors themselves did not exhibit differences in the steady-state expression levels of either Hunk or Pnck. This suggested that the differential pattern of kinase expression that was
observed in the transgenic mammary epithelial cell lines obtained from Dr. Philip Leder's laboratory is not a reflection of differential kinase expression in the tumors from which they were derived. Alternately, we hypothesized that the differential pattern of Hunk and Pnck expression might only be manifest under in vitro culture conditions.

To test this possibility, we generated 10 mammary epithelial cell lines from MMTV-neu-induced mammary tumors and 10 mammary epithelial cell lines from MMTV-c-myc-induced mammary tumors. These cell lines were grown in culture and RNA was harvested from cell pellets and assayed for steady-state levels of Hunk and Pnck mRNA expression. Surprisingly, similar to the primary tumors from which they were derived, the neu and myc-induced mammary tumor cell lines that we generated also did not display differential expression of either Hunk or Pnck. Our results suggest that the differential pattern of Hunk and Pnck expression that we repeatedly observe in the neu and myc-induced mammary tumor cell lines obtained from the Leder laboratory is more likely to be due to differences in the manner in which the neu and myc cell lines were generated, than to intrinsic differences in Hunk or Pnck expression in cell lines derived from neu and myc-induced tumors or in the mammary tumors themselves. As such, we favor the possibility that different culture conditions were employed to isolate the neu-induced tumor cell lines than were used to isolate the myc-induced tumor cell lines. Unfortunately, since these cell lines were generated more than 12 years ago, it is impossible to formally prove this hypothesis.

**Task 3: Months 1-24:** Determine the basis for differential expression of Hunk and Pnck in transgenic breast cancer cell lines.

The model that a single target cell for transformation can be driven down different pathways by neu or c-myc to yield tumors with different phenotypes predicts that genes that are preferentially expressed in neu-initiated tumors (i.e. Hunk) are either up-regulated by the neu signal transduction pathway or are down-regulated by the c-myc transduction pathway. Conversely, the model that Hunk-positive and Pnck-negative cell lines are preferentially transformed by neu, whereas Hunk-negative and Pnck-positive cell lines are preferentially transformed by myc, predicts that cell lines derived from neu-induced tumors and from myc-induced tumors represent different cell types. Our findings above
strongly argued against the first model, since we did not observe differential expression in neu and myc-induced tumors or cell lines. In fact, our observations above also argued against the second model. As such, we concluded that the experimental approach that was originally proposed in this task was no longer valid. Instead, we reasoned that differences in Hunk and Pnck gene expression patterns among the neu and myc transgenic breast cancer cell lines originally isolated in the Leder laboratory might reflect the outgrowth of different epithelial cell types under different culture conditions. Accordingly, we hypothesized that we might be able to detect such differences in cell types by comparing global gene expression profiles in these original Hunk-positive/Pnck-negative and Hunk-negative/Pnck-positive cell lines.

Standard Affymetrix protocols were used to generate and hybridize probes prepared from RNA samples from each of 9 Hunk-positive/Pnck-negative and 9 Hunk-negative/Pnck-positive cell lines. RNA isolated from these cell lines was subject to reverse transcription to make first strand cDNA that incorporated a T7 RNA polymerase promoter at the 3' end. Following completion of the second strand of cDNA, this material was used in an in vitro transcription reaction to generate biotin-labeled cRNA representing each experimental pool of mammary gland RNA. This in vitro transcribed cRNA was then fragmented to facilitate hybridization. Hybridization reactions were prepared for each sample using fragmented cRNA in addition to standardized internal controls. Hybridization reactions representing each of the 18 cell line samples were hybridized to murine U74A oligonucleotide microarrays, representing approximately 12,000 murine genes.

Using GeneChip software, expression levels were calculated for each of the 12,000 genes represented on the U74A chips for all 18 samples. This information was imported into a software database. Confidence intervals were generated for each gene in order to identify genes that were differentially expressed between Hunk-positive/Pnck-negative and Hunk-negative/Pnck-positive cell lines. Our results reveal the differential expression of approximately 600 genes between these two groups of cell lines. In-depth analysis of these data sets are currently underway.

**Technical Objective II:** Determine whether *HUNK* and *PNCK* are amplified, overexpressed or mutated in human breast cancers.

**Task 1:** Months 6-24: Determine whether *HUNK* or *PNCK* are amplified, overexpressed or mutated in human breast cancer cell lines.

This task has been completed on schedule. Protein kinases function as oncogenes in a variety of human cancers. The finding that *HUNK* and/or *PNCK* are overexpressed or mutated in human breast cell lines supports the hypothesis that these genes may play a role in breast cancer development.
cancers would imply that these molecules play an important role in human carcinogenesis. Therefore, we examined the status of the human HUNK and PNCK genes in a panel of human breast cancer cell lines as well as cell lines representing other common types of human cancers. Genomic DNA and total cellular RNA were prepared from human cancer cell lines obtained from ATCC and other commercial sources and were grown and harvested under similar conditions. To detect DNA amplifications and rearrangements, Southern blots containing genomic DNA harvested from each of these cell lines were probed with full-length human HUNK and PNCK cDNAs. Blots were subsequently reprobed with a cDNA for GAPDH as a control for equal DNA loading. These studies did not reveal any evidence for amplification of HUNK or PNCK in human cancer cell lines.

To detect alterations in HUNK and PNCK expression at the mRNA level, RNase protection analysis was performed from total RNA samples prepared from each of these cell lines. These studies revealed that HUNK and PNCK expression are highly heterogeneous in human cancer cell lines representing a variety of different types of cancer (Figs. 5-7). That is, within any one tumor type, cell lines can be found that express high levels of HUNK or PNCK, whereas the expression level of these kinases in other cell lines was low or undetectable. For example, analogous to results observed in murine cell lines, HUNK expression levels varied widely among human breast tumor cell lines as well as among cell lines derived from other types of cancers (Fig. 5). In particular, the range of HUNK expression observed in human breast tumor cell lines was comparable to that observed murine mammary tumor cell lines. Cell lines expressing HUNK at high levels, as well as cell lines with undetectable HUNK expression levels, were observed for all tumor types examined. For example, 3 of 4 colon tumor cell lines examined do not express detectable levels of HUNK, whereas one of these cell lines expresses HUNK at high levels. Similar results were observed for cell lines derived from tumors of the central nervous system, breast, lung, ovary, prostate, and kidney (Fig. 5 and data not shown). In contrast to results obtained in the murine mammary tumor cell lines, HUNK expression in human breast tumor cell lines does not appear to correlate with HER2/NEU expression (data not shown).

To further investigate the potential involvement of Pnck, or a cell type in which Pnck is expressed, in mammary carcinogenesis, we determined PNCK expression levels in a panel of human breast cancer cell lines (Fig. 6). Similar to the wide range of Pnck expression observed in the murine mammary epithelium and in murine mammary tumor cell lines, PNCK expression was detected in only a subset of human breast tumor cell lines. High levels of PNCK expression were observed in only 3 of 18 breast tumor cell lines. Eight cell lines expressed low, but detectable levels of PNCK, whereas no PNCK

![Figure 6: PNCK expression in human breast cancer cell lines](image)
expression was detected in the remaining 7 cell lines. PNCK expression levels did not correlate with c-MYC expression (data not shown). To begin to examine the potential role of PNCK in other types of human cancers, we determined the pattern of PNCK expression in a panel of human tumor cell lines from multiple tissues of origin (Fig. 7). Similar to results observed in breast tumor cell lines, PNCK expression was heterogeneous among cell lines from every tumor type examined. Most striking was the observation that PNCK is expressed in 3 of the 4 small cell lung carcinoma cell lines, but is detected in only one of ten other lung cancer cell lines. This finding suggests that PNCK expression in lung cancers may be specific to small cell lung carcinomas. In the CNS, leukemia, kidney, prostate, ovary and cervical human tumor cell lines surveyed, relatively high levels of PNCK expression were observed in a subset of samples for each tumor type. These data suggest that heterogeneous PNCK expression is not limited to breast tumor cell lines, but rather is common to a variety of human cancers.

**Figure 7: PNCK expression in human cancer cell lines**

lines. This finding suggests that PNCK expression in lung cancers may be specific to small cell lung carcinomas. In the CNS, leukemia, kidney, prostate, ovary and cervical human tumor cell lines surveyed, relatively high levels of PNCK expression were observed in a subset of samples for each tumor type. These data suggest that heterogeneous PNCK expression is not limited to breast tumor cell lines, but rather is common to a variety of human cancers.

**Task 2: Months 6-24:** Determine whether HUNK or PNCK are amplified, overexpressed or mutated in primary human breast cancers.

This task has been completed on schedule. The high degree of heterogeneity in HUNK expression levels among murine and human tumor cell lines within a given tumor type was intriguing since it suggested the possibility that distinct subtypes of tumors exist that can be distinguished on the basis of high versus low levels of HUNK expression. However, the heterogeneity in HUNK expression levels observed among these cell lines could also reflect heterogeneous expression within the primary tumors from which these cell lines were derived, or could be a consequence of changes that occurred during the establishment or maintenance of these cell lines in culture. To begin to investigate the basis of the
heterogeneity in \textit{HUNK} expression observed among tumor cell lines, \textit{HUNK} expression was examined in eight different types of primary human tumors and in benign tissues corresponding to a subset of these different tissue types. Consistent with the highly heterogeneous levels of \textit{HUNK} expression observed in tumor cell lines, \textit{HUNK} exhibited a wide dynamic range of expression among tumors in each of the tissue-types examined (Fig. 8 A-D). In contrast, \textit{HUNK} expression levels in normal tissue samples were relatively similar within a given tissue. These data suggest that the highly heterogeneous levels of \textit{HUNK} expression observed in tumor cell lines may reflect the existence of \textit{HUNK}-expressing and \textit{HUNK}-non-expressing tumors rather than an artifact of cell culture. In particular, \textit{HUNK} expression in a large subset of human primary breast cancers was actually lower than that observed in normal breast tissue (Fig. 8A and data not shown). This is particularly evident when normalizing to cytokeratin 18 expression, since \textit{HUNK} expression is restricted to the mammary epithelium (data not shown). We have confirmed this findings by quantitative real-time PCR of approximately 20 primary human breast cancers.

Similar to \textit{HUNK}, the heterogeneous pattern of \textit{PNCK} expression observed \textit{in vitro} in both murine and human breast tumor cell lines suggested the possibility that \textit{PNCK}-expressing and \textit{PNCK} non-expressing breast tumor types might exist. In order to test this hypothesis directly we used RNase protection analysis to quantitate \textit{PNCK mRNA} expression levels in a panel of 23 primary human breast tumors. The resulting expression levels were compared to \textit{PNCK} expression levels in 12 benign breast tissue samples (Fig. 9A). This analysis revealed two interesting aspects of the pattern of \textit{PNCK} expression in breast tumors compared to benign tissue: first, \textit{PNCK} is expressed at significantly higher levels in breast tumors compared to benign tissue; and second, \textit{PNCK} expression in human tumors is markedly heterogeneous.

Statistical analysis of the above \textit{PNCK} expression levels indicated that when normalized to \textit{\beta-actin} expression \textit{PNCK} expression in human primary breast cancers is approximately 5-fold higher than in benign breast tissue (student's t-test, \textit{p}=0.01; Fig. 9B). However, since \textit{PNCK} expression in the mammary gland is epithelial specific, and since tumors typically have a higher epithelial content than benign breast tissue, we also normalized \textit{PNCK} expression to the expression of the epithelial-specific
Strikingly, even after normalization to CK18 expression, PNCK expression levels were found to be 3 times higher in human primary breast tumors than in benign tissue (t-test, p=0.039).

Formally, the increase in PNCK expression levels in breast tumors compared to benign tissue could result either from increased expression among all tumors or from increased expression in a subset of tumors. In this regard, analysis of the distribution of PNCK expression among the 23 ductal carcinomas
studied revealed a wide range of PNCK expression levels, in contrast to the relatively similar levels of PNCK expression observed among benign breast tissue samples, despite the fact the mode for the benign and tumor distributions was the same (Fig. 9A and 9C). Indeed, examination of the histogram representing CK18-normalized PNCK expression levels revealed that 8 of the 23 primary breast tumors analyzed express PNCK at levels greater than 3 standard deviations above the mean observed for benign samples (Fig. 6C). This difference is highly significant since no tumors would have been predicted to express PNCK at these levels if the distribution of PNCK expression in tumors was similar to that observed in benign tissues. Even more strikingly, four breast tumors were found to express PNCK at levels greater than 10 standard deviations above the mean observed for benign tissues. Together, these data indicate that PNCK is overexpressed in human primary breast cancers compared to benign tissue, and that this observed increase is due to high levels of PNCK expression in a subset of breast tumors.

KEY RESEARCH ACCOMPLISHMENTS

• Identification of Hunk and Pnck proteins in murine tissues and verification of developmental patterns of expression in the mammary gland.

• Demonstration that HUNK expression is restricted to a subset of human breast tumor cell lines.

• Demonstration that HUNK expression is downregulated in a subset human primary breast cancers compared to benign breast tissue.

• Demonstration that PNCK expression is restricted to a subset of human breast tumor cell lines.

• Demonstration that PNCK is overexpressed in human primary breast cancers compared to benign breast tissue and that this overexpression is restricted to a subset of human breast tumors.

REPORTABLE OUTCOMES

Publication of 5 manuscripts supported by this grant:


Publication of 2 abstracts supported by this grant:


Personnel supported by this grant:

George Belka
Katherine Dugan
Judith Farrell
Heather Gardner
Jennifer Hartman
Elizabeth Keiper
Blaine Keister
Barbara Shields
Douglas Stairs
Frank Wilson

**CONCLUSIONS**

Our initial observations of the oncogene-associated pattern of *Hunk* expression in murine mammary tumor cell lines along with the observation that *Hunk* expression affects mammary epithelial cell proliferation in vivo, suggested that *Hunk* may play a role in mammary carcinogenesis. We originally noted that in murine mammary tumor cell lines, *Hunk* is expressed in an oncogene-associated manner with high levels of expression observed in cell lines derived from MMTV-neu and MMTV-H-ras transgenic mice, but not in MMTV-c-myc or MMTV-int-2/Fgf3 transgenic mice. To further investigate the role of Hunk in carcinogenesis, we examined the expression of human *HUNK* in human tumor cell lines and primary tumors from a variety of tissues including the breast. Similar to results observed in murine cell lines, *HUNK* expression levels varied widely among the human tumor cell lines and primary tumors examined in this study. In particular, our data further demonstrated that *HUNK* expression is downregulated in a subset of human primary breast cancers. Together with our previous findings that Hunk overexpression in the mammary gland inhibits epithelial proliferation, these data suggest a potential role for *HUNK* in human breast cancer.
Analogous to *HUNK*, expression of the human homologue of *Pnck* was found to be restricted to a subset of human breast tumor cell lines. Moreover, we have demonstrated that *PNCK* is overexpressed in human primary breast cancers compared to benign breast tissue and that this overexpression is restricted to a subset of human breast tumors. In aggregate, our findings are consistent with the hypothesis that *PNCK* expression is restricted to a subset of ductal carcinomas in humans, and suggest a role for *PNCK* or a cell type that expresses *PNCK* in mammary carcinogenesis. Our findings represent the first data implicating either a SNF1-related kinase or a CaM kinase in mammary carcinogenesis.
Protein Kinase Expression during Murine Mammary Development

Lewis A. Chodosh,*†,1,2 Heather Perry Gardner,*,† Jayant V. Rajan,* Douglas B. Stairs,*, Sandra T. Marquis,* and Philip A. Leder†
*Department of Molecular & Cellular Engineering and †Division of Endocrinology, Diabetes and Metabolism, University of Pennsylvania School of Medicine, 612 Biomedical Research Building II/III, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104-6160; and †Department of Genetics, Howard Hughes Medical Institute, Harvard Medical School, Boston, Massachusetts 02115

The susceptibility of the mammary gland to carcinogenesis is influenced by its normal development, particularly during developmental stages such as puberty and pregnancy that are characterized by marked changes in proliferation and differentiation. Protein kinases are important regulators of proliferation and differentiation, as well as of neoplastic transformation, in a wide array of tissues, including the breast. Using a RT-PCR-based cloning strategy, we have identified 41 protein kinases that are expressed in breast cancer cell lines and in the murine mammary gland during development. The expression of each of these kinases was analyzed throughout postnatal mammary gland development as well as in a panel of mammary epithelial cell lines derived from distinct transgenic models of breast cancer. Although the majority of protein kinases isolated in this screen have no currently recognized role in mammary development, most kinases examined were found to exhibit developmental regulation. After kinases were clustered on the basis of similarities in their temporal expression profiles during mammary development, multiple distinct patterns of expression were observed. Analysis of these patterns revealed an ordered set of expression profiles in which successive waves of kinase expression occur during development. Interestingly, several protein kinases whose expression has previously been reported to be restricted to tissues other than the mammary gland were isolated in this screen and found to be expressed in the mammary gland. In aggregate, these findings suggest that the array of kinases participating in the regulation of normal mammary development is considerably broader than currently appreciated. © 2000 Academic Press

Keywords: mammary gland; protein kinase; development; cell differentiation; carcinogenesis.

INTRODUCTION

Numerous epidemiologic and animal studies analyzing the impact of reproductive events such as puberty, pregnancy, and parity on early events in carcinogenesis suggest that the developmental state of the breast plays a critical role in the determination of breast cancer risk (Lambe et al., 1994; MacMahon et al., 1970, 1982; Newcomb et al., 1994; Russo and Russo, 1978, 1987). This implies an intrinsic relationship between the process of carcinogenesis and normal pathways of differentiation and development in the breast. Therefore, understanding the mechanisms by which reproductive events influence breast cancer susceptibility will undoubtedly require an improved understanding of normal mammary development, particularly with respect to genes that control mammary proliferation and differentiation.

Protein kinases represent the largest class of genes known to regulate differentiation, development, and carcinogenesis in eukaryotes. Therefore, we have chosen to study members of this family of regulatory proteins as one approach to elucidating the relationship between development and carcinogenesis in the breast. Several protein kinases have been implicated in the development of breast cancer either in humans or in rodent model systems. For instance, the EGF receptor and ErbB2/HER2 are each amplified and overexpressed in subsets of highly aggressive breast cancers, and these molecules may thereby provide prognostic information relevant to clinical treatment and outcome (Klijn et al., 1993; Slamon et al., 1987, 1989). Furthermore, overexpression of specific protein kinases, or
of ligands for protein kinases, in the mammary epithelium of transgenic animals results in neoplastic transformation (Cardiff and Muller, 1993; Guy et al., 1994; Muller et al., 1988, 1990). Finally, by analogy with hematopoiesis, some protein kinases are likely to be expressed in a lineage-restricted manner in the breast and as such may provide insight into biologically meaningful subpopulations of cells (Dymecki et al., 1990; Siliciano et al., 1992; Tsukada et al., 1993). These findings suggest that further analysis of protein kinase function may reveal significant features of the relationship between development and carcinogenesis in the breast, as well as provide insight into how the decision to proliferate or differentiate is made in mammary epithelial cells.

In light of the importance of this class of regulatory molecules, we initiated a systematic study of the role of protein kinases in mammary gland development and carcinogenesis. Examination of 1450 cDNA clones generated using a RT-PCR-based screening strategy identified 41 protein kinases, including 33 tyrosine kinases and 8 serine/threonine kinases, 3 of which were novel. The expression of these kinases was subsequently examined during defined stages in mammary development and in a panel of mammary tumor cell lines derived from distinct transgenic models of breast cancer. Our findings reveal an ordered series of protein kinase expression patterns that occur during each of the stages of postnatal mammary development, suggesting that these molecules may be important regulators of this process.

MATERIALS AND METHODS

Cell Culture

Mammary epithelial cell lines were derived from mammary tumors or hyperplastic lesions that arose in MMTV-c-myc, MMTV-int-2, MMTV-neu/NT, or MMTV-Ha-ras transgenic mice and included: the neu transgene-initiated mammary tumor-derived cell lines SMF, NAF, NF639, NF11005, and NK-2; the c-myc transgene-initiated mammary tumor-derived cell lines 16MB9a, 8Mala, MBp6, M158, and M1011; the Ha-ras transgene-initiated mammary tumor-derived cell lines AC816, AC236, and AC711; the int-2 transgene-initiated hyperplastic cell line HB12; and the int-2 transgene-initiated mammary tumor-derived cell line 1128 [Morrison and Leder, 1994]. Additional cell lines were obtained from ATCC and included NIH/3T3 cells and the nontransformed murine mammary epithelial cell lines NMuMG and CL-S1. All cells were cultured under identical conditions in DMEM medium supplemented with 10% bovine calf serum, 2 mM l-glutamine, 100 units/ml penicillin, and 100 mg/ml streptomycin.

Animals and Tissues

FVB mice were housed under barrier conditions with a 12-h light/dark cycle. The mammary glands from between 10 and 40 8-week-old nulliparous female mice were parous mice that had undergone a single pregnancy followed by 21 days of lactation and 2 days of postlactational regression. Total RNA was also prepared from the mammary epithelial cell lines NMuMG, CL-S1, HB12, SMF, 16MB9a, AC816, and 1128, described above.

First-strand cDNA was generated from each of these nine sources of RNA using the cDNA Cycle kit according to the manufacturer's directions (Invitrogen). These were amplified using degenerate oligonucleotide primers corresponding to conserved regions in kinase catalytic subdomains VI and IX. The degenerate primers, PTKIa (5'-GGGCCCGGATCCCA(A/C)G/A(C/T)TGAGA(T)CTCA(G/C)-3') and PTKIIa (5'-CCCGGGGAAATTCCTA(A/T)AGGACCA(A/G)/(A/G/C)G/A(TC)-3'), have previously been shown to amplify a conserved 200-bp portion of the catalytic domain of a wide variety of tyrosine kinases (Wilks, 1989, 1991; Wilks et al., 1989). Two additional degenerate oligonucleotide primers, BSTKIIa (5'-GGGCCCGGATCCCA(A/C)G/A(C/T)TGAGA(T)CTCA(G/C)-3') and BSTKIIa (5'-CCCGGGGAAATTCCTA(A/T)AGGACCA(A/G)/(A/G/C)G/A(TC)-3'), that differed from PTKIa and PTKIIa were also designed for this study. Restriction sites, underlined in the primer sequences, were generated at the 5' [Apol and BamHII] and 3' [Xmal and EcoRI] ends of the primer sequences.

Each cDNA source was amplified in three separate PCR reactions using pairwise combinations of the PTKIa/PTKIIa, BSTKIIa/BSTKIIa, or BSTKIIa/PTKIIa degenerate primers. Following 5-min denaturation at 95°C, samples were annealed at 37°C for 1 min, polymerized at 63°C for 2 min, and denatured at 95°C for 30 s for 40 cycles. The resulting ~200-bp PCR products were purified from a low-melting agarose [BBM], ligated into a T-vector (Invitrogen), and transformed in Escherichia coli. Following blue/white color selection, approximately 50 transformants were picked from each of the 27 PCR reactions (3 reactions for each of nine cDNA sources) and were subsequently transferred to gridded plates and replica plated. In total, 1450 transformants were analyzed.

Didoxcy sequencing of 100 independent transformants was performed, resulting in the identification of 14 previously described tyrosine kinases. In order to identify and eliminate additional isolates of these kinases from further consideration, filter lifts representing the 1350 remaining transformants were hybridized individually to radiolabeled DNA probes prepared from each of the 14 initially isolated kinases. Hybridization and washing were performed as described under final washing conditions of 0.1× SSC/0.1% SDS at 70°C that were demonstrated to prevent cross-hybridization between kinase cDNA inserts (Marquis et al., 1995). In this manner, 887 transformants containing inserts from the 14 tyrosine kinases that had initially been isolated were identified.
Identification of Protein Kinases Expressed in the Murine Mammary Gland

As an initial step in studying the role of protein kinases in regulating mammary proliferation and differentiation, we designed a screen to identify protein kinases expressed in the mammary gland and in breast cancer cell lines. The RT-PCR cloning strategy was employed that relies on the use of degenerate oligonucleotide primers corresponding to conserved amino acid motifs present within the catalytic subdomains VIb and IX (Hanks and Quinn, 1991; Wilks, 1991; Wilks et al., 1989). In an effort to isolate a broad array of protein kinases, two additional degenerate oligonucleotide primers, BSTKI and BSTKII, which are also directed against subdomains VIb and IX, but which differ in nucleotide sequence, were designed for use in this screen. Degenerate oligonucleotide primers were used in three pairwise combinations [PTKI/PTKII, BSTKI/BSTKII, and BSTKII/PTKII] to amplify first-strand cDNA from each of the nine sources. The resulting 150- to 300-bp PCR products from each amplification were subcloned into a plasmid vector. Approximately 50 bacterial transformants from each of the 27 PCR reactions were replica plated and screened by a combination of DNA sequencing and colony lift hybridization in order to identify the protein kinase from which each subcloned catalytic domain fragment was derived. A total of 1450 bacterial transformants were analyzed by this approach. Of these, greater than 70% contained protein kinase cDNA inserts as determined by hybridization and sequencing. Analysis of these clones resulted in the identification of 33 tyrosine kinases and 8 serine/threonine kinases (Table 1). The 19 receptor tyrosine kinases and 14 cytoplasmic tyrosine kinases isolated accounted for all but 33 of the 1056 kinase-containing clones. The remaining clones were derived from 8 serine/threonine kinases, 7 of which were represented by a single clone each, including each of the novel kinases isolated in this screen. Approximately half of the 41 kinases were isolated more than once, and most of these were isolated from more than one tissue or cell line (Table 1 and data not shown). Eight tyrosine kinases, including Jak2, Fgfr1, EphA2, Met, Igf1r, Hck, Jak1, and Neu, accounted for 830 (79%) of all clones analyzed (Table 1). Conversely, 18 kinases (44%) were represented by a single clone each, suggesting that further screening of cDNA libraries derived from these tissues and cell lines may yield additional kinases. The number of clones isolated for each kinase presumably reflects a combination of mRNA abundance and extent of homology to the oligonucleotide primers used in the amplification reaction.

Three novel protein kinases were identified in this
TABLE 1
Protein Kinases Isolated from Mammary Glands and Mammary Epithelial Cell Lines

<table>
<thead>
<tr>
<th>Receptor tyrosine kinases</th>
<th>Nonreceptor tyrosine kinases</th>
<th>Serine/threonine kinases</th>
</tr>
</thead>
<tbody>
<tr>
<td>Axil/Ufo</td>
<td>6</td>
<td>c-Abl 5</td>
</tr>
<tr>
<td>EphA2</td>
<td>121</td>
<td>Csk 46</td>
</tr>
<tr>
<td>EphA7</td>
<td>1</td>
<td>Ctk 1</td>
</tr>
<tr>
<td>EphB3</td>
<td>2</td>
<td>c-Fes 24</td>
</tr>
<tr>
<td>Egfr</td>
<td>1</td>
<td>Fyn 7</td>
</tr>
<tr>
<td>Fgf1</td>
<td>126</td>
<td>Hck 88</td>
</tr>
<tr>
<td>Fh3</td>
<td>1</td>
<td>Jak1 150</td>
</tr>
<tr>
<td>Igf1t</td>
<td>89</td>
<td>Jak2 150</td>
</tr>
<tr>
<td>InsR</td>
<td>1</td>
<td>Lyn 21</td>
</tr>
<tr>
<td>c-Kit</td>
<td>2</td>
<td>PrkMk3 3</td>
</tr>
<tr>
<td>Met</td>
<td>120</td>
<td>c-Src 23</td>
</tr>
<tr>
<td>MUSK</td>
<td>1</td>
<td>Srm 1</td>
</tr>
<tr>
<td>Neu</td>
<td>62</td>
<td>Tec 1</td>
</tr>
<tr>
<td>Ron</td>
<td>10</td>
<td>Tyk2 4</td>
</tr>
<tr>
<td>Ryk</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Tie1</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Tie2</td>
<td>27</td>
<td></td>
</tr>
<tr>
<td>Tyro10</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Tyro3</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Note. Kinases are arranged by family and class. The number of clones isolated for each kinase is shown on the right.

Expression of Protein Kinases in Mammary Epithelial Cell Lines

As a first step in investigating the range of expression patterns for the 41 protein kinases isolated in this screen, we determined kinase expression profiles in a panel of 18 murine mammary epithelial cell lines [Fig. 2]. These included 14 cell lines derived from independent tumors arising in transgenic mice expressing either the neu, c-myc, H-ras, or int-2 oncogenes under the control of the MMTV LTR, 1 cell line derived from the hyperplastic mammary epithelium of an MMTV-int-2 transgenic mouse, and 3 nontransformed, nontransgenic mammary epithelial cell lines [Fig. 2] [Leder et al., 1986; Morrison and Leder, 1994; Muller et al., 1988, 1990, Sinn et al., 1987]. Kinase expression was also investigated in NIH3T3 fibroblasts in order to identify those kinases that might be expressed in a mesenchymal- or epithelial-specific manner. All cell lines were grown under identical conditions and were harvested while actively proliferating.

Of the 41 kinases isolated in this screen, 25 were found to be ubiquitously expressed in the epithelial cell lines examined [Fig. 2 and data not shown]. Steady-state mRNA levels for 11 of these ubiquitously expressed kinases exhibited relatively little variation among cell lines. These include Tyk2, Neu, Ryk, Plk, Csk, Akt1, A-Raf, PrkMk3, and the insulin receptor. Steady-state mRNA levels for the remaining 14 ubiquitously expressed kinases varied considerably among cell lines. These include the receptor tyrosine kinases Egfr, Igf1R, Met, Tyro3, EphA2, EphA7/Hek1/Ehk3, and EphB3/Hek2, as well as the cytoplasmic tyrosine kinases jak1, jak2, c-Abl, c-Src, Lyn, and Tec and the serine/threonine kinase SLK [Fig. 2 and data not shown].

In contrast, mRNA expression of 11 of the kinases examined was detectable in only a subset of epithelial cell lines. These kinases range from those that are expressed within the majority of cell lines tested, such as Fgf1R, Fyn, Axil, and Mlk1, to kinases that are expressed in only a small number of these cell lines, such as Tyro10, c-Fes, c-Kit, and Fh3 [Fig. 2 and data not shown]. Within this latter group of kinases, Ron, Srm, and Hck are expressed at detectable

---

FIG. 1. Amino acid sequence of catalytic subdomains of novel protein kinases. Aligned amino acid sequences for isolated cDNA fragments corresponding to catalytic subdomains Vi-VI of Bstki, Bstk2, and Bstk3.

Copyright © 2000 by Academic Press. All rights of reproduction in any form reserved.
levels in only a single mammary epithelial cell line each (Fig. 2 and data not shown). Interestingly, both EphB3 and c-Kit are preferentially expressed in tumor cell lines derived from MMTV-neu and MMTV-Ha-ras transgenic animals compared to cell lines derived from MMTV-c-myc and MMTV-int-2 transgenic animals. Oncogene-associated patterns of expression have also been observed for Bstk3 and Bstk3 (Gardner et al., unpublished results). Similar patterns of expression in this panel of cell lines have previously been reported for protein tyrosine phosphatase e and other molecules (Elson and Leder, 1995; Morrison and Leder, 1994).

Additional patterns of expression that presumably reflect cell-type specificity were observed. For instance, Mlk1 is expressed in all cell lines except for NIH3T3 fibroblasts and

Copyright © 2000 by Academic Press. All rights of reproduction in any form reserved.
for MBp6, the sole mammary cell line that does not express the epithelial marker cytokeratin 18. The resulting inference that Mlik expression is epithelial-specific was subsequently confirmed by in situ hybridization (Fig. 8). By comparison with Mlik, Tyro10 exhibited an inverse pattern of expression with steady-state levels of mRNA detectable only in NIH3T3, MBp6, and the int-2-initiated tumor cell line, 1128, suggesting that this kinase is preferentially expressed in stromal compared to epithelial cells. This hypothesis was also confirmed by in situ hybridization (Figs. 10E–10H). Similarly, expression in mammary epithelial cell lines was detected neither for Tie1 nor Tie2, each of which has been shown to be expressed in an endothelial-specific manner, nor for Msk, whose expression is restricted to muscle (Ganju et al., 1995; Partanen et al., 1992; Sato et al., 1993; Valenzuela et al., 1995b).

Surprisingly, expression of the receptor tyrosine kinases EphB3/Hek2 and EphA7/Hek11/Ehk3 was demonstrated in all of the mammary epithelial cell lines examined, despite the fact that expression of these kinases has been reported to be restricted primarily to the central nervous system (Aasheim et al., 1997; Adams et al., 1999; Bergemann et al., 1998; Fox et al., 1995; Krull et al., 1997; Valenzuela et al., 1995a). Similarly, despite previous reports that expression of each of the nonreceptor tyrosine kinases Lyn, Tec, and Hck is restricted primarily to cells of hematopoietic origin, Lyn and Tec expression was detected in all 18 mammary epithelial cell lines tested, and Hck expression was detected in 2 mammary tumor cell lines [Fig. 2 and data not shown] (Kluppel et al., 1997; Quintrell et al., 1987; Sato et al., 1994; Umemori et al., 1992; Yi et al., 1991; Ziegler et al., 1987]. Interestingly, Lyn has been shown to specifically bind and phosphorylate Tec in hematopoietic cells in vivo, suggesting that Tec is a downstream effector of Lyn (Mano et al., 1994, 1996). Our finding that Lyn and Tec are also coexpressed in mammary epithelial cells suggests that this signaling pathway may function in mammary epithelial cells as well as in cells of hematopoietic origin.

**Expression of Protein Kinases during Postnatal Mammary Development**

Since the expression of regulatory molecules is frequently controlled at the level of transcription, we analyzed the temporal pattern of expression during postnatal mammary development for each of the protein kinases isolated in this screen. Kinase expression was determined in mammary epithelial cells lines tested, and Hck expression was detected in 2 mammary tumor cell lines [Fig. 2 and data not shown] (Kluppel et al., 1997; Quintrell et al., 1987; Sato et al., 1994; Umemori et al., 1992; Yi et al., 1991; Ziegler et al., 1987]. Interestingly, Lyn has been shown to specifically bind and phosphorylate Tec in hematopoietic cells in vivo, suggesting that Tec is a downstream effector of Lyn (Mano et al., 1994, 1996). Our finding that Lyn and Tec are also coexpressed in mammary epithelial cells suggests that this signaling pathway may function in mammary epithelial cells as well as in cells of hematopoietic origin.

![FIG. 3. Expression of control genes during mammary gland development. Northern hybridization analysis of mRNA expression is shown for cytokeratin 18, Gapdh, and β-actin, during postnatal developmental of the murine mammary gland. 3 μg of poly(A)' RNA isolated from the mammary glands of FVB mice at the indicated time points was hybridized to 32P-labeled cDNA probes for the genes indicated. The smear of poly(A)' RNA beneath the 28S ribosomal RNA band is shown as a loading control. Note the apparent decrease in gene expression levels during lactation for all three genes, despite the similar amount of poly(A)' present. Origins of the mammary developmental time points are as follows: adult male; nulliparous females at 2 weeks [prior to puberty], 5 weeks [during puberty], and 10 weeks [following puberty] of age; gravid females at day 7, day 14, and day 20 of pregnancy; day 9 of lactation, and day 2 and day 7 of postlactational regression.](image-url)
Protein Kinases in Mammary Development

Based on the assumption that kinases exhibiting distinctive patterns of regulation during particular stages of mammary development may be involved in regulating specific developmental events, we grouped these genes according to similarities in their developmental expression profiles. This approach revealed an ordered set of expression profiles that suggested the coordinated regulation of protein kinases acting at different stages of mammary development. While the observation that a particular kinase is expressed in a developmentally regulated manner does not prove that the kinase plays a role in development, the spatial and temporal patterns of expression for a gene often provide important clues to its biological function. Similarly, the identification of kinases with common developmental expression profiles may identify kinases whose developmental functions are related.

**Kinase Expression during Ductal Morphogenesis**

Prior to the onset of puberty at 2 weeks of age, the mammary glands of female FVB mice consist of a rudimentary epithelial tree originating from the nipple and penetrating a short distance into a mammary fat pad composed of fibroblasts and adipocytes. Following the onset of puberty at approximately 3 weeks of age, increased levels of ovarian steroids trigger the formation of club-shaped terminal end buds at the ends of growing mammary ducts. These are composed of highly proliferative, relatively undifferentiated epithelial cells that give rise to the differentiated cell types of the mammary tree, and the appearance of these structures marks the onset of the rapid cellular proliferation characteristic of ductal morphogenesis. By 5 weeks of age, over half of the mammary fat pad is filled with epithelial ducts as a consequence of ongoing ductal elongation and branching. The completion of ductal morphogenesis occurs at 10 weeks of age when most terminal end buds have reached the edge of the fat pad and have regressed.

Unlike many strains of mice in which males lack mammary glands, mammary glands are present in male FVB mice and can be studied. This represents one advantage of studying mammary development in this strain of mice. Accordingly, several protein kinases, including c-Abl, Met, Csk, hck, c-Src, Fgfr1, Axl, Jak1, Jak2, Tyro3, Mirk, and Ctk, exhibited similar levels of expression in the mammary glands of adult male mice and 2-week-old female mice [Figs. 4–9]. Presumably, this reflects the fact that both adult males and prepubescent females have low levels of circulating 17β-estradiol and possess only a rudimentary mammary epithelial tree. Conversely, levels of expression for
Kinase Expression during Pregnancy and Lactation

Early in pregnancy, alveolar epithelial cells proliferate rapidly to form alveolar buds in response to rising levels of estrogens and progesterone. Alveolar cell proliferation occurs primarily during the first half of pregnancy, whereas alveolar differentiation occurs in a graded and progressive manner throughout pregnancy. This culminates in the withdrawal of epithelial cells from the cell cycle late in pregnancy concomitant with their terminal differentiation.

Lactation, the final stage of lobuloalveolar development, occurs following parturition in the hormonal setting of high prolactin levels and declining estrogen and progesterone levels. The marked cellular changes that occur in the mammary gland during pregnancy and lactation are reflected on a molecular level by the temporally ordered expression of different milk protein genes (Robinson et al., 1995). Each of the members of this class of genes undergoes a maximal increase in expression at a characteristic time during pregnancy and can be classified as an early, intermediate, or late marker for mammary epithelial differentiation.

Similar to milk protein genes, clustering of protein kinases on the basis of similarities in their developmental expression patterns also yields an ordered temporal set of expression profiles throughout pregnancy and lactation (Figs. 5 and 6). Consistent with the dramatic changes that take place in the mammary gland during these developmental stages, over half of all kinases examined were regulated during lobuloalveolar development. These were grouped into two sets based on whether kinases were upregulated or downregulated during pregnancy.

Seventeen kinases were found to be upregulated during pregnancy, and examination of their temporal expression profiles indicates that successive waves of kinase expression occur at each stage of lobuloalveolar development (Fig. 5). Ten kinases, including EphA7, SLK, c-Abl, Met, Lyn, c-Kit, and Egfr, exhibited maximal upregulation during early pregnancy. A smaller number of kinases exhibited maximal upregulation during the remainder of lobuloalveolar development, including mid-pregnancy (Hck) as well as late pregnancy and lactation (c-Akt1 and c-Fes).

Expression of the receptor tyrosine kinase EphA7 in tissues of adult mice has principally been described in the central nervous system. In this study, we detected EphA7 expression both in mammary epithelial cell lines and in the mammary gland, where it is maximally upregulated during early pregnancy. Interestingly, during fetal development EphA7 is expressed in bone marrow pro-B and pre-B cells, but not in more mature fetal B-lineage cells or in any B-lineage cells of the adult (Aasheim et al., 1997). In light of the similarities between postnatal mammary development and the embryonic development of other organs, it is possible that EphA7 may play a lineage-specific or differentiation-dependent role in the mammary gland during early pregnancy.

The receptor tyrosine kinase Met has previously been implicated in mammary development by virtue of its ability to stimulate branching morphogenesis and lumen for-
FIG. 5. Expression of protein kinases upregulated during pregnancy. Northern hybridization analysis of protein kinase expression during postnatal development of the murine mammary gland is shown for a selection of kinases that are upregulated during pregnancy. 3 μg of poly(A)⁺ RNA isolated from the mammary glands of FVB mice at the indicated time points was hybridized to ³²P-labeled cDNA probes for the genes indicated. Northern blots are arranged with kinases exhibiting upregulation early in pregnancy at the top and kinases exhibiting upregulation late in pregnancy at the bottom. Origins of the mammary developmental time points are as in Fig. 3. Phosphorimager analyses of selected Northern blots are shown on the right. Expression levels normalized to β-actin are shown relative to adult virgin (10 wk).

Information in mammary epithelial cells (Niemann et al., 1998; Tsarfaty et al., 1992). In addition, some studies have suggested that c-Met is overexpressed in a subset of human breast cancers, and the mammary glands of transgenic mice expressing the tpr-met oncogene develop hyperplastic alveolar nodules and carcinomas (Jin et al., 1997; Liang et al., 1996). Nevertheless, a role for Met in mammary development has not been directly demonstrated.
FIG. 6. Expression of protein kinases downregulated during pregnancy. Northern hybridization analysis of protein kinase expression during postnatal development of the murine mammary gland is shown for a selection of kinases that are downregulated during pregnancy. 3 μg of poly[A]+ RNA isolated from the mammary glands of FVB mice at the indicated time points was hybridized to 32P-labeled cDNA probes for the genes indicated. Origins of the mammary developmental time points are as in Fig. 3. Phosphorimager analyses of selected Northern blots are shown on the right. Expression levels normalized to β-actin are shown relative to adult virgin (10 wk).

Unlike other kinases analyzed in this study, both c-Akt1 and c-Fes were maximally upregulated in the mammary gland during lactation. Akt1 has recently been shown to provide survival signals in response to a variety of growth factors and cytokines, and the Akt pathway is suppressed by the PTEN tumor suppressor gene. The further finding that germ-line mutations in PTEN predispose women to breast cancer suggests that Akt1 may be a prosurvival signal in the mammary epithelium as well (Li et al., 1997, 1998, Liaw et al., 1997, Stambolic et al., 1998, Steck et al., 1997). Consistent with this hypothesis, Akt1 is expressed at high levels in human breast cancer cell lines. Similarly, while c-Fes expression has not previously been reported in the mammary gland, this kinase has been implicated in the induction of terminal myeloid differentiation and in promoting the survival of differentiating myeloid cells (Ferrari et al., 1994; Manfredini et al., 1997; Yu et al., 1989). The high levels of Akt1 and c-Fes expression observed in the mammary gland during lactation suggest that these kinases may play a role in propagating survival signals in terminally differentiated cells. As such, the rapid downregulation of Akt1 and c-Fes expression at parturition may contribute to...
the onset of large-scale apoptosis at day 2 of postlactational involution. Such a model is consistent with the hypothesis that terminally differentiated cells are dependent on survival signals from hormones and growth factors to prevent death [Wyllie et al., 1992].

Ten protein kinases were found to be downregulated in the mammary gland during pregnancy. In most cases, no marked changes in expression were observed until day 14 of pregnancy. However, for each kinase downregulation persisted throughout late pregnancy, lactation, and early postlactational regression [Fig. 6]. The function of most of the downregulated kinases in mammary development is unknown. The majority of downregulated tyrosine kinases are growth factor receptors. These include Fgfr1, Axl, and the insulin receptor, each of which appears to mediate mitogenic responses in mammary epithelial cells. Overexpression of Fgfr1 and of the insulin receptor has been described in subsets of human breast cancers [Adnane et al., 1991; Ugolini et al., 1999; Webster et al., 1996]. Conversely, downregulation of mitogenic growth factor pathways during mid- and late pregnancy may be required for the withdrawal of epithelial cells from the cell cycle that accompanies terminal differentiation. This hypothesis is consistent with the finding that downregulation of Fgfr-mediated signaling is required for the terminal differentiation of myogenic cells during avian development [Itoh et al., 1996].

Alternatively, changes in the expression of some receptor tyrosine kinases, such as the insulin receptor, may reflect the marked metabolic changes that occur in mammary gland during pregnancy.

**Kinase Expression during Postlactational Involution**

Immediately following weaning, secretory alveoli rapidly involute as the majority of mammary epithelial cells die in the apoptotic process of postlactational regression or involution. Cell death begins within 2 days following weaning, and by day 7 of postlactational involution, intensive remodeling of the mammary epithelium, stroma, and extracellular matrix is well underway.

Three protein kinases identified in this screen were found to be upregulated in the involuting mammary gland [Fig. 7]. Expression of the receptor tyrosine kinase Tyro3 is dramatically upregulated in the mammary gland at day 2 of involution, yet returns to preregression levels by day 7. Since Tyro3 has been proposed to play a role in the growth and remodeling of the central nervous system, it is possible that it plays an analogous role in the mammary gland [Lai et al., 1994; Stitt et al., 1995].

Like Tyro3, Mlkl is also maximally upregulated in the mammary gland at day 2 of involution [Fig. 7]. The developmental expression profiles of Mlkl and Tyro3 share additional similarities as each kinase undergoes a modest initial upregulation in the mammary glands of nulliparous mice between 2 and 5 weeks of age and is further upregulated at the onset of pregnancy.

The developmental pattern of Mlkl expression was further investigated by in situ hybridization [Fig. 8]. This revealed that Mlkl is expressed in the mammary gland in an epithelial-specific manner, as was predicted based on the similarity of its expression pattern in cell lines to that of cytokeratin 18. During puberty, Mlkl is preferentially ex-
FIG. 8. Spatial expression of Mlk1 during mammary development. In situ hybridization analysis of Mlk1 expression during postnatal mammary development is shown. Bright-field (left) and dark-field (right) photomicrographs of mammary gland sections from female mice at 6 weeks of age (A-D), 16 weeks of age (E and F), day 7 of pregnancy (G and H), and day 2 of postlactational involution (I and J) hybridized with an 35S-labeled Mlk1-specific antisense probe. No signal over background was detected in serial sections hybridized with a sense Mlk1 probe. Exposure times were identical for all dark-field photomicrographs to illustrate changes in Mlk1 expression during pregnancy. al, alveoli; d, duct; lo, secretory lobule; st, adipose stroma; teb, terminal end bud. Original magnification 500×.
Virgin Pregnancy = Involution

Virgin Pregnancy g Involution

Cyclin A

Cyclin D1

FIG. 9. Expression of protein kinases as a function of proliferation. Northern hybridization analysis of protein kinase and cyclin expression during postnatal development of the murine mammary gland is shown. 3 μg of poly(A)+ RNA isolated from the mammary glands of FVB mice at the indicated time points was hybridized to 32P-labeled cDNA probes for the genes indicated. Origins of the mammary developmental time points are as in Fig. 3. Phosphorimager analysis of the Northern blot for Plk is shown on the right. Expression levels normalized to β-actin are shown relative to adult virgin (10 wk).

pressed in epithelial cells of terminal end buds compared to ducts (Figs. 8, cf. 8B and 8D). This finding may explain the upregulation of Mlk1 observed in the mammary glands of 5-week-old mice. In situ hybridization further revealed that the modest upregulation of Mlk1 expression that occurs during pregnancy is due to preferential induction of Mlk1 expression in developing alveoli compared to ducts, and also confirmed the dramatic upregulation of this kinase in involuting alveoli at day 2 of regression. The preferential expression of Mlk1 in specific structures within the epithelial compartment, such as terminal end buds and developing alveoli, demonstrates that the expression of this kinase is regulated spatially as well as temporally during mammary development.

In contrast to Tyro3 and Mlk1, expression of the Csk-related cytoplasmic tyrosine kinase Ctk remains low throughout virgin development and pregnancy (Fig. 7). Induction of Ctk expression is initially observed during lactation, with maximal upregulation occurring at day 7 of involution. Ctk expression has previously been described only in the brain (Brinkley et al., 1995). Together, the developmental patterns of expression observed for Tyro3, Mlk1, and Ctk suggest that these kinases may play a role in the dramatic changes that occur in the mammary gland during involution.

\textbf{Proliferation-Dependent Patterns of Kinase Expression}

An intriguing pattern of developmental expression was observed for the mammalian polo-like kinase, Plk. Plk expression is maximally upregulated in the mammary gland at day 7 of pregnancy, with a progressive decline in expression observed thereafter (Fig. 9). No expression was detected during lactation. Smaller increases in Plk expression were noted in the mammary glands of 5-week-old nulliparous animals. The observation that the upregulation of Plk expression coincides with peak alveolar proliferation rates during early pregnancy, as well as previous observations that Plk expression is cell cycle-regulated (Lee et al., 1995), suggested that the developmental pattern of expression of this kinase reflects proliferative events in the mammary gland. This hypothesis is supported by the marked similarities in the expression profiles of Plk, cyclin A, and cyclin D1 (Fig. 9). As such, these findings strongly suggest that the temporal profile of Plk expression reflects increases in mitotic activity that occur in the mammary gland during puberty and early pregnancy. Consistent with this hypothesis, the developmental expression of Plk in the mammary gland is spatially restricted to proliferating cellular compartments, particularly in terminal end buds during puberty and alveolar buds during pregnancy (data not shown).

\textbf{Spatial Regulation of Kinase Expression}

In addition to the diverse temporal patterns of expression observed for the kinases analyzed in this study, diverse spatial patterns of expression were also observed. Similar to Mlk1 and Plk, the serine/threonine kinase SLK is upregulated in the mammary epithelium at day 7 of pregnancy (Figs. 5, 7–9, and 10A–10D, and data not shown). However, whereas Mlk1 and Plk are preferentially expressed in alveoli compared to ducts at this stage of development, SLK upregulation occurs in both ducts and alveoli. This observation suggests that upregulation of SLK expression may occur in response to signals that are distributed throughout
FIG. 10. Spatial expression of SLK and Tyro3 during mammary development. In situ hybridization analysis of SLK [A–D] and Tyro3 [E–H] expression during postnatal mammary development. Bright-field (left) and dark-field (right) photomicrographs of mammary gland sections from nulliparous female mice at 16 weeks of age (A and B) or day 7 of pregnancy (C–H) hybridized with $^3$S-labeled antisense probes specific for SLK or Tyro3. Stromal cells at the edge of the mammary fat pad are shown in panels G and H. No signal over background was detected in serial sections hybridized with sense SLK or Tyro3 control probes. Exposure times were identical for dark-field photomicrographs for SLK to illustrate changes in expression during pregnancy. al, alveoli; d, duct; lu, lumen of epithelial duct; st, adipose stroma. Arrows indicate cells expressing Tyro3. Cells without detectable Tyro3 expression are indicated by arrowheads. Original magnification 500×.

the epithelium, rather than to changes specific to a subset of epithelial cells within a particular compartment.

Unlike the majority of kinases analyzed in this study, expression of the receptor tyrosine kinase Tyro10 was restricted to the stroma of the mammary gland (Figs. 10E–10H). This cell type-specificity was predicted based on
our initial finding that Tyro10 is preferentially expressed in cell lines that are negative for expression of the epithelial marker cytokeratin 18 (Fig. 2). Within the mammary gland, Tyro10 is expressed in regions immediately surrounding epithelial structures (Fig. 10E and 10F) as well as in regions at the periphery of the mammary fat pad (Fig. 10G and 10H). Interestingly, Tyro10 expression is strikingly heterogeneous in stromal cells, suggesting that the expression of this kinase may be restricted to a specific stromal cell type.

DISCUSSION

We have isolated 33 tyrosine kinases and 8 serine/threonine kinases that are expressed during the postnatal development of the murine mammary gland. Since transcription is one of the key steps at which gene expression is regulated, we chose to examine the mRNA expression of each of these kinases in a panel of transgenic mammary epithelial cell lines and in the mammary gland during multiple stages of development. Although protein kinases are typically regulated at the posttranslational level, the majority of kinases analyzed in this study were also found to be developmentally regulated at the mRNA level. Kinases were subsequently clustered into groups based on similarities in these expression patterns as a first step in drawing inferences about developmental processes in which they might be involved. In this manner, the panel of protein kinases identified in this study was used to produce a temporal map of developmental gene expression for the mammary gland.

While the temporal patterns of gene expression observed for the protein kinases surveyed in this study were diverse, application of a clustering approach revealed an ordered set of expression profiles in which successive waves of kinase expression occur during development. This finding suggests that a coordinated program of protein kinase expression exists that may play a role in regulating the cascade of events constituting mammary development.

A wide range of kinases was isolated in this study, including members of multiple receptor tyrosine kinase, cytoplasmic tyrosine kinase, and serine/threonine kinase subfamilies. A subset of the kinases that were identified in mammary gland samples was not expressed in the mammary epithelial cell lines tested, presumably as a result of their expression in a nonepithelial cell type. In contrast, virtually all of the kinases identified in mammary tumor cell lines were also found to be expressed in the mammary gland during development. This observation suggests that the expression of kinases detected in mammary epithelial cell lines is not merely a consequence of malignant transformation, nor of culture conditions, but rather suggests that these molecules may play a role in the normal physiology of the mammary gland. Of note, the kinase expression patterns observed in the panel of mammary epithelial cell lines tested were markedly heterogeneous, with dissimilar expression patterns observed even for kinases that displayed similar expression profiles during development. We conclude that kinase expression patterns in mammary gland samples and in epithelial cell lines reflect distinct aspects of mammary biology.

In recent cDNA microarray experiments in the yeast S. cerevisiae, more than 60% of characterized genes that were found to be regulated in a cell cycle-dependent manner were already known to have functions related to the cell cycle (Cho et al., 1998). Thus, while the finding that expression of a particular kinase is developmentally regulated does not prove that the kinase plays a role in development, the spatial and temporal patterns of expression for a gene may provide important clues to its biological role. Kinases exhibiting distinctive patterns of regulation during mammary development may, in fact, be involved in controlling or mediating developmental events. Similarly, the identification of kinases that share developmental expression profiles may also identify kinases whose developmental functions are related.

The vast majority of protein kinases isolated in this screen currently have no recognized role in mammary development. Since poorly characterized genes whose expressions fluctuate in parallel may not only be regulated by parallel pathways, but also may function in parallel pathways, RNA expression patterns may provide a straightforward means of gaining insight into roles played in mammary development. As such, extrapolation may yield insights into the role in mammary development played by kinases whose functions have been elucidated in other tissues. Conversely, insight into the function of kinases lacking previously described roles in murine development may be gained by extrapolation from patterns of kinase expression during mammary development.

The expression of a number of kinases isolated in our study has previously been reported to be restricted to tissues other than the mammary gland. Such kinases include EphB3, EphA7, Ctk, Lyn, Hck, and Tec. Each of these kinases is also expressed in the mammary epithelial cell lines tested. Our observation that the majority of these kinases are developmentally regulated in the mammary gland suggests that these molecules have additional unrecognized functions. It will be of great interest to determine whether the functions of these kinases in mammary development are analogous to their functions in other tissues.

RT-PCR screens designed to identify protein kinases expressed in mammary carcinomas or in the mammary gland have previously been reported by three groups: Letchtola et al. isolated 10 protein kinases from the human breast cancer cell line MCF-7; Cance et al. isolated 25 protein kinases from a human breast carcinoma and from the human breast cancer cell line 600PEI; and Andres et al. isolated 24 protein kinases from murine mammary glands (Andres et al., 1995; Cance et al., 1993; Letchtola et al., 1992). In total, these screens resulted in the identification of 43 protein kinases, 21 of which were also identified in the present study. In addition to these previously isolated kinases, our screen has resulted in the identification of an additional 20 kinases expressed in the mammary gland,
bringing the total number of kinases identified in this manner to 63.

In aggregate, beyond providing clues to the regulation of different stages of postnatal mammary development by specific protein kinases, approaches similar to those taken here should prove useful in identifying sequences of events, as well as coherent regulatory patterns, in mammary development. Moreover, by analogy with hematopoiesis, certain kinases may be expressed in the mammary gland in a lineage-restricted manner and may thereby serve as useful markers for epithelial or stromal cell subtypes. As such, it is likely that the composite spatial and temporal pattern of kinase expression in the mammary gland at any given developmental stage can provide important information regarding its physiological state and should provide insight into the molecules that regulate different stages of postnatal mammary development. Ultimately, the finding that most kinases expressed in the mammary gland are developmentally regulated suggests that the array of kinases participating in the regulation of mammary development is considerably broader than currently appreciated.

ACKNOWLEDGMENTS

The authors thank Celina D'Cruz, Stephen Master, Gerald Wertheim, and Eunkyoung Kauh for helpful discussions and for critically reading the manuscript. This research was supported by the Elsa U. Pardee Foundation, American Cancer Society RPG-99-259-01-DDC, NIH Grants CA83849, CA71513 and CA78410 from the National Cancer Institute, the Charles E. Culpeper Foundation, and U.S. Army Breast Cancer Research Program Grants DAMD17-96-1-6112 (J.P.G.), DAMD17-98-1-8235 (D.B.S.), DAMD17-98-1-8226, DAMD-99-1-9463, and DAMD-99-1-9349. L.A.C. is a Charles E. Culpeper Medical Scholar.

REFERENCES


Kluppel, M., Donoviel, D. B., Brunkow, M. E., Motro, B., and Bernstein, A. (1997). Embryonic and adult expression patterns of the Tec tyrosine kinase gene suggest a role in megakaryocyto-
Protein Kinases in Mammary Development


Received for publication November 22, 1999

Revised December 30, 1999

Accepted December 30, 1999
Cloning and Characterization of Hunk, a Novel Mammalian SNF1-Related Protein Kinase

Heather Perry Gardner,* Gerald B. W. Wertheim,* Seung I. Ha,* Neal G. Copeland,† Debra J. Gilbert,† Nancy A. Jenkins,† Sandra T. Marquis,* and Lewis A. Chodosh*†

*Department of Molecular and Cellular Engineering and †Division of Endocrinology, Diabetes, and Metabolism, University of Pennsylvania School of Medicine, 421 Curie Boulevard, 612 Biomedical Research Building Ill, Philadelphia, Pennsylvania 19104-6160; and †Mammalian Genetic Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201

Received September 24, 1999; accepted November 23, 1999

INTRODUCTION

Major insights into the molecular mechanisms of differentiation, development, and carcinogenesis have been obtained through studies of protein kinases in a wide range of biological systems. The finding that aberrantly regulated or aberrantly functioning protein kinases can disrupt normal developmental processes or promote carcinogenesis illustrates the fact that phosphorylation events play critical roles in the regulation of cell growth and differentiation. In addition, some protein kinases are expressed in a lineage-specific manner and are thereby useful markers for defining cellular subtypes (Dymecki et al., 1990; Mischak et al., 1991; Rawlings and Witte, 1994; Schnurch and Risau, 1993; Siliciano et al., 1992; Valenzuela et al., 1995). The key role played by serine/threonine kinases in regulating diverse cellular processes is exemplified by studies of SNF1-related kinases. Several members of the SNF1 family of kinases function in signal transduction pathways involved in the cellular response to nutritional or environmental stresses (Hardie et al., 1994). The Saccharomyces cerevisiae protein kinase, SNF1, and its mammalian counterpart, AMP-activated protein kinase (AMPK), function in highly conserved signal transduction pathways that promote energy conservation. SNF1 family members have also been implicated in a variety of developmental processes including the regulation of cellular proliferation and differentiation. These include MsK in murine cardiac development, SNRK in adipocyte differentiation, C-TAK1 in cell cycle control, and the Caenorhabditis elegans SNF-1 related kinase, PAR-1, in the establishment of embryonic polarity (Becker et al., 1996; Guo and Kemphues, 1995; Peng et al., 1998; Ruiz et al., 1994). In fact, SNF-1 itself has been found to mediate cell cycle arrest in response to starvation (Thompson-Jaeger et al., 1991). Thus, members of the SNF1 kinase family have been demonstrated to regulate a variety of important cellular processes.

In light of the importance of protein kinases in development and carcinogenesis, we previously performed a degenerate PCR-based screen aimed at identifying protein kinases expressed in the murine mammary gland during development and in mammary epithelial cell lines derived from different transgenic mouse models of breast cancer (Chodosh et al., 1999, submitted for publication; Gardner et al., in press; Stairs et al., 1998). In the course of these studies, we identified a cDNA encoding a catalytic domain fragment from a novel protein kinase, Hunk. In this report, we show that Hunk encodes an 80-kDa polypeptide.
associated with phosphotransferase activity. *Hunk* is evolutionarily conserved, being most closely related to the SNF1 family of serine/threonine kinases, and is located on mouse chromosome 16 in a region of conserved synteny with human chromosome 21q22. *Hunk* expression in the mouse is developmentally regulated and tissue-specific. Interestingly, within several tissues in the adult mouse, *Hunk* is expressed in a heterogeneous pattern, suggesting that the expression of this kinase is restricted to particular subtypes of cells within a variety of tissues.

**MATERIALS AND METHODS**

Cloning of a full-length *Hunk* cDNA. Poly(A)^+ RNA isolated from the MMTV-Ha-ras transgenic mammary epithelial tumor cell line, AC816 (Morrison and Leder, 1994), or from FVB mouse embryos harvested at day 14 of gestation was used to generate independent cDNA libraries using either the Uni-ZAP (AC816) or the Zap Express (day 14 embryo) lambda phage vector (Stratagene) according to the manufacturer's instructions. A total of 5 x 10^8 plaques from each library were screened by standard methods using a ([α-^32P]dCTP-labeled random-primed cDNA probe (BMB Random Prime). The cDNA clones corresponding to nucleotides 619 to 824 of *Hunk* was used to screen two independently generated AC816 cDNA libraries. The day 14 mouse embryo cDNA library was subsequently screened using cDNA fragments corresponding to nucleotides 132 to 500 and 276 to 793 of *Hunk*. Hybridization was performed at a concentration of 10^6 cpm/ml in 48% formamide, 10%/ dextran sulfate, EBC buffer composed of 50 mM Tris (pH 7.9), 120 mM NaCl, and 500 and 276 to 793 of *Hunk* generated by random-primed labeling (BMB) (Marquis et al., 1997). Poly(A)^+ RNA were precleared with 40 μL 1:1 Protein A-Sepharose:PBS (Phar-macia) followed by exposure to film (Kodak XAR-5). Bound antibodies were then eluted sequentially with 100 mM glycine, pH 2.5, and 100 mM triethylamine, pH 11.5, and neutralized with 1/10 vol of 1.0 M Tris (pH 7.5) (Harlow and Lane, 1999).

**Immunoprecipitation of *Hunk***. Protein was extracted from tissue culture cells or homogenizing murine mammary glands in EBC buffer composed of 50 mM Tris (pH 7.5), 120 mM NaCl, and 0.5% NP-40 supplemented with 1 mM β-mercaptoethanol, 50 mM NaF, 20 μg/mL aprotinin, 100 μg/mL Pefabloc (BMB), and 10 μg/mL leupeptin. Equivalent amounts of each extract were electrophoresed on 10% SDS-PAGE gels and transferred overnight onto nitrocellulose membranes. Following visualization by Ponceau staining to verify equal protein loading and even transfer, membranes were incubated with blocking solution consisting of 4% dry milk, 0.05% Tween 20, and 1X phosphate-buffered saline (PBS) at RT. Primary antibody incubation with affinity-purified antisera was performed at RT for 1 h at a final concentration of approximately 2 μg/ml in blocking solution. Following three RT washes in blocking solution, blots were incubated with a 1:10,000 dilution of a horseradish per-oxidase-conjugated goat anti-rabbit secondary antibody (Jackson Im-munoResearch) for 30 min at RT. Following three washes in blocking solution and two washes in 1X PBS, blots were developed using the ECL Plus system according to the manufacturer's instructions (Amersharm Pharmacia) followed by exposure to film (Kodak XAR-5).

**Northern analysis**. mRNA was extracted by homogenization of snap-frozen tissue sections or tissue culture cells in guanidinium isothiocyanate supplemented with 7 μL/ml of 2-mercaptoethanol followed by ultracentrifugation through cesium chloride as previously described (Marquis et al., 1995; Rajan et al., 1997). Poly(A)^+ RNA was selected using oligo(dT) cellulose (Pharmacia), separated on a 0.7% LE agarose gel, and passively transferred to a GeneScreen membrane (NEN). Northern hybridization was performed as described using a [α-^32P]-labeled cDNA probe encompassing nucleotides 1149 to 3849 of *Hunk* generated by random-primed labeling (BMB) (Marquis et al., 1995). Hybridization was carried out as detailed above for cDNA library screening.

**In vitro transcription/translation**. In vitro transcription and translation were performed on 1 μg of plasmid DNA using rabbit reticulocyte lysates in the presence of either [35S]Met or unlabelled methionine according to the manufacturer's instructions (TNT kit, Promega). Completed reactions were electrophoresed on a 10% SDS-PAGE gel and were subjected either to autoradiography or to immunoblotting as described below.

**Generation of anti-*Hunk* antisera.** GST--*Hunk* recombinant fusion proteins containing amino-terminal (amino acids 32-213) or carboxyl-terminal (amino acids 556-714) regions of *Hunk* were expressed in BL21 bacterial cells and purified using glutathione-Sepharose beads according to the manufacturer's instructions (Pharmacia). Following removal of the GST portion by cleavage with Preccession Protease (Pharmacia), the liberated carboxyl-terminal *Hunk* polypeptide was further purified by isolation on a 15% SDS-PAGE gel. Purified *Hunk* polypeptides were injected into rabbits (Strasburger and colleagues) in complete Freund's adjuvant and then placed in acrylamide gel slices (carboxyl-terminal). Antisera were affinity-purified on cyanogen bromide-coupled Sepharose columns crosslinked with their respective antigens according to the manufacturer's instructions (Pharmacia). Bound antibodies were then eluted sequentially with 100 mM glycine, pH 2.5, and 100 mM triethylamine, pH 11.5, and neutralized with 1/10 vol of 1.0 M Tris (pH 7.5) (Harlow and Lane, 1999).

**Immunoblotting analysis.** Protein extracts were generated by lysing tissue culture cells or homogenizing murine mammary glands in EBC buffer composed of 50 mM Tris (pH 7.5), 120 mM NaCl, and 0.5% NP-40 supplemented with 1 mM β-mercaptoethanol, 50 mM NaF, 20 μg/mL aprotinin, 100 μg/mL Pefabloc (BMB), and 10 μg/mL leupeptin. Equivalent amounts of each extract were electrophoresed on 10% SDS-PAGE gels and transferred overnight onto nitrocellulose membranes. Following visualization by Ponceau staining to verify equal protein loading and even transfer, membranes were incubated with blocking solution consisting of 4% dry milk, 0.05% Tween 20, and 1X phosphate-buffered saline (PBS) at RT. Primary antibody incubation with affinity-purified antisera was performed at RT for 1 h at a final concentration of approximately 2 μg/ml in blocking solution. Following three RT washes in blocking solution, blots were incubated with a 1:10,000 dilution of a horseradish per-oxidase-conjugated goat anti-rabbit secondary antibody (Jackson Im-munoResearch) for 30 min at RT. Following three washes in blocking solution and two washes in 1X PBS, blots were developed using the ECL Plus system according to the manufacturer's instructions (Amersharm Pharmacia) followed by exposure to film (Kodak XAR-5).

**Kinase assay.** Protein was extracted from snap-frozen lactating murine mammary glands and from 8Mala cells (Morrison and Leder, 1994) by dounce homogenization in EBC buffer containing protease inhibitors. Extracts containing 820 μg protein in 1 ml EBC were precleared with 40 μl 1:1 Protein A-Sepharose:PBS (Pharmacia) for 1 h at 4°C. One-quarler of the precleared lysate was incubated at 4°C overnight with 1.5 μg/ml of affinity-purified anti-sera raised against the amino-terminus of *Hunk*. Immune complexes were precipitated with 40 μl of 1:1 Protein A-Sepharose:PBS. In vitro
kinase activity of the resulting immunoprecipitates was assayed under final reaction conditions consisting of 20 mM Tris (pH 7.5), 5 mM MgCl2, 100 μM dATP, 0.5 μCi/μl [α-32P]ATP, and 0.15 μg/μl histone H1 for 45 min at 37°C. Reactions were electrophoresed on a 15% SDS-PAGE gel and were subjected to autoradiography.

RNase protection analysis. Ribonuclease protection analysis was performed as described (Marquis et al., 1995). Body-labeled antisense riboprobes were generated using linearized plasmids containing nucleotides 276 to 500 of the Hunk cDNA and 1142 to 1241 of β-actin (GenBank Accession No. X08672) using [α-32P]UTP and the Promega in vitro transcription system with T7 polymerase. The β-actin antisense riboprobe was added to each reaction as an internal control. Probes were hybridized with RNA samples at 58°C overnight in 50% formamide/100 mM Pipes (pH 6.7). Hybridized samples were digested with RNase A and T1, purified, electrophoresed on a 6% denaturing polyacrylamide gel, and subjected to autoradiography.

In situ hybridization. In situ hybridization was performed as described (Marquis et al., 1995). Antiactin and sense probes were synthesized with the Promega in vitro transcription system using [35S]-UTP and [32S]-CTP from the T7 and SP6 RNA polymerase promoters of a PCR template containing sequences corresponding to nucleotides 276 to 793 of Hunk, a region demonstrated to recognize both mRNA transcripts. Exposure times were 6 weeks in all cases.

Interspecific mouse backcross mapping. Interspecific backcross progeny were generated by mating (C57BL/6J × Mus spretus)F1 females and C57BL/6J males as described (Copeland and Jenkins, 1991). A total of 205 N1 mice were used to map the Hunk locus (see below for details). DNA isolation, restriction enzyme digestion, agarose gel electrophoresis, Southern transfer, and hybridization were performed essentially as described (Jenkins et al., 1982). All blots were prepared with Hybond-N nylon membrane (Amersham). A 520-bp EcoRI fragment corresponding to nucleotides 276 to 793 of the Hunk cDNA was labeled with [α-32P]dCTP using a nick-translation labeling kit (Boehringer Mannheim). Washing was performed at a final stringency of 1.0 × SSC/0.1% SDS at 65°C. A major fragment of 6.8 kb was detected in SacI-digested C57BL/6J DNA, and a major fragment of 5.8 kb was detected in SacI-digested M. spretus DNA. The presence or absence of the 5.8-kb SacI M. spretus-specific fragment was followed in backcross mice.

A description of the probes and RFLPs for the loci linked to Hunk including App, Tam1, and Erg has been reported previously (Fan et al., 1996). Recombination distances were calculated using Map Manager, version 2.6.5. Gene order was determined by minimizing the number of recombination events required to explain the allele distribution patterns.

RESULTS

We previously performed a screen designed to detect protein kinases expressed in the murine mammary gland and in breast cancer cell lines to identify regulatory molecules potentially involved in mammary development and carcinogenesis. RT-PCR with degenerate oligonucleotide primers was employed to amplify catalytic subdomains of protein kinases expressed in six murine breast cancer cell lines or in the murine mammary gland during various stages of development (Chodosh et al., 1999, submitted for publication; Gardner et al., in press; Stairs et al., 1998). Individual PCR products were subcloned and screened by a combination of DNA sequencing and colony-lift hybridization. Examination of approximately 1500 cDNA clones from this screen resulted in the identification of 41 protein kinases including 33 tyrosine kinases and 8 serine/threonine kinases, 3 of which were novel.

One of these novel putative serine/threonine kinases, originally referred to as Bstk1, was first identified as a 207-bp RT-PCR product isolated from a mammary epithelial cell line derived from an adenocarcinoma arising in an MMTV-neu transgenic mouse (Chodosh et al., 1999, submitted for publication). The cDNA encoding Bstk1 was subsequently found to be upregulated in the mammary gland during early pregnancy and following treatment with 17β-estradiol and progesterone. In addition, Bstk1 was found to be preferentially expressed in mammary tumor cell lines derived from MMTV-neu as compared with MMTV-c-myc transgenic mice (Gardner et al., submitted for publication). Based upon this expression pattern, Bstk1 was renamed Hunk, for hormonally upregulated, neu-tumor-associated kinase.

Isolation of cDNA Clones Encoding Hunk

To isolate the full-length mRNA transcript from which Bstk1 was derived, the initial 207-bp RT-PCR product was used to screen a cDNA library prepared from the H-ras transformed mammary epithelial cell line, AC816 (Morrison and Leder, 1994). A cDNA probe derived from the 5' end of the longest clone isolated, G3, was subsequently used to screen a day 14 murine embryonic cDNA library. Six additional nonchimeric cDNA clones ranging in length from 4.4 to 5.0 kb were isolated from this library; each of these clones possessed a poly(A) tail and a restriction pattern similar to that of G3 (data not shown). Dideoxy sequencing of the 5' and 3' termini of these clones in addition to restriction mapping revealed that all seven cDNA clones were contiguous. The longest cDNA clones isolated from each library, G3 and E8, were completely sequenced on both strands (Fig. 1). Comparison of the 5024-nt sequence of clone E8 with that of clone G3 revealed that clone E8 contains an additional 40 nucleotides at its 5' end and that the length of a poly(T) tract in the 3'-untranslated region (UTR) of the two clones differs by a single nucleotide. There were no additional differences between these two clones.

The 5024-nucleotide sequence of clone E8, hereafter referred to as Hunk, contains the entire 207-bp RT-PCR fragment, Bstk1, from positions 618 to 824 (Fig. 1). Hunk possesses an open reading frame (ORF) 2142 nucleotides in length beginning with a putative initiation codon at nucleotide 72. Comparison of the nucleotide sequence surrounding this site with the Kozak (1987, 1991) consensus sequence, GCC^5′_CCA^3′_UGG, reveals matches at positions −4, −3, and −2. The nucleotide sequence of the 5'−UTR and the first 100 nt of the Hunk ORF are extremely GC-rich (>80%). Other genes bearing such GC-rich sequences have been found to be subject to translational control (Kozak, 1991). The 3'-UTR of Hunk is 2.8 kb in length and lacks a canonical AATAAA polyadenylation signal, containing instead the relatively uncommon signal, ATTACA, 18 nucleotides upstream of the poly(A) tract (Bishop et al., 1991).
FIG. 1. Nucleotide and deduced amino acid sequence of Hunk. The composite nucleic acid sequence and conceptual translation of full-length Hunk cDNA are shown. Nucleotide coordinates are shown on the left. Amino acid coordinates are shown in boldface type on the right. A light shaded box indicates the kinase catalytic domain. Dark shaded boxes denote amino acid motifs characteristic of serine/threonine kinases. The SNF1 homology region, SNF1, is denoted by a hatched box. The GC-rich region in the 5'-UTR and the putative polyadenylation sequence in the 3'-UTR are underlined by thin and thick lines, respectively. An asterisk denotes the stop codon. A bracket in the 3'-UTR denotes the poly(A) tract, which differs in length between the two independent cDNA clones (clone ES is shown here).
While this work was in progress, a 588-nucleotide portion of the catalytic domain of Hunk was independently isolated by another group and shown to recognize an mRNA approximately 4 kb in length (Korobko et al., 1997). Subsequently, this same group deposited a 5026-nt full-length sequence in GenBank (Accession No. AF055919) that is 10 nucleotides shorter at the 5' end and 98% identical to Hunk. No additional information is available regarding the cloning, localization, function, or in vivo expression of this molecule.

The conceptual ORF of Hunk comprises 714 amino acids and encodes a polypeptide of predicted molecular mass 79.6 kDa. This polypeptide can be divided into an amino-terminal domain of 60 amino acids, a 260-amino-acid kinase catalytic domain, and a 394-amino-acid carboxy-terminal domain. The carboxy-terminal domain of Hunk contains a 46-amino-acid conserved motif located 18 amino acids C-terminal to the catalytic domain that is homologous to the previously described SNF1 homology region or SNH (Becker et al., 1996). The 330 amino acids carboxy-terminal to the SNH lack homology to other known proteins.

The putative catalytic domain of Hunk contains each of the invariant amino acid motifs characteristic of all protein kinases as well as sequences specific to serine/threonine kinases (Hanks and Quinn, 1991; Hanks et al., 1988). In particular, the DLKPEN motif in subdomain VI of the Hunk cDNA predicts serine/threonine kinase specificity (ten Dijke et al., 1994). Hunk also contains the serine/threonine consensus sequence, G(T/S)XX(Y/F)X, in subdomain VIII N-terminal to the APE motif conserved among all protein kinases. In addition, several amino acids in subdomains I, VII, VIII, IX, X, and XI that are conserved among tyrosine kinases are absent from the Hunk ORF. Thus, primary sequence analysis strongly suggests that Hunk encodes a functional serine/threonine kinase.

To determine whether the length of the cDNA clone encoding Hunk is consistent with the size of the Hunk mRNA message, Northern hybridization was performed on poly(A)+ RNA isolated from a Hunk-expressing mammary epithelial cell line (Fig. 2A). This analysis revealed a predominant mRNA transcript 5.1 kb in length, as well as a less abundant transcript approximately 5.6 kb in length, suggesting that clone E8 may correspond to the shorter Hunk mRNA transcript.

The finding that all six cDNA clones isolated from a cDNA library generated from mRNA containing both 5.1- and 5.6-kb Hunk mRNA species contain poly(A) tails and are colinear suggests that the 5.6-kb transcript may contain additional 5' or 3' sequence relative to our longest cDNA clone. Consistent with this supposition is the observation that insertions or deletions relative to our Hunk cDNA sequence were not detected using multiple PCR primer pairs to perform RT-PCR on first-strand cDNA prepared from RNA containing both transcripts (data not shown). The failure to identify cDNA clones containing additional 5' sequence may be related to the GC-rich nature of the 5' UTR of Hunk and the tendency of reverse transcriptase to terminate prematurely in such regions. Alternatively, the difference in size between the 5.1- and 5.6-kb transcripts may be due to utilization of an alternate downstream polyadenylation site during mRNA processing.

To confirm the coding potential of the Hunk cDNA, in vitro transcription and translation of clone E8 were performed in the presence of [35S]Met. This yielded an 80-kDa labeled polypeptide species, consistent with the 79.6-kDa predicted size of Hunk (data not shown), suggesting that the predicted initiation codon at nucleotide 72 is capable of functioning as a translation initiation site.

Detection of Hunk in Mammalian Cells

To detect the polypeptide encoded by the Hunk locus, anti-Hunk antisera were raised against recom-
binant proteins encoding amino-terminal (amino acids 32-213) and carboxyl-terminal (amino acids 556-714) regions of Hunk. Each of the antisera raised against the amino- and carboxyl-termini of Hunk identifies a polypeptide of approximately 80 kDa present in extracts from mammary epithelial cells that express Hunk mRNA, but not in extracts from mammary epithelial cells that do not (Fig. 2C; and data not shown). To demonstrate that this 80-kDa polypeptide corresponds to Hunk, protein extracts prepared from two mammary epithelial cell lines that express Hunk mRNA and from two mammary epithelial cell lines that do not express Hunk mRNA were subjected to immunoprecipitation/immunoblotting protocols (Fig. 2B). Immunoprecipitation of Hunk using antisera raised against the amino-terminus of Hunk, followed by immunoblotting with antisera raised against the carboxyl-terminus of Hunk, identified an 80-kDa polypeptide only in extracts prepared from cells that express Hunk mRNA (Fig. 2B). Similarly, immunoprecipitation of Hunk using antisera raised against the carboxyl-terminus of Hunk, followed by immunoblotting with antisera raised against the amino-terminus of Hunk, also identified an 80-kDa polypeptide only in extracts prepared from cells that express Hunk mRNA (data not shown). The 80-kDa polypeptide was not detected when immunoblotting was performed on immunoprecipitates prepared from Hunk-expressing cells when immunoprecipitation was carried out using either of two control affinity-purified antisera (Fig. 2B; and data not shown). We conclude that this 80-kDa polypeptide represents the endogenous Hunk gene product in these mammary epithelial cell lines.

To prove that clone E8 encodes the predominant form of Hunk found in mammary epithelial cells, we determined whether the in vitro translated product of clone E8 comigrates with endogenous Hunk. Immunoblotting of protein extracts prepared from the Hunk mRNA-expressing mammary epithelial cell line SMF and from rabbit reticulocyte lysates programmed with sense RNA prepared by in vitro transcription of clone E8 identified comigrating 80-kDa polypeptides (Fig. 2C). No band was detected in reticulocyte lysates programmed with an empty vector or in whole-cell lysates from a cell line that does not express Hunk mRNA. The observation that the 80-kDa polypeptide identified by anti-Hunk antisera comigrates with the polypeptide obtained following in vitro transcription and translation of clone E8 strongly suggests that clone E8 contains the entire ORF encoding the predominant form of Hunk found in mammary epithelial cells. Nevertheless, due to the absence of in-frame stop codons upstream of the putative translation initiation codon, the possibility that additional 5' coding sequence exists cannot be excluded.

Predicted Structure and Homology to Previously Isolated Protein Kinases

Multiple sequence alignment was used to determine the homology between the kinase catalytic domain of Hunk and other previously isolated protein kinases (Fig. 3A). This analysis revealed that Hunk displays highest homology to the S. cerevisiae SNF1 family of serine/threonine kinases. The SNF1 family of protein kinases is composed of at least two subfamilies. The first subfamily includes SNF1 and its plant homologues including NPK5, AKin10, BKIN12, and Rkin1 as well as the mammalian SNF1 functional homologue, AMPK (Alderson et al., 1991; Carling et al., 1994; Le Guen et al., 1992; Muranaka et al., 1994). More recently, additional mammalian SNF1-related kinases have been identified that define a second subfamily. These include C-TAK1/p78, MARK1, MARK2/Emk, SNRK, and Msk, as well as the C. elegans kinase, PAR-1 (Becker et al., 1996; Drewes et al., 1997; Peng et al., 1997, 1998; Ruiz et al., 1994). Less closely related to either subfamily are Wpk4, Melk, and KIN1, SNF1-related kinases found in wheat, mice, and Schizosaccharomyces pombe, respectively (Heyer et al., 1997; Levin and Bishop, 1990; Sano and Youssefian, 1994). Similar to these more distantly related SNF1 kinases, Hunk does not appear to belong to a previously defined SNF1 subfamily. Thus, based upon homology within the kinase domain, Hunk appears to represent a new branch of the SNF1 family tree.

Outside of a conserved kinase catalytic domain, SNF1-related protein kinases contain a region of homology referred to as the SNH or SNF1 homology domain (Becker et al., 1996). Although amino acids in this motif are conserved, the functional significance of the SNH domain is unknown. Multiple sequence alignment confirms the presence of the SNH in all SNF1 family members shown in Fig. 3A and permits refinement of the conserved features of this domain (Fig. 3B). This analysis reveals that the SNH is anchored approximately 20 amino acids carboxy-terminal to the kinase domain, spans approximately 45 amino acids, and extends further toward the amino terminus than previously reported. Our consensus identifies amino acids exhibiting greater than 70% conservation among the SNF1 family members as residues that are specific for particular SNF1 kinase subfamilies.

Although most conserved residues are shared among all family members, some residues are relatively specific for a particular subfamily. For example, the consensus amino acid at position 32 of the SNH is glutamine in subfamily I SNF1 kinases and tyrosine in subfamily II kinases. Subclass-specific residues are also found at positions 37 (A versus V) and 45 (K/R versus N). More distantly related SNF1 family members such as Wpk4 and KIN1 also have SNH domains, though the degree of homology is lower and in some cases the spacing is not conserved. Outside of its kinase and SNH domains, Hunk displays no detectable homol-
ogy to other members of the SNF1 family or to other known molecules.

**Chromosomal Localization**

The mouse chromosomal location of *Hunk* was determined by interspecific backcross analysis using progeny derived from matings of [(C57BL/6J × *M. spreutus*)F1 × C57BL/6J] mice (Fig. 4). This interspecific backcross mapping panel has been typed for over 2800 loci that are well distributed among all the autosomes as well as the X chromosome (Copeland and Jenkins, 1991). C57BL/6J and *M. spreutus* DNA samples were digested with several enzymes and analyzed by Southern blot hybridization for informative restriction fragment length polymorphisms (RFLPs) using a mouse *Hunk* cDNA probe. The 5.8-kb SacI *M. spreutus* RFLP (see Materials and Methods) was used to follow the segregation of the *Hunk* locus in backcross mice. The mapping results indicated that *Hunk* is located in the distal region of mouse chromosome 16 linked to *App, Tiam1,* and *Erg.* Although 104 mice were analyzed for every marker and are shown in the segregation analysis (Fig. 4), up to 152 mice were typed for some pairs of markers. Each locus was analyzed in pairwise combinations for recombination frequencies using the additional data. The ratios of the total number of mice exhibiting recombinant chromosomes to the total number of mice analyzed for each pair of loci and the most likely gene order are: centromere→*App*→*Hunk*→*Tiam1*→*Tiam2*→*Erg* (see Materials and Methods). No recombinants were detected between *Hunk* and *Tiam1* in 130 animals typed in common, suggesting that the two loci are within 2.3 cM of each other (upper 95% confidence limit).

We have compared our interspecific map of chromosome 16 with a composite mouse linkage map that reports the map location of many uncloned mouse mutations (http://www.informatics.jax.org/). *Hunk* mapped in a region of the composite map that lacks mouse mutations (data not shown).
CLONING OF A NOVEL MAMMALIAN SNF1-RELATED KINASE

Hunk Encodes a Functional Protein Kinase

To address whether Hunk encodes a functional kinase, transgenic mice were engineered to overexpress Hunk in the mammary gland using the mouse mammary tumor virus LTR to direct Hunk expression (Gardner et al., submitted for publication). Affinity-purified amino-terminal and carboxyl-terminal anti-Hunk antisera were used in immunoblotting experiments to detect Hunk in protein extracts prepared from the mammary glands of wildtype mice or MMTV-Hunk transgenic mice harvested at day 9 of lactation studies revealed intense organ-specific expression of Hunk protein as substrates (Fig. 5B; and data not shown). Hunk immunoprecipitates were able to phosphorylate both histone H1 and MBP in vitro. As predicted based on the relative quantities of Hunk immunoprecipitated from transgenic and wildtype mammary glands, Hunk-associated phosphotransferase activity was substantially greater in immunoprecipitates prepared from transgenic compared to wildtype mammary glands. No activity was observed in immunoprecipitates prepared from a cell line known not to express Hunk mRNA. These findings demonstrate that anti-Hunk antisera coimmunoprecipitate Hunk and a phosphotransferase, strongly suggesting that Hunk encodes a functional protein kinase.

Analysis of Hunk mRNA Expression

To begin to analyze the biological role played by Hunk, the spatial and temporal pattern of mRNA expression of this gene was determined both during fetal development and in adult tissues in the mouse. Northern hybridization analysis was performed on RNA isolated from FVB embryos at embryonic days E6.5, E13.5, and E18.5 using a unique Hunk cDNA probe. Hunk expression was not detected at E6.5, was dramatically up-regulated at E13.5, and was subsequently down-regulated at E18.5 (Fig. 6A). Similar to results obtained in mammary epithelial cells, analysis of embryonic mRNA revealed Hunk mRNA transcripts approximately 5.1 and 5.6 kb in length. Unlike expression in the mammary epithelial cell line, however, the 5.6-kb Hunk mRNA transcript was more abundant than the 5.1-kb transcript at E13.5, whereas the abundance of the two transcripts was equivalent at E18.5. This pattern suggests that Hunk transcripts may be regulated in both a developmental stage-specific and a tissue-specific manner.

To determine the spatial localization of Hunk mRNA expression during fetal development, 35S-labeled antisense probes were used to perform in situ hybridization on E13.5 and E18.5 embryos (Figs. 6B–6K). These studies revealed intense organ-specific expression of Hunk mRNA at E13.5 in the brain, skin, and developing bone, as well as more diffuse expression throughout the embryo. Expression of Hunk was more restricted at

![FIG. 4. Hunk maps in the distal region of mouse chromosome 16. Hunk was mapped to mouse chromosome 16 by interspecific backcross analysis. The segregation patterns of Hunk and flanking genes in 104 backcross animals that were typed for all loci are shown at the top of the figure. For individual pairs of loci, more than 104 animals were typed (see text). Each column represents the chromosome identified in the backcross progeny that was inherited from the (C57BL/6J × M. spretus)F1 parent. The shaded boxes represent the presence of a C57BL/6J allele, and white boxes represent the presence of a M. spretus allele. The number of offspring inheriting each type of chromosome is listed at the bottom of each column. A partial chromosome 16 linkage map showing the location of Hunk in relation to linked flanking genes is shown to the left of the chromosome, and the recombination distances between loci in centimorgans are shown to the left of the chromosome, and the positions of loci in human chromosomes, where known, are shown to the right. References for the human map positions of loci cited in this study can be obtained from the GDB (Genome Data Base).](image)
E18.5, with particularly prominent hybridization in the brain, lung, salivary gland, olfactory epithelium, skin, whisker hair follicles, and kidney. Thus, *Hunk* expression during fetal development occurs in a developmentally regulated and tissue-specific manner.

The distribution of *Hunk* expression in tissues of the adult mouse was analyzed by RNase protection (Fig. 7A). High levels of *Hunk* expression were detected in ovary, thymus, lung, and brain, with modest levels of expression in breast, uterus, liver, kidney, and duodenum. *Hunk* mRNA expression was very low or undetectable in heart, skeletal muscle, testis, spleen, and stomach.

The spatial pattern of *Hunk* expression was determined in murine tissues by *in situ* hybridization (Figs. 7B–7M). Interestingly, this analysis revealed that *Hunk* is expressed in only a subset of cells within each expressing organ. In the duodenum, *Hunk* is expressed in a subset of epithelial cells located in duodenal crypts, whereas little or no expression is observed in more differentiated epithelial cells of the duodenum or in the mesenchymal compartment of this tissue (Figs. 7B and 7C). Heterogeneity is also observed among the crypt cells themselves, whereby cells expressing *Hunk* mRNA at high levels are located adjacent to cells expressing *Hunk* at substantially lower levels. Heterogeneous expression patterns are also observed in other tissues. For instance, *Hunk* mRNA expression in the uterus is restricted to isolated epithelial cells located in mesometrial glands (Figs. 7D and 7E). Similarly, *Hunk* expression in the prostate is found within only a subset of ductal epithelial cells (Figs. 7F and 7G). *Hunk* expression in the ovary is found principally in the stroma, with little or no expression detected in developing follicles or corpora lutea (Figs. 7H and 7I). *Hunk* expression in the thymus is limited primarily to the thymic medulla with lower levels of expression in the thymic capsule (Figs. 7J and 7K). High-power examination revealed that, as in other tissues, expression in the thymic medulla is markedly heterogeneous (Fig. 7L). *Hunk* is expressed throughout the brain, with particularly high levels in the cortex, dentate gyrus, and CA1–3 region of the hippocampus (Fig. 7M). High-power examination also revealed marked heterogeneity in *Hunk* expression among different cell types in the cerebral cortex (data not shown). Thus, *Hunk* is expressed in a variety of tissues of the adult mouse, and expression within these tissues is generally restricted to a subset of cells within a particular compartment or compartments.
FIG. 7. Tissue-specific expression of Hunk in adult tissues. (A) RNase protection analysis of Hunk mRNA expression in tissues of the adult mouse. 30 μg of RNA isolated from the indicated murine tissues was hybridized with antisense RNA probes specific for Hunk and for β-actin. (B-M) Spatial localization of Hunk expression in tissues of the adult mouse. Bright-field (B, D, F, H, J) and dark-field (C, E, G, I, K, L, M) photomicrographs of in situ hybridization analysis performed on sections of duodenum (B, C), uterus (D, E), prostate (F, G), ovary (H, I), thymus (J-L), and brain (M), hybridized with a 35S-labeled Hunk antisense probe. No signal over background was detected in serial sections hybridized with a sense Hunk probe. Arrows indicate cells expressing Hunk at high levels. CA1 and CA3, regions of the hippocampus; cl, corpus luteum; co, cortex; d, epithelial duct; dg, dentate gyrus; eg, endometrial gland; fo, follicle; ic, intestinal crypt; me, medulla; mg, mesometrial gland; mu, mucosa; pc, parietal cortex; se, serosa; st, stroma. Magnification: 10× (M), 90× (H-K), 180× (B, C), 300× (D, E) or 500× (F, G, L, M).

DISCUSSION

We initially identified the novel serine/threonine kinase, Hunk, in a screen designed to isolate protein kinases involved in mammary development and carcinogenesis. We have now described the cloning, chromosomal localization, and activity of this kinase and have characterized its expression in the mouse. Hunk is located on distal mouse chromosome 16, is transcribed as 5.1- and 5.6-kb mRNA species, and encodes an 80-kDa protein containing each of the amino acid motifs characteristic of serine/threonine kinases. Consistent with this, antisera that specifically immunoprecipitate Hunk coimmunoprecipitate phosphotransferase activity, and overexpression of Hunk in mammary epithelial cells increases the level of this phosphotransferase activity. Hunk expression in the mouse is developmentally regulated and tissue-specific both during fetal development and in the adult. Interestingly, within multiple tissues Hunk expression is restricted to subsets of cells within specific cellular compartments. These data suggest a role for Hunk in developmental processes in multiple tissues.

Several lines of evidence suggest that the Hunk cDNA sequence obtained represents the full-length Hunk ORF. First, Northern hybridization analysis of poly(A)+ RNA isolated from mammary epithelial cell lines using a Hunk-specific cDNA probe identifies a predominant mRNA species 5.1 kb in length, consistent with the 5025-nt cDNA sequence obtained for clone E8. Second, in vitro transcription and translation
of clone E8 yield a polypeptide that is detected by anti-Hunk antisera, that comigrates with endogenous Hunk, and whose size is consistent with that predicted for the Hunk ORF. Third, comparison of the sequence of clone E8 with a recently isolated human Hunk cDNA clone reveals a high level of homology within the predicted ORF and a lower level of homology 5' of the predicted initiation codon and 3' of the predicted termination codon (H. P. Gardner et al., in preparation). Finally, the observation that anti-Hunk antisera appear to recognize a single polypeptide species in lysates from cells known to express both transcripts provides evidence that we have isolated the entire ORF and that the 5.6-kb Hunk mRNA contains additional 5' or 3' untranslated sequence. Taken together, these findings suggest that the cDNA clones isolated represent a full-length Hunk transcript and contain the complete coding region.

Within the kinase catalytic domain, Hunk is most closely related to the SNF1 family of protein kinases, although Hunk appears to define a new branch on the SNF1 family tree. SNF1 is composed of a heterotrimeric complex that is activated by glucose starvation and is required for the expression of genes in response to nutritional stress (Carlson et al., 1981; Celenza et al., 1989; Ciriacy, 1977; Fields and Song, 1989; Wilson et al., 1996; Yang et al., 1992, 1994; Zimmermann et al., 1977). Like SNF1, the mammalian SNF1-related kinase, AMPK, is involved in the cellular response to environmental stresses, particularly those that elevate cellular AMP:ATP ratios. Once activated, AMPK functions to decrease energy-requiring anabolic pathways such as sterol and fatty acid synthesis while upregulating energy-producing catabolic pathways such as fatty acid oxidation (Moore et al., 1991; Ponticos et al., 1998). AMPK complements the snf1 mutation in yeast and phosphorylates some of the same targets as SNF1 (Hardie, 1999; Hardie et al., 1997, 1999; Woods et al., 1996). Like SNF1, AMPK is a heterotrimer composed of α, β, and γ subunits that are homologous to the subunits of SNF1 (Hardie, 1999). Thus, AMPK and SNF1 are closely related both functionally and structurally, demonstrating that the regulatory pathways in which they operate have been highly conserved during evolution.

Other SNF1 family members in plants, including Rkin1, BKin12, AKin10, NPK5, and Wpk4, have been implicated in nutritional and environmental stress responses (Alderson et al., 1991; Muranaka et al., 1994; Sano and Youssefian, 1994; Wilson et al., 1996). Like Hunk, several plant SNF1 family members are expressed in a tissue-specific manner. For example, AKin10 is expressed in roots, shoots, and leaves, whereas RKin1 is detected in developing endosperms but not in shoots (Alderson et al., 1991; Le Guen et al., 1992).

More recently, SNF1-related kinases have been identified in mammals and have been implicated in development processes, particularly in the regulation of cellular proliferation and differentiation. For instance, C-TAK1/p78 appears to be involved in cell cycle regulation based on its ability to phosphorylate and inactivate Cdc25c (Peng et al., 1997, 1998). Since Cdc25c controls entry into mitosis by activating cdc2, inactivation of Cdc25c by C-TAK1 would be predicted to regulate proliferation negatively. Consistent with this model, C-TAK1/p78 is down-regulated in adenocarcinomas of the pancreas (Parsa, 1988).

Perhaps the most compelling evidence that SNF1 kinases are involved in development is the observation that mutations in the C. elegans SNF1-related kinase PAR-1 result in an inability to establish polarity in the developing embryo (Guo and Kemphues, 1995). Specifically, par-1 mutations disrupt P granule localization, asymmetric cell divisions, blastomere fates, and mitotic spindle orientation during early embryogenesis. In an analogous manner, the mammalian PAR-1 homologue MARK2/Emk is asymmetrically localized in epithelial cells in vertebrates, and expression of a dominant negative form of MARK2 disrupts both cell polarity and epithelial cell–cell contacts (Bohm et al., 1997). In addition, overexpression of either MARK2 or its close family member MARK1 results in hyperphosphorylation of microtubule-associated proteins, disruption of the microtubule array, and cell death (Drewes et al., 1997).

Additional SNF1-related molecules, such as Msk and SNRK, have been implicated in vertebrate differentiation and development on the basis of their temporal and spatial patterns of expression (Becker et al., 1996; Ruiz et al., 1994). For example, Msk is expressed in presumptive myocardial cells during embryogenesis and is down-regulated following primitive heart tube formation, whereas SNRK is up-regulated during adipoocyte differentiation. In a similar manner, our analysis of Hunk mRNA expression patterns suggests the possibility of a developmental role for Hunk in specific tissues. Hunk is expressed at high levels in the embryo during midgestation as cells are rapidly proliferating and differentiating and is down-regulated in the embryo prior to parturition. During fetal development, Hunk mRNA is expressed in a tissue-specific manner and is restricted to particular compartments within expressing tissues. Similarly, Hunk is also expressed in a tissue-specific manner in the adult mouse, and its expression is restricted to subsets of cells within these tissues. In aggregate, these data indicate that SNF1 family members participate in a wide range of developmental processes in higher eukaryotes and suggest that Hunk may also play an important role in one or more of these processes.

Outside the catalytic domain, a region of homology exists between SNF1 family members previously described as the SNH, or SNF1 homology region (Becker et al., 1996). Since the distance between the catalytic domain and the SNH is conserved and since many kinases contain autoregulatory domains, it is plausible that the SNH domain functions to regulate kinase ac-
tivity (Yokokura et al., 1995). Consistent with this speculation is the presence of weak homology between the SNH domain of SNF1 kinases and the autoinhibitory domain of the closely related family of calcium-calmodulin regulated kinases (data not shown). This homology does not extend into the adjacent calmodulin binding region, consistent with the observation that SNF1 kinases are not regulated by calcium. Regardless, the presence of the SNH domain in all SNF1 kinases raises the possibility that members of this family of molecules may be regulated by a common mechanism.

The distal portion of mouse chromosome 16 shares a region of conserved synteny with human chromosome 21q (summarized in Fig. 4). In particular, Tiam1 has been mapped to 21q22.1. Mutations or segmental trisomy in this region of human chromosome 21 are associated with Alzheimer disease and Down syndrome, respectively. The close linkage between Tiam1 and Hunk in the mouse suggests that the human homologue of Hunk will map to 21q22, as well. In fact, BLAST alignment of Hunk to sequences in GenBank reveals homology to human genomic DNA sequences cloned from 21q22.1 (gi4835629). This indicates that the human homologue of Hunk lies within a region of chromosome 21q22 believed to contribute to several of the phenotypic features characteristic of Down syndrome (Delabar et al., 1993; Korenberg et al., 1994; Rahmani et al., 1989). In this regard, it is interesting to note that Hunk is expressed at high levels throughout the brain during murine fetal development as well as in the adult, with particularly high levels being found in the hippocampus, dentate gyrus, and cortex. Whether increased Hunk expression in the brain is related to the pathophysiology of Alzheimer disease or Down syndrome is unknown.

ACKNOWLEDGMENTS

The authors thank Christopher J. Sarkissian and Douglas B. Stairs for providing control antisera and technical expertise, members of the Chodosh laboratory for helpful discussions and for critically reading the manuscript, and Deborah B. Householder and Jayant V. Rajan for excellent technical assistance. This research was supported by the Elsa U. Pardee Foundation (L.A.C.), NIH Grants CA83849, CA71513, and CA78410 (L.A.C.) from the National Cancer Institute and the National Institute of Diabetes and Digestive and Kidney Diseases, RPG-99-259-01-DCC from the American Cancer Society (L.A.C.), the Dolores Zohrab Liebmann Fund (G.B.W.), the Charles E. Culpeper Foundation (L.A.C.), U.S. Army Breast Cancer Research Program Grants DAMD17-96-1-6112 (H.P.G.), DAMD17-99-1-9463, DAMD17-99-1-9349, and DAMD17-98-1-8226 (L.A.C.), and the National Cancer Institute, DHHS, under contract with ABL (N.A.J.). L.A.C. is a Charles E. Culpeper Medical Scholar.

REFERENCES


resembles mutations which activate the adenylate cyclase pathway. Genetics 129: 697–706.


Cloning, Characterization, and Chromosomal Localization of Pnck, a Ca\(^{2+}\)/Calmodulin-Dependent Protein Kinase

Heather Perry Gardner,* Jayant V. Rajan,* Seung I. Ha,* Neal G. Copeland,† Debra J. Gilbert,† Nancy A. Jenkins,† Sandra T. Marquis,* and Lewis A. Chodosh*†

*Department of Molecular and Cellular Engineering and †Division of Endocrinology, Diabetes, and Metabolism, 612 Biomedical Research Building III/IV, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, Pennsylvania 19104-6160; and ‡Mammalian Genetic Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201

Received September 20, 1999; accepted November 23, 1999

INTRODUCTION

Calcium is an important second messenger in eukaryotic cells. Many of the effects of calcium are mediated via its interaction with calmodulin and the subsequent activation of Ca\(^{2+}\)/calmodulin-dependent (CaM) kinases. CaM kinases are involved in a wide variety of cellular processes including muscle contraction, neurotransmitter release, cell cycle control, and transcriptional regulation. While CaMKII has been implicated in learning and memory, the biological role of the other multifunctional CaM kinases, CaMKI and CaMKIV, is largely unknown. In the course of a degenerate RT-PCR protein kinase screen, we identified a novel serine/threonine kinase, Pnck. In this report, we describe the cloning, chromosomal localization, and expression of Pnck, which encodes a 38-kDa protein kinase whose catalytic domain shares 45-70% identity with members of the CaM kinase family. The gene for Pnck localizes to mouse chromosome X, in a region of conserved synteny with human chromosome Xq28 that is associated with multiple distinct mental retardation syndromes. Pnck is upregulated during intermediate and late stages of murine fetal development with highest levels of expression in developing brain, bone, and gut. Pnck is also expressed in a tissue-specific manner in adult mice with highest levels of expression detected in brain, uterus, ovary, and testis. Interestingly, Pnck expression in these tissues is restricted to particular compartments and appears to be further restricted to subsets of cells within those compartments. The chromosomal localization of Pnck, along with its tissue-specific and restricted pattern of spatial expression during development, suggests that Pnck may be involved in a variety of developmental processes including development of the central nervous system.

Many protein kinases function as intermediates in signal transduction pathways that control complex processes such as differentiation, development, and carcinogenesis (Birchmeier et al., 1993; Bolen et al., 1992; Rawlings and Witte, 1994). Accordingly, studies of protein kinases in a wide range of biological systems have led to a more comprehensive understanding of the regulation of cell growth and differentiation (Bolen, 1993; Fantl et al., 1993; Hardie, 1990). Not surprisingly, several members of the protein kinase family have been shown to be involved in the pathogenesis of cancer both in humans and in rodent model systems (Cardiff and Muller, 1993; Dickson et al., 1992; Guy et al., 1992, 1994; Slamon et al., 1989). In light of these findings, we performed a screen designed to identify and study the role of protein kinases in mammary development and carcinogenesis (Chodosh et al., 2000, in press; Gardner et al., in press; Stairs et al., 1998). In the course of these studies, we identified a novel serine/threonine kinase, Pnck (pregnancy-upregulated nonubiquitous CaM kinase), that is related to the Ca\(^{2+}\)/calmodulin-dependent (CaM) family of protein kinases.

Ca\(^{2+}\) is an important intracellular second-messenger molecule in eukaryotic signal transduction pathways. Many of the effects of Ca\(^{2+}\) are mediated through its interaction with the Ca\(^{2+}\)-binding protein, calmodulin. The Ca\(^{2+}\)/calmodulin complex is, in turn, required for maximal activation of CaM-dependent protein kinases, which ultimately regulate cellular processes as diverse as neurotransmitter release, metabolism, and gene transcription (Fukunaga and Miyamoto, 1999; Lukas et al., 1998; Matthews et al., 1994; Nairn and Piciotto, 1994; Polishchuk et al., 1995; Schulman, 1993; Sheng et al., 1991). In addition to their regulation by CaM, CaM kinases share structural and functional homology both in the kinase catalytic domain and in a regulatory region composed of composite autoinhibitory and CaM-
binding domains (Hanks and Quinn, 1991; Hanks et al., 1988; Haribabu et al., 1995; Knighton et al., 1992; Picciotto et al., 1996; Yokokura et al., 1995). Despite these similarities, significant differences exist between CaM kinase family members. For instance, this family includes members with high substrate specificity, such as myosin light-chain kinase (MLCK) and phosphorylase kinase, as well as members with broader substrate specificities collectively referred to as the multifunctional CaM kinases, such as CaMKI, CaMKIV, and members of the CaMII subfamily (Braun and Schulman, 1995; Cawley et al., 1993; Herring et al., 1990; Matthews et al., 1994; Schulman, 1993). Other properties that differ among CaM kinase family members include their subcellular localization, regulation by autophosphorylation, and regulation by other proteins. In addition, CaM kinases have unique amino- and carboxyl-terminal domains that contribute to kinase-specific differences in subcellular localization, subunit interactions, and other protein–protein interactions.

Much of the information available regarding the multifunctional CaM kinases is derived from studies conducted in the brain, in part because each of these kinases is expressed at high levels in this organ. However, CaMII is the only multifunctional CaM kinase whose biological function has been defined (Hanley et al., 1987; Jensen et al., 1991b; Lin et al., 1987; Picciotto et al., 1993; Tobimatsu and Fujisawa, 1989; Tobimatsu et al., 1988). The CaMII holoenzyme is an oligomeric complex composed of combinations of independently encoded, highly homologous α, β, γ, and δ subunits. Mice with targeted disruption of CaMIIα are deficient in long-term potentiation and exhibit specific defects in learning and memory (Silva et al., 1992a, b). Unlike the α subunit of CaMII whose expression is restricted to the brain, CaMII, CaMKIV, and the δ and γ subunits of CaMII have a broader tissue distribution and therefore presumably have as yet unrecognized functions in other tissues (Hanley et al., 1987; Lin et al., 1987; Naito et al., 1997; Picciotto et al., 1993, 1995; Tobimatsu and Fujisawa, 1989; Tobimatsu et al., 1988).

In this report, we describe the cloning, chromosomal localization, and initial characterization of Pnck, a member of the CaM kinase family of protein serine/threonine kinases. We have isolated cDNA clones for Pnck that encode a 38-kDa polypeptide. The gene for Pnck localizes to mouse chromosome X in a region of conserved synteny with human chromosome 9q28 that has been implicated in distinct mental retardation syndromes (Lubs et al., 1999). Pnck expression is developmentally regulated and tissue-specific during murine fetal development with high levels of expression in developing brain, bone, and gut. Pnck expression is also tissue-specific in adult mice with highest levels of expression in the hippocampus and dentate gyrus of the brain. Interestingly, within expressing tissues, Pnck expression is restricted to subsets of cells within particular compartments. These data suggest a role for Pnck in the development of the central nervous system and other tissues.

**MATERIALS AND METHODS**

**Cloning of a full-length Pnck cDNA.** The original catalytic domain fragment, Bsk3, was isolated from first-strand cDNA derived from mammary glands of mice at day 2 of postlactational involution using the degenerate oligonucleotide primers BSTKα (5'-GGGCGCGGATCCG/G/A/G/C/A/G/G/A/G/C/A/G/C/T-3') and PT-KIα (5'-CCGGGGAATTCCA/G/A/G/C/A/G/G/A/G/C/A/G/C-A/T-3') (Chodosh et al., in press; Wilks, 1989, 1991; Wilks et al., 1989). This original fragment, corresponding to nucleotides 501 to 704 of full-length Pnck, was used to screen 5 × 10⁶ lambda phage plaques from an oligo(dT)-primed murine brain cDNA library according to standard protocols (CPMB). Primary screening yielded a total of 73 clones of varying hybridization intensity that were positive on duplicate filters. Ten clones with medium to high hybridization intensity were plaque purified, and plasmids were liberated by in vivo excision according to the manufacturer's instructions (Stratagene).

**Sequence analysis.** Sequence analysis, including prediction of open reading frames, calculation of predicted molecular weights, multiple sequence alignment, and phylogenetic analysis, was performed using MacVector (Oxford Molecular Group), ClustalW, ClustaiX, and DendroMaker 4.0. Pairwise and multiple sequence alignments of kinase catalytic domains I–XI were performed using the ClustalW alignment program. Calculations were made using the BLOSUM series with an open gap penalty of 10, an extended gap penalty of 0.05, and a delay divergent of 40%. Phylogenetic calculations with the same parameters were performed using the ClustalX multisequence alignment program. An unrooted phylogenetic tree was drawn using DendroMaker 4.0.

**Tissue preparation.** FVB mouse embryos were harvested at specified time points following timed matings. Day 0.5 postcoital was defined as noon of the day on which a vaginal plug was observed. Tissues used for RNA preparation were harvested from 15- to 16-week-old virgin mice and snap-frozen on dry ice. Tissues used for in situ hybridization analysis were embedded in OCT compound.

**RNA analysis.** RNA was prepared by homogenization of snap-frozen tissue samples in guanidinium isothiocyanate supplemented with 7 M urea 2-mercaptoethanol followed by ultracentrifugation through cesium chloride as previously described (Marquis et al., 1995; Rajan et al., 1997). Poly(A)⁺ RNA was selected using oligo(dT) cellulose (Pharmacia), separated on a 1% LE agarose gel, and passively transferred to a Gene Screen membrane (NEN). Northern hybridization was performed as described using a ³²P-labeled cDNA probe encompassing nucleotides 1135 to 1509 of Pnck generated by random-primed labeling (BMB) (Marquis et al., 1995). Southern hybridization analysis was performed on a zebiot (Clontech) hybridized with a ³²P-labeled cDNA probe corresponding to nucleotides 1321 to 1509 from the 3'-UTR of Pnck. Hybridization and washes were performed according to the manufacturer's directions (Clontech). A single band was detected in genomic DNA from both mouse and rat, confirming that, under these conditions, this Pnck-specific 3'-UTR probe recognizes a single locus.
Ribbonuclease protection analysis was performed as described (Marquis et al., 1995). Body-labeled antisense riboprobes were generated using linearized plasmids containing nucleotides 1321 to 1509 of Pnck and 1142 to 1241 of β-actin (GenBank Accession No. X03672) using [α-32P]UTP and the Promega in vitro transcription system with T7 polymerase. A β-actin antisense riboprobe was added to each reaction as an internal control. Probes were hybridized with RNA samples at 58°C overnight in 50% formamide/100 mM Pipes (pH 6.7). Hybridized samples were digested with RNase A and T1, purified, electrophoresed on a 6% denaturing polyacrylamide gel, and subjected to autoradiography.

In vitro transcription and translation. In vitro transcription and translation were performed on 1 μg of plasmid DNA using rabbit reticulocyte lysates and the presence of [35S]methionine according to the manufacturer's instructions (TNT kit, Promega). Completed reactions were electrophoresed on a 10% SDS-PAGE gel and were subjected to autoradiography.

Interspecific mouse backcross mapping. Interspecific backcross progeny were generated by mating (C57BL/6J × M. spretus)F1 females and C57BL/6J males as described (Copeland and Jenkins, 1991). A total of 205 N2 mice were used to map the Pnck locus (see text for details). DNA isolation, restriction enzyme digestion, agarose gel electrophoresis, Southern blot transfer, and hybridization were performed essentially as described (Jenkins et al., 1982). All blots were probed with Hybond-N+ nylon membrane (Amersham). The probe, a 375-bp fragment corresponding to nucleotides 1135 to 1509 of mouse Pnck cDNA, was labeled with [α-32P]dCTP using a nick-translation labeling kit (Boehringer Mannheim); washing was performed at a final stringency of 1.0× SSC, 0.1% SDS at 65°C. A fragment of 13.0 kb was detected in PstI-digested C57BL/6J DNA, and a fragment of 5.1 kb was detected in PstI-digested M. spretus DNA. The presence or absence of the 5.1-kb PstI M. spretus-specific fragment was followed in backcross mice.

A description of the probes and RFLPs for the loci linked to Pnck including Tnfβ, Il-1α, and Ar has been reported previously (Cennamini et al., 1998). Recombination distances were calculated using Map Manager, version 2.6.5. Gene order was determined by minimizing the number of recombination events required to account for the allele distribution patterns.

In situ hybridization. In situ hybridization was performed as described (Marquis et al., 1995). Antisense and sense probes were synthesized with the Promega in vitro transcription system using [35S]UTP and [32S]CTP from the T7 and SP6 RNA polymerase promoters of a PCR template containing sequences corresponding to nucleotides 1135 to 1509 of Pnck.

RESULTS

To isolate regulatory molecules potentially involved in development and carcinogenesis, a degenerate RT-PCR-based screen was performed to identify protein kinases expressed in murine breast cancer cell lines and in the mammary gland during development (Chodosh et al., 1999, in press; Gardner et al., in press; Stairs et al., 1998). This screen resulted in the identification of 41 protein kinases including 33 tyrosine kinases and 8 serine/threonine kinases, 3 of which were novel.

One of these novel kinases, originally called Bstk3, is the subject of this study. Bstk3 was subsequently found to be upregulated in the mammary gland during pregnancy and to be expressed in a punctate pattern in multiple tissues. Therefore, Bstk3 was renamed Pnck, for pregnancy-upregulated, nonubiquitous CaM kinase, to reflect this unique temporal and spatial expression pattern.

Isolation of cDNA Clones Encoding Pnck

Of approximately 1500 clones examined in the context of a screen for expressed protein kinases, a single clone corresponding to Bstk3 was isolated from the mammary glands of mice undergoing early postnatal-regional regression. To isolate the full-length mRNA transcript from which Bstk3 was derived, this initial 204-bp RT-PCR product was used to screen a murine brain cDNA library. Three cDNA clones ranging from 1455 to 1554 nucleotides in length were isolated by these means. All three clones were completely sequenced and were found to differ only in their respective 5′-UTRs (Fig. 1B). The sequence of each cDNA clone contains the entire 204-bp RT-PCR fragment, Bstk3, as well as a 1029-nucleotide open reading frame (ORF) and a 420-bp 3′-UTR containing a polyadenylation signal and poly(A) tract (Fig. 1A).

Inspection of the nucleotide sequence surrounding the putative initiation codon at nucleotide 105 of the longest clone, U7, reveals matches with the Kozak translational initiation consensus sequence at positions −1, −3, −5, and −6 (Kozak, 1987, 1991). Conceptual translation of the Pnck ORF yields a 343-amino-acid polypeptide of predicted molecular mass 38.6 kDa. The coding sequence for Pnck can be divided into a 14-amino-acid unique amino-terminal segment, a 256-amino-acid kinase catalytic domain, a 41-amino-acid regulatory domain, and a 32-amino-acid unique carboxyl-terminal region. The Pnck kinase catalytic domain contains all of the amino acid motifs conserved among serine/threonine kinases.

To determine whether the lengths of the cDNA clones encoding Pnck are consistent with the size of the Pnck mRNA transcript, Northern hybridization was performed. Due to potential cross-hybridization between Pnck and homologous CaM kinase family members, Southern hybridization was used to confirm the specificity of a probe generated from the 3′-UTR of Pnck (data not shown). This Pnck-specific probe was used for Northern hybridization analysis performed on poly(A)+ RNA isolated from adult murine brain. Consistent with the lengths of the isolated Pnck cDNA clones, this analysis revealed an mRNA transcript approximately 1.6 kb in length (Fig. 2A).

To confirm the coding potential of the Pnck ORF, in vitro transcription and translation were performed in the presence of [35S]methionine using each of the three Pnck cDNA clones as template. In each case, incubation of plasmid DNA with reticulocyte lysate yielded a single labeled polypeptide species of approximately 38 kDa, consistent with the predicted Pnck ORF (Fig. 2B). This demonstrates that the predicted initiation codon is capable of functioning as a translation initiation site. Since clone U7 contains multiple in-frame termination codons upstream of this putative initiation codon, these findings suggest that we have isolated the entire Pnck coding sequence. However, since the alternate 5′-UTR sequence present in clone V1 does not contain
an upstream termination codon, we cannot exclude the possibility that alternate polypeptides encoded by the *Pnck* locus that have distinct amino-terminal sequences exist.

**Homology to Related Protein Kinases**

Multiple sequence alignment of Pnck kinase catalytic subdomains I–XI was used to determine the relationship between Pnck and other CaM kinases (Fig. 3) (Hanks and Quinn, 1991; Hanks et al., 1988). Pnck lies within the group of multifunctional CaM kinases and is most similar to CaMKII. Within the kinase domain, Pnck is 70% identical to CaMKII, 50% identical to CaMKIV, and approximately 45% identical to members of the CaM kinase II subfamily at the amino acid level. Pnck is also homologous to members of the CaM kinase family in the regulatory domain, although the extent of similarity is lower than that found in the catalytic domain. While Pnck is most closely related to CaMKII in both the catalytic and
Analysis and depiction of results were performed using the ClustalX multisequence alignment program and DendroMaker 4.0. Evolutionary relationships are proportional to horizontal branch distances. Phylogenetic tree illustrating the relationship of Pnck and CaMKI is significantly lower than that between CaMKII subfamily members, most of which exhibit greater than 90% amino acid identity within their catalytic and regulatory domains. Moreover, outside of these conserved functional domains, the amino- and carboxyl-terminal regions of Pnck bear no significant similarity to CaMKI, CaMKIV, or other CaM kinase family members.

**Chromosomal Localization**

The chromosomal location of murine Pnck was determined by interspecific backcross analysis using progeny derived from matings of [(C57BL/6J × M. spretus)F₁ × C57BL/6] mice. This interspecific backcross mapping panel has been typed for over 2800 loci that are well distributed among all the autosomes as well as the X chromosome (Copeland and Jenkins, 1991). C57BL/6J and M. spretus DNAs were digested with several enzymes and analyzed by Southern blot hybridization for informative restriction fragment length polymorphisms (RFLPs) using a cDNA probe specific for the 3'-UTR of Pnck. The 5.1-kb PstI M. spretus RFLP (see Materials and Methods) was used to follow the segregation of the Pnck locus in backcross mice. The mapping results indicated that Pnck is located in the central region of the mouse X chromosome linked to Tnfsf5, Illrak, and Ar. Although 106 mice were analyzed for every marker and are shown in the segregation analysis (Fig. 4), up to 142 mice were typed for some pairs of markers. Each locus was analyzed in pairwise combinations for recombination frequencies using the additional data. The ratios of the total number of mice exhibiting recombinant chromosomes to the total number of mice analyzed for each pair of loci and the most likely gene order are centromere–Tnfsf5–15/137–Pnck–0/134–Illrak–9/142–Ar. The recombination frequencies expressed as genetic distances in centimorgans ± the standard error are –Tnfsf5–11.0 ±...
No recombinants were detected between *Pnck* and *II1rak* in 134 animals typed in common, suggesting that the two loci are within 2.2 cM of each other (upper 95% confidence limit).

We have compared our interspecific map of the X chromosome with a composite mouse linkage map that reports the map location of many uncloned mouse mutations (provided from Mouse Genome Database, http://www.informatics.jax.org/). *Pnck* maps to a region of the composite map that lacks uncloned mouse mutations (data not shown). The central region of the mouse X chromosome shares a region of conserved homology with the long arm of the human X chromosome (summarized in Fig. 4). In particular, *II1rak* has been mapped to Xq28. The close linkage between *II1rak* and *Pnck* in mouse suggests that the human homologue of *Pnck* will map to Xq28, as well.

**Analysis of Pnck mRNA Expression**

To begin to determine the biological role of *Pnck*, the developmental expression pattern of *Pnck* mRNA was analyzed during murine embryogenesis. Northern hybridization analysis was performed on poly(A)' RNA isolated from embryos during early, mid-, and late gestation using a *Pnck*-specific probe (Fig. 5A). Compared to mRNA expression levels in early embryogenesis, steady-state *Pnck* mRNA levels are markedly upregulated in the embryo during midgestation and remain elevated through embryonic day 18.5.

To investigate the spatial pattern of *Pnck* expression during fetal development, *in situ* hybridization analysis was performed on embryonic sections at day 14.5 of gestation using an 32P-labeled *Pnck*-specific antisense probe (Fig. 5B). This analysis revealed tissue-specific expression of *Pnck* in the embryo at midgestation with the highest levels of expression detected in developing bone, the outer lining of the stomach, and the developing central nervous system, including periventricular regions and the trigeminal ganglion.

The expression profile of *Pnck* in tissues of the adult mouse was determined by RNase protection analysis (Fig. 6A). As in the embryo, *Pnck* expression in the adult mouse is highest in brain. In addition, moderate to low levels of *Pnck* expression are detected in hormonally responsive tissues such as uterus, ovary, testis, and mammary gland, as well as in other tissues such as stomach, heart, and skeletal muscle. Lower, but detectable, levels of *Pnck* expression were observed in thymus, spleen, duodenum, and lung.

Finally, the spatial expression pattern of *Pnck* in adult murine tissues was determined by *in situ* hybridization analysis (Fig. 6B–M). Interestingly, within expressing tissues *Pnck* mRNA was detected in only a subset of cells. In the brain, *Pnck* expression is highest in the dentate gyrus and CA1–3 regions of the hippocampus (Figs. 6B, 6C, 6G, and 6I). *Pnck* is also expressed at relatively high levels in the cortex and is markedly heterogeneous with highly expressing cells found adjacent to nonexpressing cells (Figs. 6J and 6K). *Pnck* is expressed throughout the ovary, but is preferentially localized in the thecal cell layers immediately surrounding the corpora lutea (Figs. 6H and 6I). In the testis, *Pnck* is expressed at high levels in mature spermatids residing at the center of seminiferous tubules and, to a lesser extent, in cells located adjacent to the basement membrane (Figs. 6D and 6E). Finally, in the dorsolateral prostate, *Pnck* mRNA is detected in a stromal layer of cells immediately surrounding the prostatic epithelial ducts. As in other tissues, *Pnck* expression in this compartment is spatially heterogeneous (Figs. 6L and 6M).

**DISCUSSION**

We have described the cloning, chromosomal localization, and developmental expression pattern of *Pnck*,...
A new member of the CaM kinase family of serine/threonine kinases that is most closely related to CaMKI. Pnck expression during embryogenesis is developmentally regulated and tissue-specific with highest levels of expression detected in the developing brain, bone, and gut. Interestingly, Pnck expression in adult animals is both tissue-specific and markedly heterogeneous. Pnck expression is restricted to specific compartments within several tissues. Moreover, within these compartments, Pnck expression is heterogeneous with expressing cells found adjacent to non-expressing cells. The Pnck locus maps to the mouse X chromosome in a region of conserved synteny with human chromosome Xq28, a region associated with several mental retardation syndromes. In aggregate, our data suggest that Pnck may be involved in a variety of developmental processes.

Within the catalytic and regulatory domains conserved among all CaM kinases, Pnck is most closely related to the multifunctional CaM kinases, CaMKI, CaMKIV, and members of the CaMKII subfamily. CaMKI is a monomeric kinase that is expressed in

FIG. 6. Expression of Pnck in adult tissues. (A) RNase protection analysis of Pnck mRNA expression in tissues of the adult mouse. RNase protection analysis was performed using 30 μg of RNA isolated from the indicated murine tissues using antisense RNA probes specific for Pnck as well as for β-actin as an internal control. tRNA was used as a negative control for nonspecific hybridization. (B-M) Spatial localization of Pnck expression in tissues of the adult mouse. Bright-field (B, D, F, H, J, L) and dark-field (C, E, G, I, K, M) photomicrographs of in situ hybridization analysis performed on sections of brain (B, C, F, G, J, K), testis (D, E), ovary (H, I), and prostate (L, M), hybridized with an 35S-labeled Pnck antisense probe. No signal over background was detected in serial sections hybridized with a sense Pnck probe. Arrows and arrowheads indicate Pnck expressing and Pnck nonexpressing cells, respectively. bm, basement membrane; CA1 and CA3, regions of the hippocampus; co, cortex; d, duct; dg, dentate gyrus; fo, follicle; se, seminiferous tubule; sp, spermatids; st, stroma. Magnifications: 10× (B, C), 300× (D-M). Exposure times were 6–7 weeks.
multiple tissues and is reported to phosphorylate several substrates including synapsin, the cystic fibrosis transmembrane conductance regulator, and transcription factors such as the cyclic AMP response element-binding protein, CREB and ATF-1 (Lukas et al., 1998; Nairn and Picciotto, 1994; Nastuk and Nairn, 1996; Sheng et al., 1991). CaMKIV is located in the nucleus and has been proposed to mediate CaM-induced changes in gene expression (Jensen et al., 1991a; Sun et al., 1996). In contrast to CaMKI and IV, which function as monomers, CaMKII forms 300- to 600-kDa multimers composed of different combinations of α, β, γ, and δ subunits (Schulman, 1993). While the α and β subunits are expressed predominantly in brain, the γ and δ CaMKII subunits are expressed ubiquitously (Hanley et al., 1987; Lin et al., 1987; Tobimatsu and Fujisawa, 1989; Tobimatsu et al., 1988).

Functional analysis of CaM kinase mutants as well as crystal structure information has been used to define amino acids involved in the regulation of this family of molecules (Goldberg et al., 1996; Haribabu et al., 1995; Yokokura et al., 1995). Carboxyl-terminal to their catalytic domain, CaM kinases possess a regulatory region that is composed of an autoinhibitory domain and a CaM-binding domain. Current evidence suggests that CaM binding disrupts an interaction between the autoinhibitory domain and the kinase catalytic domain, thereby resulting in kinase activation. In contrast to other CaM kinases, the activities of CaMKI and CaMKIV are dependent upon phosphorylation by a CaM-dependent kinase kinase, CaMKK (Haribabu et al., 1995; Tokumitsu et al., 1994, 1995). Since Pnck may be regulated in a manner similar to that of other CaM kinases, particularly CaMKI, structural homologies between Pnck and other CaM kinases may help elucidate the mechanisms by which Pnck activity is regulated.

The homology between Pnck and CaMKI raises the issue of whether Pnck should be classified as a CaMKI family member. Currently, the only widely recognized CaM kinase subfamily is that of CaMKII. Primary amino acid sequences of CaMKII subfamily members are typically greater than 90% identical in the catalytic and regulatory domains and actually function together in a multiprotein complex. In contrast, while the 70% amino acid identity in the catalytic domain between Pnck and CaMKI is greater than that between Pnck and other CaM kinases, the similarity between Pnck and CaMKI is significantly less than the approximately 90% identity observed between CaMKII family members. Moreover, there is currently no evidence to suggest that CaMKI family members function as subunits in a manner analogous to CaMKII subfamily members. As such, while the primary amino acid sequence of Pnck is most similar to that of CaMKI, it is unclear at present whether this kinase should be classified as a CaMKI family member.

While this work was in progress, the rat homologue of Pnck was described and shown to be expressed as two isoforms, tentatively named CaMKIβ1 and CaMKIβ2 (Naito et al., 1997). Similar to the clones isolated for Pnck, CaMKIβ1 and CaMKIβ2 differ in their 5'-UTR regions and are homologous to Pnck clones V1 and U7, respectively. However, unlike the full-length clones isolated for Pnck, CaMKIβ1 contains a unique carboxy-terminal coding region that appears to result from an alternative splicing event. Whether this form exists in the mouse remains to be determined. Northern hybridization analysis using a probe encompassing portions of the highly conserved kinase domain and regulatory region of CaMKI isoforms detected a 1.8-kb band exclusively in brain, whereas a 4.0-kb band was detected in all other tissues. RT-PCR analysis detected approximately equal levels of CaMKIβ1 in all tissues examined in the rat, including tissues that we find to express low or undetectable levels of Pnck in the mouse as determined by RNase protection analysis using a probe specific for the 3'-UTR of Pnck. Insofar as the tissue-specific expression pattern of Pnck has been confirmed by in situ hybridization analysis, it is possible that cross-hybridization of the CaMKIβ probe used for Northern hybridization with other CaM kinases or the nonlinear nature of RT-PCR may underlie the discrepancy between the tissue-specific pattern of Pnck expression and the ubiquitous expression pattern reported for its rat homologue, CaMKIβ.

Several CaM kinases are expressed at high levels in the brain including CaMKI, CaMKII, and CaMKIV (Lukas et al., 1998; Miyano et al., 1992; Picciotto et al., 1995). In fact, it has been estimated that CaMKII accounts for approximately 22% of all protein found in the hippocampus (Hanson and Schulman, 1992). It is therefore perhaps not surprising that Pnck is also expressed at high levels in the murine brain both in the adult and during embryogenesis. In the adult brain, Pnck is expressed at highest levels in the hippocampus and dentate gyrus, two areas of the brain involved in learning and memory.

While expression of CaMKI, CaMKIV, and isoforms of CaMKII has been reported in tissues other than the brain, a physiological role for these enzymes in other tissues has not been described. Similar to these multifunctional kinases, Pnck is expressed in a variety of tissues other than the brain. Moreover, in most tissues examined, Pnck is expressed in a spatially heterogeneous manner with expression restricted to a subset of cells. Although little is known about the role of CaM or CaM kinases in development, evidence suggests that both CaM and CaM kinases may play such a role. Point mutations in the Drosophila calmodulin gene result in defects in development with phenotypes ranging from pupal lethality to ectopic wing vein formation and melanotic scales on the cuticle (Nelson et al., 1997). Additionally, CaMKIV has been implicated in T cell development based upon its regulation in the thymus during T cell development (Krebs et al., 1997). The observation that Pnck expression is developmentally regulated and spatially restricted to distinct compartments of the
• ovary, testis, prostate, and brain suggests that Pnck may play a biological role in these tissues. As such, the elucidation of signaling pathways in which Pnck is involved may shed light on the broader physiological role played by CaM kinases.

We have mapped the murine gene encoding Pnck to within 2.2 cM of Illrak in the central region of the X chromosome. The observation that Illrak, as well as markers that lie within 2.2 cM on either side of Illrak, have been mapped to human chromosome Xq28 strongly suggests that the human homologue of Pnck will map to Xq28 as well. Chromosome Xq28 is one of the most densely mapped regions of the human chromosome, and several distinct mental retardation syndromes including Fragile X and X-linked mental retardation (XLMR) have been mapped to this region (Knight et al., 1993; Lubs et al., 1999). Interestingly, the only biological role described for any of the multifunctional CaM kinases is that of CaMKII in learning and memory. This suggests that CaM kinases may play an important role in signal transduction pathways controlling cognitive function (Silva et al., 1992a, b; Soderling, 1993). In addition to mental retardation, many of these syndromes include phenotypes such as short stature, cleft palate, altered hand or digit size, and sterility (Lubs et al., 1999). Given that Pnck is expressed at high levels in the brain, developing ovary, and testis, it will be interesting to determine whether Pnck plays a role in one or more of these Xq28-linked syndromes.

**ACKNOWLEDGMENTS**

The authors thank Douglas B. Stairs for providing control expression plasmids, Deborah B. Householder for excellent technical assistance, and members of the Chodosh laboratory for helpful discussions and for critically reading the manuscript. This research was supported by the Elsa U. Pardee Foundation (L.A.C.), American Cancer Society RPG-99-259-01-DDC (L.A.C.), NIH Grants CA83849, CA71513, and CA78410 from the National Cancer Institute (L.A.C.), the Charles E. Culpeper Foundation (L.A.C.), and U.S. Army Breast Cancer Research Program Grants DAMD17-96-1-6112 (H.P.G.), DAMD17-98-1-5220 (L.A.C.), DAMD-99-1-9483 (L.A.C.), and DAMD-99-1-9549 (L.A.C.), and by the National Cancer Institute, DHHS, under contract with ABL (N.A.J.). L.A.C. is a Charles E. Culpeper Medical Scholar.

**REFERENCES**


Developmental role of the SNF1-related kinase Hunk in pregnancy-induced changes in the mammary gland

Heather Perry Gardner¹, George K. Belka¹, Gerald B. W. Wertheim¹, Jennifer L. Hartman¹, Seung I. Ha¹, Phyllis A. Gimotty², Sandra T. Marquis¹ and Lewis A. Chodosh¹,*

¹Department of Molecular & Cellular Engineering, 612 Biomedical Research Building II/III, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
²Department of Biostatistics and Epidemiology 631 Blockley Hall, University of Pennsylvania School of Medicine, 423 Guardian Drive, Philadelphia, PA 19104-6021, USA
³Division of Endocrinology, Diabetes and Metabolism, 612 Biomedical Research Building II/III, University of Pennsylvania School of Medicine, 421 Curie Boulevard, Philadelphia, PA 19104-6160, USA
*Author for correspondence (e-mail: chodosh@mail.med.upenn.edu)

Accepted 7 August; published on WWW 26 September 2000

SUMMARY

The steroid hormones 17β-estradiol and progesterone play a central role in the pathogenesis of breast cancer and regulate key phases of mammary gland development. This suggests that developmental regulatory molecules whose activity is influenced by ovarian hormones may also contribute to mammary carcinogenesis. In a screen designed to identify protein kinases expressed in the mammary gland, we previously identified a novel SNF1-related serine/threonine kinase, Hunk (hormonally upregulated Neu-associated kinase). During postnatal mammary development, Hunk mRNA expression is restricted to a subset of mammary epithelial cells and is temporally regulated with highest levels of expression occurring during early pregnancy. In addition, treatment of mice with 17β-estradiol and progesterone results in the rapid and synergistic upregulation of Hunk expression in a subset of mammary epithelial cells, suggesting that the expression of this kinase may be regulated by ovarian hormones. Consistent with the tightly regulated pattern of Hunk expression during pregnancy, mammary glands from transgenic mice engineered to misexpress Hunk in the mammary epithelium manifest temporally distinct defects in epithelial proliferation and differentiation during pregnancy, and fail to undergo normal lobuloalveolar development. Together, these observations suggest that Hunk may contribute to changes in the mammary gland that occur during pregnancy in response to ovarian hormones.

Key words: Mammary gland, Protein kinase, Transgenic, Cell differentiation, Hormone, Mouse, Hunk

INTRODUCTION

A wealth of epidemiological evidence indicates that ovarian hormones play a crucial role in the etiology of breast cancer (Kelsey et al., 1993). Specifically, the observations that early menarche, late menopause and postmenopausal hormone replacement therapy are each associated with increased breast cancer risk, whereas early oophorectomy is associated with decreased breast cancer risk, have led to the hypothesis that breast cancer risk is proportional to cumulative estradiol and progesterone exposure (Henderson et al., 1988; Pike et al., 1993). As such, elucidating the mechanisms by which hormones contribute to mammary carcinogenesis is a central goal of breast cancer research.

In addition to their roles in the pathogenesis of breast cancer, estradiol and progesterone are the principal steroid hormones responsible for regulating the development of the mammary gland during puberty, pregnancy and lactation (Topper and Freeman, 1980). For example, estradiol action is required for epithelial proliferation and ductal morphogenesis during puberty, whereas progesterone action is required for ductal arborization and alveolar differentiation during pregnancy (Bocchinfuso and Korach, 1997; Humphreys et al., 1997; Topper and Freeman, 1980). The effects of estradiol and progesterone in a given tissue are ultimately determined by the activation and repression of their respective target genes. Consequently, understanding the effects of estradiol and progesterone in the breast will require the identification of downstream targets of these hormones, and the analysis of these targets will undoubtedly contribute to our understanding of both mammary development and carcinogenesis.

Protein kinases function as molecular switches in signal transduction pathways that regulate cellular processes such as proliferation and differentiation. Accordingly, aberrant expression or mutations in several members of the protein kinase family have been shown to be involved in the pathogenesis of breast cancer both in humans and in rodent model systems (Cardiff and Muller, 1993; Cooper, 1990; Di Fiore et al., 1987; Muller et al., 1988). Moreover, overexpression of protein kinases such as ERBB2/neu in
human breast cancers has been shown to provide prognostic information relevant to clinical outcome and response to therapy (Klijn et al., 1993; Slamon et al., 1987, 1989). Given the important roles played by protein kinases in development and carcinogenesis, we previously carried out a PCR-based screen to identify kinase family members expressed either during mammary development or in epithelial cell lines derived from different transgenic mouse models of breast cancer (Chodosh et al., 1999, 2000). A total of 41 protein kinases were identified in this screen including 33 tyrosine kinases and eight serine/threonine kinases, three of which were novel (Chodosh et al., 2000; Gardner et al., 2000a,b; Stairs et al., 1998).

One of these novel kinases, Hunk, is an 80 kDa putative serine/threonine kinase that bears homology to the SNF1 family of protein kinases (Gardner et al., 2000b). Several members of this family, including SNF1 in Saccharomyces cerevisiae and AMP-activated protein kinase in mammals, regulate metabolic changes that occur in response to nutritional and environmental stresses (Hardie et al., 1994). Other SNF1-related kinases, including PAR1, MARK1, MARK2 and MARK3/KP78/C-TAK1, have been implicated in the regulation of developmental processes (Bohm et al., 1997; Guo and Kempheus, 1995; Peng et al., 1997; Ruiz et al., 1994). For example, in both Caenorhabditis elegans and Drosophila, par-1 is required for the establishment of anterior-posterior axis formation during embryogenesis (Guo and Kempheus, 1995; Shulman et al., 2000). Analogously, a mammalian homolog of PAR1, MARK2/EMK, is asymmetrically localized in polarized epithelial cells, and expression of a dominant negative form of MARK2 disrupts cell polarity (Bohm et al., 1997). Consistent with a developmental role for this molecule, disruption of murine Emk1 results in dwarfism, pituitary defects and hypertrophy (Bessone et al., 1999). Additional SNF1-related kinases such as MsK and SNRK have been implicated in vertebrate development on the basis of their temporal and spatial patterns of expression (Becker et al., 1996; Ruiz et al., 1994). These data suggest a role for SNF1 family members in development in higher eukaryotes.

We have previously described the cloning, activity and chromosomal localization of Hunk and have shown that Hunk mRNA expression is temporally and spatially regulated during embryonic development (Gardner et al., 2000b). In the developing embryo, Hunk is expressed at high levels within a subset of organs during mid-gestation and is downregulated in some, but not all, tissues prior to parturition. As in the embryo, Hunk expression in the adult mouse is tissue specific, with highest levels observed in ovary, lung and brain. Interestingly, within multiple tissues Hunk mRNA expression is restricted to specific compartments and within these compartments is further restricted to a subset of cells. For example, Hunk expression in the duodenum is limited to a subset of epithelial cells in duodenal crypts, whereas little or no expression is observed in more differentiated cells of the duodenal epithelium. The tissue-specific, temporally regulated and spatially restricted pattern of Hunk expression in the mouse suggest a developmental role for this kinase in multiple tissues.

In this report, we investigate the role of Hunk in the mammary gland. During postnatal mammary development, Hunk mRNA expression is spatially restricted to a subset of epithelial cells and is tightly regulated, with highest levels of expression occurring early in pregnancy. Moreover, treatment of mice with 17β-estradiol and progesterone results in the rapid and synergistic induction of Hunk expression in the mammary epithelium, suggesting that Hunk upregulation during early pregnancy may be due to increases in circulating levels of ovarian hormones. Finally, misexpression of Hunk in the mammary epithelium of MMTV-Hunk transgenic mice results in decreased proliferation and impaired differentiation of alveolar epithelial cells during distinct periods of pregnancy and lactation. Taken together, our data suggest that Hunk may contribute to mammary development by regulating pregnancy-induced changes in the alveolar epithelium that occur in response to estrogen and progesterone.

**MATERIALS AND METHODS**

**Animal and tissue preparation**

FVB mice were housed under barrier conditions with a 12-hour light/dark cycle. Mammary glands from pregnant females were harvested at specified timepoints after timed matings. Female mice were housed with male mice every third night and day 0.5 was defined as noon of the day on which a vaginal plug was observed. Gestational stage was confirmed by analysis of embryos. Transgenic mothers were housed with wild-type mothers immediately after parturition to ensure pup survival and equivalent suckling stimuli. Both transgenic and wild-type females were observed to nurse pups. For experiments involving chronic hormone treatment, adult female FVB mice were subject to bilateral oophorectomy and allowed to recover for two weeks prior to hormonal injections that were administered as previously described (Marquis et al., 1995). For short-term hormone administration experiments, four-month-old virgin female FVB mice were injected subcutaneously with either phosphate buffered saline (PBS) or a combination of 5 mg progesterone in 5% gum arabic and 20 µg of 17β-estradiol in PBS. Four animals from each treatment group were sacrificed 24±1 hours after injection. Tissues used for RNA analysis were snap frozen on dry ice. Tissues used for in situ hybridization analysis were embedded in OCT compound.

For whole mount analysis, number four mammary glands were spread on glass slides and fixed for 24 hours in 10% neutral buffered formalin. Glands were subsequently immersed in 70% ethanol for 15 minutes followed by 15 minutes in deionized water prior to staining in 0.05% Carmine/0.12% aluminum potassium sulfate for 24-48 hours. Glands were dehydrated sequentially in 70%, 90% and 100% ethanol for 10 minutes each, and then cleared in toluene or methyl salicylate overnight. For histological analysis, mammary glands were fixed as above and transferred to 70% ethanol prior to paraffin embedding. Sections 5 µm thick were cut and stained with Hematoxylin and Eosin. For BrdU analysis, animals were injected with 50 µg BrdU per g total bodyweight two hours before sacrifice followed by fixation and paraffin embedding.

**Generation of MMTV-Hunk transgenic mice**

A full-length cDNA clone, G3, encoding Hunk, was digested with Smal and SpeI to liberate a 3.2 kb fragment containing the complete coding sequence for Hunk (GenBank Accession number AF167987). This fragment was cloned downstream of the mouse mammary tumor virus long terminal repeat (MMTV LTR) into the multiple cloning site of pBS-MMTV-pA (E. Gunther, unpublished), which consists of the MMTV LTR upstream of the H-ras leader sequence (Huang et al., 1981) and SV40 splicing and polyadenylation signals. Linearized plasmid DNA was injected into fertilized eggs harvested from superovulated FVB mice. Tail-derived DNA was prepared as described (Hogan et al., 1994). Mice were genotyped by Southern hybridization analysis and by two independent PCR reactions designed to amplify a region within the SV40 portion of the transgene.
and a region spanning the junction between Hunk and SV40 sequences. A portion of the \textit{Gapdh} (glyceraldehyde-3-phosphate dehydrogenase) locus was amplified as a positive control for PCR reactions. Oligonucleotide primer sequences were \textit{Gapdh.F}, CTCAGTTCAAGGTGCTAAGCAAAGC; \textit{Gapdh.R}, AGGGTTTCT-TACCTCTGGAGCC; \textit{SV40.F}, CCTTAAACCGCTCTGTA-CG; \textit{SV40.B}, GACAGGCCCTCATCAGTAGTGG; Hunk.F, CCTTCTTCTCCTGGACCC; PolyA.A, AGCGGTAGTACCGTCC-ACG. Southern hybridization analysis of tail-derived genomic DNA digested with \textit{SphI} was performed according to standard methods using a probe specific to the \textit{SV40} portion of the transgene. Four founder mice were identified harboring the MMTV-Hunk transgene in tail-derived DNA that passed the transgene to offspring in a Mendelian fashion. These were screened for transgene expression by Northern hybridization and RNase protection analysis. One founder line, MHK3, was identified that expressed the MMTV-Hunk transgene at high levels. Of note, a subset of transgene-positive MHK3 animals was found not to express the MMTV-Hunk transgene. All MHK3 non-expressing animals were analyzed by Southern hybridization analysis to confirm transgene presence and the expected MHK3-specific integration site.

\textbf{RNA preparation and analysis}

RNA preparation, northern hybridization and labeling of cDNA probes was performed as previously described (Marquis et al., 1995). The \textsuperscript{32}P-labeled cDNA probe for \textit{Hunk} encompassed nucleotides 275 to 793 (GenBank Accession number AF167987). Probes for milk protein gene expression were: \textit{\beta}-casein, nt 181-719 (GenBank Accession number X04490); \kappa-casein, nt 125-661 (GenBank Accession number M10114); lactoferrin, nt 993-2065 (GenBank Accession number D85110); \textit{WAP}, nt 131-483 (GenBank Accession number X11158); and e-casein, nt 83-637 (GenBank Accession number V00740).

Ribonuclease protection analysis was performed as described using body-labeled antisense riboprobes specific to nucleotides 276 to 793 of \textit{Hunk} and 1142-1241 of \textit{\beta}-actin (GenBank Accession number X03672; Marquis et al., 1995). In order to distinguish transgenic from endogenous \textit{Hunk} expression in MHK3 animals, RNase protection analysis was performed using an antisense riboprobe spanning the 3' end of the \textit{Hunk} cDNA and the 5' end of the \textit{SV40} polyadenylation signal sequence. A \textit{\beta}-actin antisense riboprobe was added to each reaction as an internal control. Signal intensities were quantitated by phosphorimager analysis (Molecular Dynamics).

In situ hybridization was performed as described (Marquis et al., 1995; Roy et al., 1997) using a PCR template containing nucleotides 276 to 793 of \textit{Hunk}. Exposure times were 6 weeks in all cases.

\textbf{Protein analysis}

Generation of anti-Hunk antiserum, immunoblotting and immunoprecipitation were performed as described (Gardner et al., 2000b). Protein was extracted from mammary glands by dounce homogenization in EBC buffer as described (Gardner et al., 2000b). For immunoprecipitation, 500 \mu g of protein (3 mg/ml) was preclared with 1/10 of 1:1 protein A-agarose in PBS overnight at 4°C. Preclared lysate was centrifuged at 4°C in EBC (50 mM Tris-HCl, pH 7.9; 120 mM NaCl; 0.5% NP40) plus 5% Tween 20 (Biorad) with or without affinity-purified antiserum raised against the C terminus of Hunk (0.4 \mu g/ml). Immune complexes were precipitated by incubating with 40 \mu l of 1:1 protein A-agarose in PBS for 1 hour at 4°C. Complexes were washed sequentially with EBC plus 5% Tween 20, EBC (2x), and PBS (2x). One-fifth of the precipitated complexes were used in an in vitro kinase reaction as previously described with 5 \mu M ATP and 0.5 \mu g/\mu l histone H1 (Gardner et al., 2000b). The remaining precipitate was electrophoresed on a 10% SDS-PAGE gel, transferred onto a PVDF membrane, and immunoblotted with an antibody against the C terminus of Hunk as described (Gardner et al., 2000b).

\textbf{Immunohistochemistry}

Mammary glands from nulliparous wild-type and MHK3 transgenic females were fixed in 4% parafomaldehyde overnight and transferred to 70% ethanol prior to paraffin embedding. 5 \mu m sections were dewaxed in xylene and sequentially rehydrated in 100%, 95% and 70% ethanol, followed by PBS. Sections were incubated in Antigen Unmasking Solution (Vector) for 30 minutes at 100°C and then transferred to PBS at room temperature (RT). Sections were incubated for 2 hours at RT with antibody raised against the C terminus of Hunk, washed in PBS (x3), then incubated with 1:500 biotinylated goat anti-rabbit antibody (Vector) in 1% BSA/PBS for 30 minutes at RT. After washing in PBS (x3), slides were incubated in a 1:250 dilution of Avidin (Vector) for 15 minutes at RT and washed in PBS (3x). NBT and BCIP substrate addition was performed in alkaline phosphate buffer for 3 minutes according to manufacturer instructions (MBI). Sections were counterstained for 10 minutes in 0.5% (w/v) Methyl Green in 1.0 M NaOAc, pH 4.0.

\textbf{BrdU}

Paraffin-embedded 5 \mu m sections were dewaxed as above, pretreated in 2N HCl for 20 minutes at RT, washed in 0.1 M borate buffer, pH 8.5 (x2) and rinsed in PBS. BrdU immunohistochemistry was performed using the Vectastain Elite ABC Kit (Vector Laboratories), rat anti-BrdU IgG (Vector), and a secondary biotinylated rabbit anti-rat IgG antibody according to manufacturer instructions. Sections were counterstained with Methyl Green as described above. The areas of BrdU-positive and -negative nuclei were quantitated by color segmentation analysis of digitally captured images using Image-Pro Plus software (Media Cybernetics). The percentage of BrdU-positive epithelial cells was determined after normalizing nuclear area to the average nuclear size of either BrdU positive or negative cells.

\textbf{RESULTS}

\textit{Hunk}, initially termed Bstk1, was identified as a 207 bp RT-PCR product isolated from an epithelial cell line derived from a mammary adenocarcinoma arising in an MMTV-neu transgenic mouse (Chodosh et al., 1999, 2000; Gardner et al., 2000b). Bstk1 was subsequently renamed \textit{Hunk} to reflect the upregulation of this kinase in the mammary gland both during pregnancy and in response to ovarian hormones, as well as the preferential expression of this kinase in transgenic murine mammary epithelial cell lines overexpressing the \textit{neu/Erbb2} oncogene (this report and data not shown).

\textit{Hunk} expression is developmentally regulated in the mammary gland

RNase protection analysis was used to determine the temporal pattern of \textit{Hunk} expression during the postnatal development of the murine mammary gland (Fig. 1A). Mammary glands were harvested from male FVB mice, virgin mice at developmental time points prior to puberty (2 weeks), during puberty (5 weeks) and after puberty (10 weeks and 15 weeks), as well as from mice during early, mid and late pregnancy (days 7, 14 and 20), lactation (day 9), and postlactational regression (days 2, 7 and 28). This analysis revealed that steady-state levels of \textit{Hunk} mRNA were low and remained relatively constant throughout virgin development. During early pregnancy (day 7), when alveolar buds begin to proliferate rapidly and differentiate, \textit{Hunk} mRNA levels underwent a dramatic increase and then returned to baseline by mid-pregnancy (Fig. 1A,B). The apparent decline in \textit{\beta}-actin expression seen by RNase protection analysis during late...
Fig. 1. Temporal regulation of Hunk expression during mammary gland development. (A) RNase protection analysis of Hunk mRNA expression during postnatal developmental of the murine mammary gland. 40 µg of total RNA isolated from mammary glands at the indicated timepoints was hybridized to a 32P-labeled antisense RNA probe specific for Hunk. A 32P-labeled antisense RNA probe specific for β-actin was included in the same hybridization reaction as an internal loading control. (B) Phosphorimager analysis of RNase protection analysis in A. Hunk expression was quantitated and normalized to β-actin expression to correct for dilutional effects due to large-scale increases in expression of milk protein genes during late pregnancy and lactation. Expression levels are shown relative to adult virgin (15 wk). (C) In situ hybridization analysis of Hunk expression during pregnancy and lactation. Bright-field (top panel) and dark-field (bottom panel) photomicrographs of mammary gland sections from day 7 pregnant, day 20 pregnant or day 9 lactating animals hybridized with an 35S-labeled Hunk-specific antisense probe. No signal over background was detected in serial sections hybridized with a sense Hunk probe. Exposure times were identical for all dark-field photomicrographs to illustrate changes in Hunk expression during pregnancy. al, alveoli; d, duct; lo, lobule; st, adipose stroma.

pregnancy, lactation and early postlactational regression results from a dilutional effect that is due to large-scale expression of genes for milk proteins during these developmental stages (Buhler et al., 1993; Gavin and McMahon, 1992; Marquis et al., 1995). Normalization of Hunk expression to β-actin to control for this dilutional effect confirmed that Hunk expression returned to baseline levels by mid-pregnancy and decreased further during lactation and early postlactational regression (Fig. 1B). An essentially identical expression profile was observed during pregnancy when Hunk mRNA levels were normalized to cytokeratin 18, an epithelial-specific marker, indicating that developmental changes in Hunk expression are not the result of changes in epithelial cell content in the gland during pregnancy (data not shown). This conclusion is supported by the finding that Hunk mRNA expression levels decreased from day 7 to day 14 of pregnancy, despite ongoing increases in epithelial cell content that occur during this stage of development. Furthermore, changes in Hunk expression did not appear to be the result of increased cellular proliferation, since the pattern of Hunk expression observed during pregnancy did not correlate with levels of epithelial proliferation that, unlike Hunk expression, remained elevated during mid-pregnancy (see Fig. 5B).

In order to determine whether the observed pregnancy-induced changes in Hunk mRNA expression levels represent global changes in expression throughout the mammary gland, or changes in expressing subpopulations of cells, in situ hybridization was performed (Fig. 1C and data not shown). Consistent with the results from RNase protection analysis, in situ hybridization confirmed that Hunk expression in the mammary gland was highest at day 7 of pregnancy and decreased progressively throughout the remainder of pregnancy and lactation. This analysis also revealed that Hunk was expressed exclusively in the epithelium throughout mammary gland development and that Hunk upregulation during pregnancy appeared to result from both the upregulation
of Hunk in a subset of cells and an increase in the proportion of Hunk-expressing epithelial cells (Fig. 1C and data not shown).

The observation that cells highly expressing Hunk are found adjacent to non-expressing cells indicates that, as in other organs of the adult mouse, Hunk expression in the mammary gland is spatially restricted (Figs 1C and 2). This heterogeneous expression pattern is particularly striking in terminal end buds and epithelial ducts of the adolescent gland (Fig. 2). These data suggest that the murine mammary epithelium is composed of Hunk-expressing and Hunk non-expressing cell types.

Hunk expression is regulated by ovarian hormones

The observation that Hunk mRNA levels in the mammary gland increase during pregnancy suggests that the expression of this gene may be modulated by estrogen and progesterone. In order to test this possibility, oophorectomized FVB mice were treated for fourteen days with 17β-estradiol alone, progesterone alone, or a combination of both hormones. Intact (sham) and oophorectomized, non-hormone treated (OVX) animals were used for comparison.

Hunk mRNA levels were quantitated by RNase protection analysis of RNA prepared from mammary glands or uteri pooled from at least 10 animals in each experimental group (Fig. 3). Steady-state Hunk mRNA levels were approximately fourfold lower in the mammary glands of oophorectomized mice compared with intact mice, suggesting that maintenance of basal levels of Hunk expression in the mammary glands of nulliparous mice requires ovarian hormones (Fig. 3A). Treatment of oophorectomized animals with 17β-estradiol alone increased Hunk mRNA expression but to levels below those observed in intact animals, whereas treatment with progesterone alone increased Hunk mRNA expression to levels comparable with those observed in intact animals. In contrast, treatment of oophorectomized animals with both 17β-estradiol and progesterone resulted in a 14-fold increase in the level of Hunk mRNA relative to control oophorectomized animals and a 3-fold increase relative to intact animals, similar to increases in Hunk expression observed during early pregnancy. These observations suggest that the increase in Hunk mRNA expression observed in the mammary gland during early pregnancy may result, either directly or indirectly, from increases in circulating levels of estrogens and progesterone.

Treatment of mice with ovarian hormones also affected Hunk expression in the uterus (Fig. 3B). Steady-state Hunk mRNA levels were nearly two-fold higher in oophorectomized animals compared with intact mice suggesting that circulating levels of 17β-estradiol may repress Hunk expression in the uterus of nulliparous mice. Consistent with this suggestion, treatment of oophorectomized animals with 17β-estradiol either alone or in combination with progesterone decreased Hunk expression to levels below those observed in either intact or oophorectomized animals. In contrast to findings in the mammary gland, progesterone treatment had little if any effect on Hunk expression in the uterus. These results suggest that the increase in Hunk mRNA expression observed in the uterus following oophorectomy is due, either directly or indirectly, to loss of tonic inhibition of Hunk expression by estradiol. The observation that the combination of estradiol and progesterone has opposing effects on Hunk expression in the mammary gland and uterus is consistent with the opposing physiological effects of these hormones on proliferation and differentiation in these tissues.

The effects of estradiol and progesterone on Hunk expression in the mammary gland and uterus were confirmed by in situ hybridization analysis performed on tissues from the experimental animals described above (Fig. 3D and data not shown). Consistent with RNase protection results, oophorectomy resulted in a marked decrease in Hunk mRNA expression in the mammary epithelium and the combination of 17β-estradiol and progesterone resulted in a synergistic increase in Hunk expression. Reminiscent of Hunk expression during early pregnancy, the upregulation of Hunk mRNA levels
in oophorectomized animals treated with a combination of 17β-estradiol and progesterone occurred in a subset of epithelial cells in both ducts and developing alveolar buds.

Since the above experiments involved the chronic administration of hormones, sufficient time elapsed during hormone treatment for significant developmental changes to occur in both the mammary glands and uteri of oophorectomized animals. As such, these experiments do not distinguish whether changes in Hunk expression reflect direct regulation by ovarian hormones, or are a consequence of the changes in epithelial proliferation and differentiation that occur in response to the chronic administration of ovarian hormones. To address this issue, intact mice were treated with a combination of 17β-estradiol and progesterone for 24 hours before sacrifice (Fig. 3C). Mice treated in such a manner do not develop the marked morphological changes characteristic of long-term hormone administration. Analysis of Hunk mRNA expression levels in these mice revealed a pattern similar to that observed in mice treated chronically with hormones. Within 24 hours of the administration of 17β-estradiol and progesterone, steady-state levels of Hunk mRNA increased in the mammary gland and decreased in the uterus. These findings suggest that the regulation of Hunk expression by estradiol and progesterone is not solely a consequence of changes in mammary and uterine tissue architecture that occur in response to chronic hormone treatment, but rather may result from direct regulation by these hormones.

**Generation of MMTV-Hunk transgenic animals**

The tightly regulated expression of Hunk observed in the mammary gland during pregnancy and in response to ovarian hormones suggests the possibility that Hunk may play a role in mediating pregnancy-induced changes in the mammary gland. To test this hypothesis, transgenic mice overexpressing Hunk in a mammary-specific fashion were generated using the MMTV LTR. Activity of the MMTV LTR is upregulated in mammary epithelial cells during pregnancy and lactation in response to rising levels of prolactin, progesterone and glucocorticoids. Since endogenous Hunk expression is heterogeneous and is transiently upregulated during early pregnancy, MMTV-driven expression of Hunk in transgenic mice would be predicted to alter the temporal and spatial profile of Hunk expression in the mammary gland.

A cDNA encoding the full-length Hunk protein was cloned downstream of the MMTV LTR and injected into superovulated FVB mice. One of four founder lines, MHK3, was found to express the Hunk transgene at high levels in the mammary gland and was therefore studied further (Fig. 4A). The tissue specificity of transgene expression in the MHK3 line was determined by RNase protection analysis using a transgene-specific probe (Fig. 4B). This analysis confirmed that nulliparous MHK3 transgenic females express high levels of the MMTV-Hunk transgene in the mammary gland and lower but detectable levels of transgene expression in the spleen, salivary gland, lung and thymus, as has been observed for other MMTV transgenic mouse models.

The hormonally responsive nature of the MMTV LTR often results in low levels of expression in the mammary glands of nulliparous transgenic animals and high levels of transgene expression during pregnancy that peak during lactation. In contrast, MHK3 animals express high levels of
Fig. 3D
the MMTV-Hunk transgene in the nulliparous state. In addition, MMTV-Hunk transgene expression levels in mammary glands from pregnant or lactating MHK3 animals were found to vary less than threefold relative to nulliparous MHK3 animals, a range of expression that is far less than that typically found in MMTV-based transgenic mouse models (data not shown). Together, these data indicate that MMTV-Hunk transgene expression is high relative to endogenous Hunk expression during all stages of postnatal mammary development.

To determine if Hunk mRNA levels in transgenic mice resulted in changes in Hunk protein levels, antisera specific to Hunk were used to analyze Hunk expression levels in extracts prepared from lactating mammary glands of MHK3 transgenic and wild-type mice (Fig. 4C; Gardner et al., 2000b). Western analysis of immunoprecipitated Hunk using Hunk-specific antisera revealed increased amounts of Hunk protein in extracts prepared from transgenic when compared with wild-type mammary glands (Fig. 4C). The inability to detect Hunk protein in extracts from wild-type lactating glands was consistent with the barely detectable levels of endogenous Hunk mRNA expression during this developmental stage (Fig.
hybridization analysis for all non-expressing MHK3 transgenic in MHK3 transgenic glands, with the difference between wild-
transgene integration site was confirmed by Southern yield over this developmental interval was significantly lower
MMTV-Hunk transgene. The presence of the MHK3-specific nulliparous mammary glands. In contrast, the increase in RNA
specific and relatively homogenous manner. animals this analysis revealed an approximately 20-fold
transgenic animals overexpress Hunk in a mammary epithelial- mammary development (Fig. 5A). As expected, in wild-type
expression observed in other MMTV transgenic models or the content in MHK3 mammary glands, we determined the
homogeneous, unlike the heterogeneous patterns of transgene confirm our initial observations regarding reduced RNA
exogenously expressed Hunk was restricted to the epithelium during pregnancy and lactation is due to a combination of
mice. As described for other MMTV transgenic models, the peak of lactation. The dramatic increase in RNA content
almost two orders of magnitude from the nulliparous state to
of MHK3 mice. In addition, Hunk expression in the mammary increased epithelial cell number and increased milk protein
expression in transgenic compared with wild-type mammary of total RNA isolated from mammary glands harvested
immunoprecipitates prepared from transgenic when compared rates comparable with those observed for offspring of wild-
immunoprecipitation reactions were carried out in the absence of anti-Hunk antisera. The resulting immunoprecipitates were
incubated with γ-32P-ATP and histone H1. As predicted, based on the relative quantities of Hunk in these extracts, Hunk-
associated kinase activity was substantially greater in immunoprecipitates prepared from transgenic when compared with
wild-type mammary glands. These experiments confirm that MHK3 transgenic animals manifest increased levels of both Hunk protein and Hunk-associated kinase activity.

To investigate the spatial pattern of Hunk protein expression in MHK3 transgenic animals, immunohistochemistry was performed on mammary glands harvested from nulliparous transgenic and wild-type female mice (Fig. 4E). Consistent with high levels of MMTV-Hunk mRNA expression in MHK3 mice, this analysis revealed high levels of Hunk protein expression in transgenic compared with wild-type mammary glands. As described for other MMTV transgenic models, exogenously expressed Hunk was restricted to the epithelium of MHK3 mice. In addition, Hunk expression in the mammary epithelium of MHK3 animals was found to be relatively homogeneous, unlike the heterogeneous patterns of transgene expression observed in other MMTV transgenic models or the heterogeneous expression of endogenous Hunk mRNA. These data indicate that compared with wild-type animals, MHK3 transgenic animals overexpress Hunk in a mammary epithelial-specific and relatively homogeneous manner.

Notably, some MHK3 transgenic animals did not express the MMTV-Hunk transgene. The presence of the MHK3-specific transgene integration site was confirmed by Southern hybridization analysis for all non-expressing MHK3 transgenic mice. A similar type of transgene silencing has been observed in other MMTV transgenic models (Betzl et al., 1996; Sternlicht et al., 1999).

Hunk overexpression results in impaired lactation
Consonant with the hypothesis that Hunk plays a role in mammary gland development during pregnancy, we initially noted that the number of pups successfully reared by MHK3 transgenic females was significantly reduced compared with wild-type animals, with many pups dying within 1-2 days of birth independent of pup genotype. In contrast, offspring of transgenic males mated to wild-type females displayed survival rates comparable with those observed for offspring of wild-type crosses. These observations suggested that the inability to successfully rear pups was due to a defect in the ability of MHK3 transgenic females to lactate.

Consistent with the presence of a lactation defect in MHK3 mice, we initially noted that mammary glands from pregnant or lactating transgenic animals contained lower amounts of RNA compared with their wild-type counterparts. The amount of total RNA isolated from wild-type murine mammary glands is highly dependent upon developmental stage and can increase almost two orders of magnitude from the nulliparous state to the peak of lactation. The dramatic increase in RNA content during pregnancy and lactation is due to a combination of increased epithelial cell number and increased milk protein gene expression by individual alveolar epithelial cells. To confirm our initial observations regarding reduced RNA content in MHK3 mammary glands, we determined the yield of total RNA isolated from mammary glands harvested from either wild-type or MHK3 transgenic females during mammary development (Fig. 5A). As expected, in wild-type animals this analysis revealed an approximately 20-fold increase in RNA yield from lactating when compared with nulliparous mammary glands. In contrast, the increase in RNA yield over this developmental interval was significantly lower in MHK3 transgenic glands, with the difference between wild-
Fig. 6. Morphological defects in MHK3 transgenic mice during late pregnancy and lactation. Number four mammary glands from MHK3 transgenic and wild-type females were harvested at day 12.5 and day 18.5 of pregnancy, and day 2 of lactation. At least three transgene-expressing mice and three wild-type mice were analyzed for each timepoint. A representative photomicrograph is shown for each group. (A) Whole-mount analysis of transgenic and wild-type mammary glands at the indicated timepoints. Harvested glands were fixed and stained with Carmine dye in order to visualize epithelial ducts and alveoli. (B) Representative Hematoxylin and Eosin-stained sections of paraffin-embedded transgenic and wild-type mammary glands. al, alveoli; lo, lobule; st, adipose stroma.

type and transgenic glands becoming more pronounced towards late-pregnancy and lactation (wild-type versus transgenic, t-test $P=0.047$ (day 18.5 of pregnancy) and $P=0.0007$ (day 2 of lactation). In fact, at day 2 of lactation only one third of the total amount of RNA was isolated from transgenic when compared with wild-type glands. Non-expressing MHK3 transgenic females exhibited RNA yields indistinguishable from wild-type animals, indicating that the reduction in RNA observed in MHK3 animals was dependent upon expression of the Hunk transgene (Fig. 5A). These data suggest the possibility of impaired mammary development in MHK3 animals during pregnancy and lactation.

**Hunk overexpression decreases epithelial proliferation during mid-pregnancy**

Lobuloalveolar development during pregnancy involves both proliferation and differentiation of alveolar epithelial cells. Alveolar cell proliferation occurs primarily during the first two trimesters of pregnancy, while alveolar differentiation occurs in a graded and progressive manner throughout pregnancy. To determine whether the decrease in RNA yield obtained from MHK3 transgenic glands during pregnancy is related to a decrease in cellular proliferation in these mice, we compared BrdU incorporation rates in epithelial cells from wild-type and transgenic mammary glands (Fig. 5B). Wild-type and MHK3 transgenic female mice at different developmental stages were pulse labeled with BrdU before sacrifice and the percentage of BrdU-positive epithelial cells was determined by quantitative analysis of anti-BrdU-stained sections. As predicted based upon the similar morphology of wild-type and transgenic mammary glands in nulliparous animals (data not shown), no significant difference in the percentage of BrdU-positive cells...
was observed between wild-type and transgene-expressing mammary glands harvested from nulliparous animals. Moreover, a dramatic increase in epithelial proliferation was observed at day 6.5 of pregnancy both in wild-type and transgenic animals relative to nulliparous females. In contrast, at day 12.5 of pregnancy, epithelial proliferation rates remained high in wild-type glands but dropped markedly in glands from MHK3 animals (wild-type versus transgenic at day 12.5, t-test, P=0.004). By comparison, no differences in epithelial proliferation rates were observed between wild-type and transgenic glands at day 18.5 of pregnancy. Furthermore, no differences in apoptosis rates were observed between wild-type and MHK3 transgenic glands during virgin development, pregnancy or lactation, as evidenced by similar levels of TUNEL-positive cells (data not shown). Since MMTV-Hunk transgene expression levels in MHK3 animals are roughly comparable in the mammary gland throughout pregnancy and do not coincide with the observed defect in proliferation, we conclude that Hunk overexpression inhibits mammary epithelial proliferation specifically during mid-pregnancy.

Hunk overexpression impairs lobuloalveolar development

Our finding of increased pup death among offspring of MHK3 females, together with the decreased RNA content of mammary glands from lactating MHK3 animals, suggested that MHK3 female glands may have a defect in lobuloalveolar development. To address this hypothesis directly, MHK3 transgene female mice were sacrificed at different stages of pregnancy and lactation for morphological analysis. Analysis of both whole mounts and Hematoxylin and Eosin stained sections at day 6.5 and day 12.5 of pregnancy revealed no obvious morphological differences between the mammary glands of wild-type and MHK3 transgenic animals, despite the fact that epithelial cell proliferation is markedly impaired in MHK3 female mice at day 12.5 of pregnancy (Figs 5B and 6, and data not shown). In contrast, marked morphological differences were observed between wild-type and transgenic animals at day 18.5 of pregnancy. Analysis of whole mounts and Hematoxylin and Eosin stained sections at this stage of development consistently showed decreased lobuloalveolar development in MHK3 transgenic animals (Fig. 6). In addition to their larger size, alveoli in wild-type mice at day 18.5 of pregnancy contained copious amounts of lipid, whereas those of MHK3 mice did not.

In addition to the abnormalities observed at day 18.5 of pregnancy, decreased lobuloalveolar development was also observed in MHK3 females at day 2 of lactation. Normally during lactation the mammary gland is filled with casein-secreting lobules such that by whole-mount analysis the gland is entirely opaque, and by histological analysis no white adipose tissue is seen (Fig. 6). In contrast, lobuloalveolar units in lactating Hunk-overexpressing transgenic animals were smaller and appeared less developed by whole-mount analysis compared with wild-type and non-expressing MHK3 females (Fig. 6A and data not shown). Consequently, only half of the mammary fat pad of lactating MHK3 mice was occupied by secretory alveoli (Fig. 6B). While this may be due in part to decreased epithelial cell proliferation observed during mid-pregnancy, morphometric analysis of Hematoxylin and Eosin stained sections from MHK3 mice at day 18.5 of pregnancy and day 2 of lactation revealed that compared with their wild-type counterparts, the mammary glands of MHK3 animals consist of a normal number of alveoli that are uniformly smaller and less differentiated morphologically, rather than a smaller number of morphologically normal alveoli. (Fig. 6B and data not shown). Moreover, alveoli in lactating transgenic animals were less distended with milk when compared with wild-type glands. In contrast, similar analyses performed on the mammary glands of non-expressing MHK3 transgenic animals during lactation revealed no morphological defects (data not shown). These observations suggest that dysregulated expression of Hunk impairs terminal differentiation of the mammary gland during late pregnancy and lactation in a manner potentially distinct from the observed defect in epithelial proliferation.

Hunk overexpression inhibits mammary epithelial differentiation

The dramatic changes in epithelial differentiation that occur in the mammary gland during lobuloalveolar development are reflected on a molecular level by the tightly regulated and temporally ordered expression of genes for milk proteins (Robinson et al., 1995). While steady-state mRNA levels for each of these genes typically increase throughout pregnancy, each gene undergoes a maximal increase in expression at a characteristic time during pregnancy. These differential expression profiles permit individual genes to be classified as early (β-casein), intermediate (κ-casein, lactoferrin), late-intermediate (WAP) or late (α-casein) markers of mammary epithelial differentiation (Robinson et al., 1995; C. D'Cruz, unpublished). As such, the expression of these genes can be used as a molecular correlate for the extent of mammary epithelial differentiation. Accordingly, analysis of temporal expression patterns of milk protein genes permits the degree of lobuloalveolar differentiation to be reproducibly and objectively determined at the molecular level.

To confirm that the defect in lobuloalveolar development observed in MHK3 transgenic mice included a defect in differentiation, and was not simply a consequence of reduced epithelial cell numbers, we examined the expression of a panel of molecular differentiation markers in wild-type and MHK3 animals during lobuloalveolar development. We reasoned that if the defect in lobuloalveolar development was solely due to reduced epithelial cell mass, then the absolute level of expression of milk protein genes in MHK3 animals should be similar to that observed in wild-type animals when normalized for epithelial content. Similarly, if alveolar cells present in MHK3 glands differentiate normally during pregnancy, then the levels of expression of early, mid and late differentiation markers relative to each other should be similar to that observed in wild-type animals. As such, the observation that the absolute levels of expression of multiple differentiation markers are reduced despite normalizing for epithelial content, or that the expression of these differentiation markers relative to each other is altered compared to wild-type animals, would indicate that mammary epithelial differentiation is impaired in MHK3 animals and is independent of the observed proliferation defect.

To determine whether MHK3 animals manifest a defect in differentiation in addition to the defect in proliferation demonstrated above, we determined mRNA expression levels...
for a panel of early, intermediate and late markers of mammary epithelial differentiation in mammary glands from transgenic and wild-type animals during pregnancy and lactation (Fig. 7). Although few if any morphological differences were noted in transgenic mice before day 18.5 of pregnancy, when normalized to β-actin expression, steady-state levels of expression for all five milk protein genes were reduced in mammary glands from MHK3 transgenic mice compared with
wild-type mice beginning as early as day 6.5 of pregnancy and persisting throughout pregnancy and into lactation (Fig. 7). In contrast, expression levels of the epithelial cell marker, cytokeratin 18, did not differ significantly between wild-type and transgenic glands at any stage of pregnancy or lactation when normalized to β-actin expression (Fig. 7).

Accurate interpretation of gene expression levels in the mammary glands of mice bearing defects in lobuloalveolar development requires normalization to reference genes, such as β-actin, in order to control for differences in dilutional effects caused by expression of milk protein genes. Although β-actin levels do not change significantly on a per cell basis during pregnancy and lactation, the enormous contribution of the expression of milk protein genes to the total RNA pool results in an apparent decrease in the expression of reference genes when comparing equal amounts of total RNA (Figs 1 and 7). The magnitude of this dilutional effect correlates with the differentiation state of the mammary gland. Thus, the lower levels of expression of milk protein genes observed in the less differentiated MHK3 glands results in a less severe dilutional effect and apparent increases in β-actin and cytokeratin 18 expression in the mammary glands of MHK3 animals compared with wild-type animals at day 18 of pregnancy and day 2 of lactation. Therefore, in aggregate our findings indicate that the reduced expression of differentiation markers in MHK3 animals during pregnancy and lactation is not simply due to a reduction in epithelial cell content and suggests that mammary glands from Hunk-overexpressing transgenic mice are less differentiated than wild-type glands at each stage of lobuloalveolar development.

As further controls for these experiments, expression of milk protein genes was analyzed in non-expressing MHK3 transgenic females at day 2 of lactation (Figs 7 and 8, and data not shown). No differences in the expression either of cytokeratin 18 or of alveolar differentiation markers were observed between non-expressing MHK3 glands and glands from wild-type mice, consistent with the lack of morphological or functional defects in non-expressing MHK3 glands. Together, these findings strongly suggest that the abnormalities in mammary epithelial differentiation observed in MHK3 mice are due to MMTV-Hunk transgene expression rather than to site-specific integration effects such as the insertional disruption of an endogenous gene.

To analyze further the impact of MMTV-Hunk transgene expression on lobuloalveolar development, a multivariate regression analysis was performed on the above normalized gene expression data to quantify the effects of transgene expression on mammary epithelial differentiation during a developmental interval from day 6.5 of pregnancy to day 2 of lactation (Fig. 7E,F). This analysis revealed that the expression of four epithelial differentiation markers (β-casein, κ-casein, WAP and ε-casein) was significantly lower in the mammary glands of transgenic animals compared with wild-type animals across all developmental time points. No differences were observed in cytokeratin 18 expression between wild-type and transgenic glands, confirming that normalization to β-actin expression was sufficient to control for differences in epithelial cell content. These results indicate that the mammary glands of MHK3 animals are significantly less differentiated than wild-type glands throughout pregnancy and into lactation.

Interestingly, the average reductions in mRNA expression levels observed for the late differentiation marker, ε-casein (Tg effect=-1.87; 6.5-fold), and the late-intermediate differentiation marker, WAP (Tg effect=-1.53; 4.6-fold), were considerably more pronounced than the reductions in expression observed for the early differentiation marker, β-casein (Tg effect=-0.70; 2.0-fold), and the intermediate differentiation marker, κ-casein (Tg effect=-0.94; 2.6-fold) (Fig. 7). The observation that transgene expression had a greater effect on the expression of late differentiation markers compared with early differentiation markers suggests that late events in mammary epithelial differentiation are disproportionately affected during lobuloalveolar development in MHK3 mice. This finding is consistent with the morphological defects observed in these mice during late pregnancy.

**Hunk upregulates lactoferrin expression in MHK3 mice**

Surprisingly, while the expression of all 5 epithelial differentiation markers examined was reduced in the mammary glands of MHK3 transgenic animals throughout pregnancy, expression of the gene for lactoferrin was actually higher in transgenic animals compared with wild-type animals at day 2 of lactation (Figs 7D and 8). This finding prompted us to analyze the impact of Hunk overexpression on lactoferrin
expression in nulliparous MHK3 mice. Consistent with results obtained in lactating MHK3 animals, steady-state levels of lactoferrin mRNA were significantly higher in the mammary glands of nulliparous MHK3 expressing transgenic animals compared with either non-expressing MHK3 transgenic animals or age-matched nulliparous wild-type animals (Fig. 8). In contrast to lactoferrin, mRNA expression levels of the epithelial differentiation markers, β-casein, κ-casein, α-lactalbumin (Lalba - Mouse Genome Informatics), WDNM1 (Expi - Mouse Genome Informatics) and WAP, in adolescent nulliparous females were not significantly affected by Hunk overexpression (Fig. 8 and data not shown). Consistent with this finding, the rate of ductal elongation and extent of epithelial side-branching in mammary glands from 5- to 6-week-old nulliparous transgenic mice was comparable with that observed in wild-type mice as analyzed by whole-mount and histological analysis (data not shown). These observations suggest that Hunk does not cause precocious differentiation of the mammary gland during puberty, but may specifically activate pathways resulting in lactoferrin upregulation. Similarly, the observation that lactoferrin expression is upregulated in the mammary glands of lactating MHK3 animals, despite the global inhibitory effect of Hunk overexpression on mammary epithelial differentiation during late pregnancy, suggests that the effects of Hunk on lactoferrin expression are distinct from those on mammary epithelial differentiation.

DISCUSSION

The data presented in this report demonstrate that expression of the novel SNF1-related serine/threonine kinase, Hunk, in the mammary gland is tightly regulated during mammary development with a transient peak during early pregnancy; rapidly and synergistically induced in response to estradiol and progesterone; and spatially restricted within a subset of mammary epithelial cells throughout postnatal development. These data suggest a role for Hunk in mammary development, particularly with respect to pregnancy-induced changes in the mammary gland. Consistent with this hypothesis, misexpression of Hunk in the mammary gland disrupts normal lobuloalveolar development during pregnancy and lactation. Specifically, dysregulated Hunk expression results in decreased epithelial cell proliferation exclusively during mid-pregnancy as well as impaired alveolar cell differentiation throughout pregnancy and lactation. Together, these data suggest that Hunk may contribute to pregnancy-induced changes in the mammary gland, and that Hunk may play a role in the response of the mammary epithelium to ovarian hormones.

Although Hunk mRNA expression levels are markedly upregulated during early pregnancy, a developmental stage that is characterized by rapid alveolar cell proliferation, multiple lines of evidence suggest that Hunk expression is not simply a correlate of proliferation. For instance, the temporal profile of Hunk expression in the mammary gland during development is distinct from that of bona fide markers of proliferation such as cyclin A, cyclin D1, PCNA and PLK (Chodosh et al., 2000; Master et al., unpublished). Specifically, the upregulation of Hunk expression in the mammary gland is confined to early pregnancy, whereas the above proliferation markers are not only upregulated during early pregnancy, but also during mid-pregnancy as well as puberty. Moreover, Hunk is not preferentially expressed in proliferative as compared to non-proliferative compartments in the mammary gland (i.e. terminal end buds versus ducts during puberty, alveoli versus ducts during early pregnancy). Finally, analysis of actively growing versus confluent or serum-starved mammary epithelial cells reveals no difference in Hunk mRNA levels (H. P. G., unpublished). These observations suggest that Hunk expression does not simply reflect the proliferative state of the mammary epithelium, but rather may reflect other developmental pathways or events in the mammary gland.

Hunk upregulation in the mammary gland during early pregnancy is transient. This observation raises the intriguing possibility that the tightly regulated pattern of Hunk expression during pregnancy is required for normal lobuloalveolar development. We have tested this hypothesis by misexpressing Hunk in the mammary glands of transgenic mice. Forced overexpression of an MMTV-Hunk transgene in the mammary epithelium throughout postnatal development results in a defect in lobuloalveolar development with molecular abnormalities first discernible during early pregnancy, cellular abnormalities discernible during mid-pregnancy and morphological abnormalities discernible late in pregnancy. Specifically, Hunk overexpression results in a defect in epithelial proliferation that is restricted to mid-pregnancy and a defect in differentiation that is manifest throughout the developmental interval spanning day 6.5 of pregnancy to day 2 of lactation. In contrast, forced overexpression of Hunk in nulliparous animals has no obvious effect on patterns of proliferation or differentiation, or on the morphology of the mammary epithelial tree. Together, our findings suggest the possibility that the defects observed in lobuloalveolar development in MHK3 mice are due to the failure to downregulate Hunk expression during mid-pregnancy, rather than to Hunk overexpression per se.

Our finding that Hunk overexpression inhibits alveolar proliferation during mid-pregnancy was surprising given that Hunk is normally upregulated in the mammary gland during early pregnancy - the stage of pregnancy associated with maximum alveolar proliferation. This suggests either that the normal role of Hunk may be to negatively regulate mammary epithelial proliferation during pregnancy, or that the inhibitory effect of Hunk on proliferation at day 12.5 of pregnancy is a consequence of overexpression during a developmental stage at which Hunk is normally downregulated. Alternatively, the developmental profile of endogenous Hunk activity may be different from that of steady-state levels of Hunk mRNA.

Interestingly, the human SNF1-related kinase, C-TAK1/KP78/MARK3, has been shown to phosphorylate and inactivate Cdc25c, thereby preventing activation of Cdc2 and presumably inhibiting entry of cells into mitosis (Peng et al., 1997, 1998). Consistent with this hypothesis, expression of KP78 protein has been reported to be downregulated in adenocarcinomas of the pancreas (Parsa, 1988). Thus, there is precedent for the negative regulation of cellular proliferation by mammalian SNF1 family members. Whether Hunk interacts with Cdc25c, negatively regulates cellular proliferation when expressed at physiological levels or is altered in human malignancies is unknown.

We have demonstrated defects in both mammary epithelial
proliferation and differentiation in MHK3 animals during pregnancy. For example, the lower total RNA yield obtained from transgenic glands as compared with wild-type glands during late pregnancy and lactation probably reflects, in part, the reduced epithelial cell content of MHK3 transgenic glands, since the increase in total RNA present in the mammary gland during lobuloalveolar development is a result both of increases in epithelial cell number and increases in expression of milk protein genes on a per-cell basis (Fig. 5B). As such, we initially considered the possibility that the decreased expression of markers for mammary epithelial differentiation observed in MHK3 animals during pregnancy and lactation is a consequence of the decreased alveolar proliferation evident in MHK3 mice at day 12.5 of pregnancy, and the resulting decrease in epithelial cell mass. However, several lines of evidence indicate that the abnormalities in mammary epithelial differentiation that we have described in MHK3 animals cannot be explained by a decrease in epithelial cell mass. First, the fact that defects in alveolar differentiation in MHK3 animals actually precede the reduction in epithelial proliferation that occurs at day 12.5 strongly argues that defects in differentiation cannot solely be a consequence of defects in proliferation. In addition, RNA extracted from a mammary gland composed of a smaller number of appropriately differentiated epithelial cells would be predicted to give rise to a normal distribution of milk protein gene expression (i.e. early versus late), and to normal levels of expression of milk protein genes when normalized to epithelial cell content. In contrast, our observations indicate that both the level and the composition of milk protein RNA produced by the mammary glands of MHK3 animals during pregnancy and lactation is abnormal even after controlling for differences in epithelial content between wild-type and transgenic glands. Consistent with this conclusion, the morphology of the alveolar epithelial cells present in the mammary glands of MHK3 animals at day 18.5 of pregnancy is less differentiated compared with those present in their wild-type counterparts. Thus, we conclude that the reduced expression of differentiation markers in MHK3 transgenic glands reflects the less differentiated state of the mammary epithelial cells present, rather than a reduced number of appropriately differentiated mammary epithelial cells. As such, our data indicate that the defects in differentiation that occur in MHK3 animals as a consequence of Hunk overexpression are separable from and, at least in part, independent of the defects in proliferation that occur in these animals.

With regard to the analysis presented in this manuscript, it is important to note that during pregnancy and lactation, a similar magnitude of reduction in the expression of differentiation markers was observed in the mammary glands of MHK3 animals compared with wild-type animals regardless of whether levels of expression of milk protein genes were normalized to β-actin or to the epithelial cell marker, cytokeratin 18 (Fig. 7 and data not shown). That is, when normalized to β-actin expression, cytokeratin 18 expression levels do not differ between MHK3 transgenic animals and wild-type animals at any stage of lobuloalveolar development. Presumably, this reflects the fact that mammary epithelial cells contribute the vast majority of RNA to the total RNA pool during pregnancy and lactation, an observation that explains why cytokeratin 18 levels show little change during pregnancy when normalized to β-actin expression. Thus, normalizing mRNA expression levels to β-actin mRNA levels itself effectively controls for the decreases in epithelial cell content that occur in MHK3 animals.

Surprisingly, lactoferrin expression in the mammary glands of both nulliparous and lactating mice was elevated in Hunk-overexpressing MHK3 animals compared either with wild-type animals or with non-expressing MHK3 transgenic animals. This observation suggests that while Hunk overexpression may inhibit mammary epithelial differentiation globally during pregnancy and lactation, the effects of Hunk overexpression on lactoferrin expression may be more specific. In support of this hypothesis, we have compared gene expression patterns in wild-type and MHK3 nulliparous transgenic glands using oligonucleotide-based cDNA microarrays. These microarray studies revealed that of the approx. 5500 genes analyzed, the gene for lactoferrin is one of only 16 genes whose expression changes by more than 2.5-fold in transgenic when compared with wild-type glands (H. P. G., unpublished). As noted above, the mammary glands of nulliparous MHK3 animals are morphologically indistinguishable from those of wild-type littermates. Thus, our findings indicate that the effects of Hunk overexpression on lactoferrin gene regulation are relatively specific, and are unlikely to be secondary to marked abnormalities in mammary gland morphology or to global changes in gene expression. Since lactoferrin expression in several tissues has been shown to be regulated by 17β-estradiol, EGF, protein kinase C and cAMP-mediated pathways (Teng, 1995), the specific upregulation of lactoferrin expression in MHK3 transgenic mice may provide a clue to signal transduction pathways in which Hunk may be involved.

Hunk is expressed in a heterogeneous, epithelial-specific manner throughout postnatal mammary development. This heterogeneous expression pattern is particularly striking in the terminal end bud during puberty and throughout the mammary epithelium during pregnancy, and suggests that Hunk may be a marker for a previously undescribed subtype of mammary epithelial cell or may be a marker for a particular cellular state. An intriguing hypothesis regarding the heterogeneous pattern of Hunk expression in both developing alveolar buds and epithelial ducts during pregnancy is that this heterogeneity may reflect the differing ability of mammary epithelial cells to respond to ovarian hormones. Testing this hypothesis will require the ability to colocalize the expression of endogenous Hunk protein with steroid hormone receptors and other markers of hormone responsiveness.

Finally, we have demonstrated that treatment of mice with 17β-estradiol and progesterone results in the rapid and synergistic upregulation of Hunk expression in the mammary gland. These findings suggest that the upregulation of Hunk expression in response to hormones is not a consequence of the marked changes in epithelial differentiation or epithelial cell number that occur either during early pregnancy or in response to the chronic administration of 17β-estradiol and progesterone. Interestingly, unlike the effect of steroid hormones on Hunk expression in the mammary gland, treatment of mice with 17β-estradiol either alone or in combination with progesterone results in downregulation of Hunk expression in the uterus. The opposing effects of combined estradiol and progesterone treatment on Hunk expression in the mammary gland and uterus is reminiscent
of the dichotomous effects of these hormones on epithelial proliferation in these tissues. As such, our finding that the effect of steroid hormones on Hunk expression in the mammary gland and uterus parallels the dichotomous response of these tissues to estradiol and progesterone provides additional support for the hypothesis that Hunk may be a downstream effector of estrogen and progesterone, and suggests a potential explanation for the dichotomous response of these tissues to steroid hormones.

In aggregate, our findings raise the possibility that the upregulation of Hunk expression in the mammary gland by estradiol and progesterone may contribute to changes in the mammary epithelium that occur during pregnancy by mediating the effects of steroid hormones. Ultimately, elucidating the mechanisms by which hormones regulate Hunk expression, and by which Hunk may regulate mammary epithelial proliferation and differentiation, may yield insights into the complex role which hormones play in mammary development and carcinogenesis.

REFERENCES


homolog of C. elegans PAR-1 organizes the oocyte cytoskeleton and directs oskar mRNA localization to the posterior pole. *Cell* 101, 377-388.


The CaM Kinase, *Pnck*, Is Spatially and Temporally Regulated during Murine Mammary Gland Development and May Identify an Epithelial Cell Subtype Involved in Breast Cancer

Heather Perry Gardner, Seung I. Ha, Carol Reynolds, and Lewis A. Chodosh

Department of Molecular and Cellular Engineering [H. P. G., S. I. H., L. A. C.] and Division of Endocrinology [L. A. C.], Diabetes and Metabolism, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104-6160, and Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 [C. R.]

ABSTRACT

While screening for protein kinases expressed in the murine mammary gland, we identified previously a Ca²⁺/calmodulin-dependent kinase, *Pnck*, that is most closely related to CaMKI. In this report, we show that *Pnck* is temporally regulated during murine mammary development with highest levels of expression observed late in pregnancy, concomitant with the decreased cellular proliferation and terminal differentiation of the mammary epithelium. Consistent with this finding, *Pnck* is up-regulated in confluent mammary epithelial cells and is down-regulated as serum-starved cells are stimulated to reenter the cell cycle. In the mammary gland, *Pnck* is expressed in an epithelial-specific and markedly heterogeneous manner, suggesting that the expression of this kinase may be restricted to a particular mammary epithelial cell type. Potentially related to its heterogeneous *in vivo* expression pattern, *Pnck* expression is oncogene-associated in murine epithelial cell lines derived from mammary tumors arising in different transgenic mouse models of breast cancer; cell lines derived from mammary tumors initiated by *v-myc* or int-2/Fgf3 express *Pnck*, whereas cell lines initiated by neu or H-ras do not. In an analogous manner, expression of the human homologue of *Pnck* is restricted to a subset of human breast cancer cell lines. Moreover, *PnCK* was found to be highly overexpressed in a subset of human primary human breast cancers compared with benign mammary tissue. Together, our data suggest that *Pnck* may play a role in mammary development, and that expression of this kinase may be restricted to a mammary epithelial cell type that is transformed in a subset of human breast cancers.

INTRODUCTION

A woman’s lifetime risk of developing breast cancer is intrinsically related to reproductive events, particularly those that affect the differentiated state of the breast. Results from both human epidemiology and animal model systems indicate that an early first full-term pregnancy results in a permanent change in the breast that confers a decreased risk for the subsequent development of breast cancer (1–4). The findings that aborted pregnancies, the majority of which occur prior to the third trimester, are not protective against breast cancer and that lactation has only a minimal protective effect compared with full-term pregnancy suggest that parity-induced protection against breast cancer results from physiological changes that occur late in pregnancy (5, 6). As a consequence, the protective effect of parity has been hypothesized to result from the impact of terminal differentiation on the susceptibility of the mammary epithelium to carcinogenesis (2, 3). Nevertheless, the molecular and cellular basis for this phenomenon is unknown. As such, understanding the developmental changes that occur in the breast late in pregnancy is essential for understanding the protected state of the breast associated with parity.

In an attempt to better understand the relationship between development and carcinogenesis in the breast, we previously carried out a screen designed to identify protein kinases that are expressed in the murine mammary gland during development and in mammary tumor cell lines (7–10). This resulted in the identification of the novel serine/threonine kinase, *Pnck*, so named to reflect its temporally and spatially regulated pattern of expression in the mammary gland as described in this report. *Pnck* is a member of the CaM-dependent family of protein kinases and is most closely related to CaMKI (9). However, no significant homology is detected between *Pnck* and members of the CaM kinase family outside of the highly conserved catalytic and regulatory domains, suggesting that *Pnck* may have functions unique to this family of molecules.

Ca²⁺ is a key intracellular signaling molecule that exerts some of its effects by binding to calmodulin and activating CaM kinases. Calmodulin, in turn, has been implicated in development. For example, point mutations in the *Drosophila* calmodulin gene result in defects in development including pupal lethality and ectopic wing vein formation (11). Furthermore, calmodulin expression is regulated during cardiac development, and overexpression of calmodulin in murine cardiomyocytes results in cardiomyocyte hypertrophy (12). Like calmodulin, CaM kinases have been proposed to play diverse roles in development including CaMKIV in T-cell maturation and CaMKII in cell cycle regulation (13–16). However, developmental roles for multifunctional CaM kinases, including CaMKII, have not been defined.

We previously characterized the temporal and spatial patterns of *Pnck* expression during murine development (9). In murine embryos, *Pnck* expression is highest in developing brain, bone, and gastrointestinal tract. In adult mice, high levels of *Pnck* expression are found in the brain, uterus, ovary, and testis. Interestingly, within several tissues, *Pnck* expression is limited to particular epithelial or stromal compartments, and within these compartments, *Pnck* expression is further restricted to a subset of cells (9). As such, the tissue-specific and spatially restricted patterns of *Pnck* expression suggest that this kinase may be involved in a variety of developmental processes.

In this report, we demonstrate that the CaM kinase, *Pnck*, is spatially and temporally regulated during murine mammary development with highest levels of expression observed late in pregnancy as alveolar epithelial cells exit the cell cycle and undergo terminal differentiation. Potentially related to this temporal pattern of expression, *Pnck* is up-regulated in confluent mammary epithelial cells and down-regulated as serum-starved cells are stimulated to reenter the cell cycle. We further show that *Pnck* expression in the mammary gland is restricted to a subset of epithelial cells during development and that *Pnck* is expressed in an oncogene-associated manner in cell...
lines derived from murine mammary tumors with defined initiating events. Similarly, expression of the human homologue of Prck is restricted to a subset of human breast tumor cell lines and is highly overexpressed in a subset of primary human breast cancers. Taken together, our data suggest that Prck may be expressed within a mammary epithelial cell type that is involved in differentiation as well as transformation.

MATERIALS AND METHODS

Animal and Tissue Preparation. FVB mice were housed under barrier conditions with a 12-h light/dark cycle. After sacrifice at the indicated developmental time points, the #3, 4, and 5 mammary glands were harvested. For RNA analysis, the lymph node embedded in mammary gland #4 was removed prior to harvest. Tissue samples were set up such that all mice were sacrificed at ~16 weeks of age for comparison to adult nulliparous females. Day 0.5 postcoitus was defined as noon of the day on which a vaginal plug was observed. Time points at day 2 and day 7 of regression were obtained after removing pups at day 9 of lactation. Time points at day 28 of regression were obtained after 21 days of lactation. Tissues from 10 to 20 mice were pooled for each developmental time point. Tissues used for RNA analysis were snap frozen on dry ice. Tissues used for in situ hybridization analysis were embedded in OCT compound.

Tissue Culture. Murine cells were cultured in DMEM medium supplemented with 10% bovine calf serum, 2 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin. Human cell line lines were cultured in the same medium with the addition of 5 µg/ml insulin. Transformed murine mammary epithelial cell lines were derived from tumors or hyperplastic lesions that arose in transgenic mice engineered to express different oncogenes under the control of the MMTV long terminal repeat. Cell lines from MMTV-c-myc, MMTV-int-2/Fgf3, MMTV-neu/NT, or MMTV-H-ras transgenic mice have been described previously (17). NIH 3T3, NMuMG, and CL-S1 murine cells, as well as human breast tumor cell lines, were obtained from American Type Culture Cells. HC11 cells were the kind gift of Jeff Rosen (Baylor College of Medicine, Houston, TX).

Actively growing cells were harvested at ~70% confluence. Confluent cells were reseeded daily and harvested 3 days after confluence. For serum starvation experiments, subconfluent cells were maintained in 0.1% serum for 2 days prior to refeeding in 10% bovine calf serum and harvested at the indicated time points.

RNA Analysis. RNA was prepared by homogenization of snap-frozen tissue samples or tissue culture cells in guanidinium isothiocyanate supplemented with 7 µl/ml 2-mercaptoethanol, followed by ultracentrifugation through cesium chloride as described previously (18, 19). Poly(A) RNA was selected using oligo(dT) cellulose (Pharmacia). For Northern hybridization analysis, RNA was separated on a 6% denaturing polyacrylamide gel and passively transferred to a Gene Screen membrane (DuPont NEN). Hybridization was performed as described using a random primed, 32P-labeled cDNA probe encompassing nucleotides 1355-1529 of c-myc (GenBank accession no. X01023), nucleotides 589-1287 of cytokeratin 18 (GenBank accession no. M11686), or a 1.2-kb fragment containing the entire open reading frame of cyclin D3 (19). RNase protection analysis was performed as described (19). Body-labeled antisense riboprobes were generated using [a-32P]UTP and the Promega in vitro transcription system with T7 polymerase in combination with linearized plasmids resulting from the massive increases in milk protein gene expression that occur during late pregnancy and lactation (7, 9). To begin to investigate the potential role of Prck in mammary development, we examined the temporal profile of Prck expression during the postnatal development of the murine mammary gland (Fig. 1). Prck expression was normalized to β-actin expression to control for dilutional effects resulting from the massive increases in milk protein gene expression that occur during late pregnancy and lactation (7, 9). From the data shown in Fig. 1B, as verified by quantitative in situ hybridization analysis, expression of Prck expression to β-actin expression provides a more accurate assessment of changes in gene expression on a per cell basis than normalization solely to the amount of RNA assayed (Fig. 2).

RESULTS

Temporal Pattern of Prck Expression during Mammary Development. In the course of screening for protein kinases with a potential role in mammary development and carcinogenesis, we isolated a CaM kinase family member, Prck, from the mammary glands of mice undergoing early postnatal development (7, 9). To begin to investigate the potential role of Prck in mammary development, we examined the temporal profile of Prck expression during the postnatal development of the murine mammary gland (Fig. 1). Prck expression was normalized to β-actin expression to control for dilutional effects resulting from the massive increases in milk protein gene expression that occur during late pregnancy and lactation (7, 9). From the data shown in Fig. 1B, as verified by quantitative in situ hybridization analysis, expression of Prck expression to β-actin expression provides a more accurate assessment of changes in gene expression on a per cell basis than normalization solely to the amount of RNA assayed (Fig. 2).

Prck mRNA expression levels were found to be low and relatively constant in nulliparous animals between 2 and 16 weeks of age, a period that encompasses ductal morphogenesis (Fig. 1). In contrast, a 2-fold up-regulation of Prck expression was observed early in pregnancy as compared with age-matched nulliparous animals. Prck ex-
expression remained elevated during mid-pregnancy and attained maximal levels of expression (5-fold) late in pregnancy, concomitant with the cessation of proliferation and terminal differentiation of the alveolar epithelium. *Pnck* expression levels returned to baseline during lactation and early postlactational regression. Notably, steady-state levels of *Pnck* mRNA were higher in the mammary glands of parous animals after 4 weeks of postlactational involution as compared with age-matched nulliparous animals.

**Heterogeneous Expression of *Pnck* in the Mammary Epithelium.** To determine whether pregnancy-induced changes in *Pnck* mRNA expression levels represent global changes in expression throughout the mammary gland or changes within a subpopulation of cells, *in situ* hybridization analysis was performed (Fig. 2). Consistent with our RNase protection results, *in situ* hybridization confirmed that *Pnck* expression peaks late in pregnancy. Furthermore, throughout postnatal development *Pnck* expression was detected only in the mammary epithelium and was strikingly heterogeneous during pregnancy, with highly expressing cells located adjacent to cells in which *Pnck* expression was low or undetectable. The spatial heterogeneity of *Pnck* expression was most marked during late pregnancy, at which time only a small fraction of epithelial cells was observed to express *Pnck* at high levels. The heterogeneous spatial pattern of *Pnck* expression differs from that observed for other protein kinases that we have examined, as well as for genes such as *cytokeratin 18*, *Gapdh*, and *β-actin* (7).

**Pnck Expression in Vitro.** The observation that *Pnck* expression peaks late in pregnancy as alveolar epithelial cells exit the cell cycle and undergo terminal differentiation suggested that *Pnck* mRNA expression may be inversely related to mammary epithelial proliferation. To investigate this possibility, *Pnck* mRNA levels were analyzed in actively proliferating or confluent mammary epithelial cell lines (Fig. 3A). This analysis revealed that steady-state levels of *Pnck* mRNA were an average of 3.7-fold higher in confluent cells compared with actively proliferating cells (Student’s *t* test, *P* < 0.01). To distinguish whether this increase in *Pnck* expression was attributable to decreased proliferation or to the establishment of cell-cell contacts in confluent cells, *Pnck* expression levels were analyzed in subconfluent serum-starved mammary epithelial cells as they reentered the cell cycle after refeeding (Fig. 3B). Consistent with the up-regulation of *Pnck* expression observed in confluent cells, refeeding of serum-starved cells resulted in a rapid decrease in *Pnck* expression that began within 1 h and reached a nadir at 4 h after refeeding. Identical results were observed in a second mammary epithelial cell line (data not shown).
MMTV transgenic mice expressing either the cell lines derived from independent adenocarcinomas arising in mRNA expression was examined in a panel of mammary epithelial expressed in an epithelial cell subtype in the mammary gland, (Con). B. RNase protection analysis of Pnck expression in serum-starved 16MB9a cells at the indicated times after refeeding. Thirty µg of total RNA isolated from cells at each time point were hybridized with 32P-labeled antisense riboprobes specific for Pnck or β-actin.

Pnck Expression in Transgenic Mammary Tumor Cell Lines. To begin to examine the potential role of Pnck in mammary tumorigenesis and to investigate the hypothesis that Pnck is expressed in an epithelial cell subtype in the mammary gland, Pnck mRNA expression was examined in a panel of mammary epithelial cell lines derived from independent adenocarcinomas arising in MMTV transgenic mice expressing either the neu/NT, c-myc, H-ras, or int-2/Flgf3 oncogenes in the mammary epithelium (Ref. 17; Fig. 4). All cell lines were proliferating at similar rates when harvested as evidenced by their similar levels of cyclin D3 mRNA expression. Pnck expression was not detected in NIH 3T3 fibroblasts, consistent with its epithelial-specific pattern of expression in the mammary gland in vivo. Interestingly, Pnck was expressed in all seven cell lines derived from mammary tumors or hyperplasias arising in MMTV-c-myc and MMTV-int-2/Flgf3 transgenic mice. In contrast, Pnck expression was undetectable in the eight cell lines derived from mammary tumors arising in MMTV-neu and MMTV-H-ras transgenic mice, despite the fact that RNase protection analysis was performed using poly(A)+ RNA. Similarly, Pnck expression was not detected in any of the three nontransformed mammary epithelial cell lines examined including confluent or differentiating HC11 cells (Fig. 4 and data not shown). Analysis of the expression of 40 other protein kinases identified in our screen indicated that this particular oncogene-associated pattern of expression is unique to Pnck (7, 20). Of note, Pnck expression did not appear to correlate with absolute levels of either endogenous c-myc or c-myc transgene expression (Fig. 4). This observation suggests that the oncogene-restricted pattern of Pnck expression may not be the result of c-myc-induced activation of Pnck transcription.

Pnck Expression in Human Breast Tumor Cell Lines and Primary Breast Tumors. To further investigate the potential involvement of Pnck, or a cell type in which Pnck is expressed, in mammary carcinogenesis, we determined Pnck expression levels in a panel of human breast cancer cell lines (Fig. 5). Similar to the wide range of Pnck expression observed in the murine mammary epithelium and in murine mammary tumor cell lines, Pnck expression was detected in only a subset of human breast tumor cell lines. High levels of Pnck expression were observed in 3 of 18 breast tumor cell lines. Eight cell lines expressed low but detectable levels of Pnck, whereas no Pnck expression was detected in the remaining seven cell lines. As in murine mammary tumor cell lines, Pnck expression levels did not correlate with c-MYC expression (data not shown).

The heterogeneous pattern of Pnck expression observed in vitro in both murine and human breast tumor cell lines suggested the possibility that Pnck-expressing and Pnck-nonexpressing breast tumor types might exist. To test this hypothesis directly, we used RNase protection analysis to quantify Pnck mRNA expression levels in a panel of 23 primary human breast tumors. The resulting expression levels were compared with Pnck expression levels in 12 benign breast tissue samples (Fig. 6A). This analysis revealed two interesting aspects of the pattern of Pnck expression in breast tumors compared with benign tissue: (a) Pnck is expressed at significantly higher levels in breast tumors compared with benign tissue; and (b) Pnck expression in human tumors is markedly heterogeneous.

Statistical analysis of the above Pnck expression levels indicated that when normalized to β-actin expression, Pnck expression in human primary breast cancers is ~5-fold higher than in benign breast tissue (Student’s t test, P = 0.01; Fig. 6B). However, because Pnck expression in the mammary gland is epithelial specific and because tumors typically have a higher epithelial content than benign breast tissue, we also normalized Pnck expression to expression of the epithelial-specific marker, cytokeratin 18, (CK18), to control for the increased epithelial cell content of tumors (Fig. 6B). Strikingly, even after normalization to CK18 expression, Pnck expression levels were...
found to be three times higher in human primary breast tumors than in benign tissue (t test, \( P = 0.039 \)).

Formally, the increase in \( PNCK \) expression levels in breast tumors compared with benign tissue could result either from increased expression among all tumors or from increased expression in a subset of tumors. In this regard, analysis of the distribution of \( PNCK \) expression among the 23 ductal carcinomas studied revealed a wide range of \( PNCK \) expression levels, in contrast to the relatively similar levels of \( PNCK \) expression observed among benign breast tissue samples. Notably, the mode for the benign and tumor distributions was the same (Fig. 6A and C). Indeed, examination of the histogram representing \( CK18 \)-normalized \( PNCK \) expression levels revealed that 8 of the 23 primary breast tumors analyzed expressed \( PNCK \) at levels greater than 3 SDs above the mean observed for benign samples (Fig. 6C). This difference is highly significant because no tumors would have been predicted to express \( PNCK \) at these levels if the distribution of \( PNCK \) expression in tumors was similar to that observed in benign tissues. Even more strikingly, four breast tumors were found to express \( PNCK \) at levels \( > 10 \) SDs above the mean observed for benign tissues. Together, these data indicate that \( PNCK \) is overexpressed in human primary breast cancers compared with benign tissue, and that this observed increase is attributable to high levels of \( PNCK \) expression in a subset of breast tumors.

**DISCUSSION**

We have demonstrated that expression of the CaM kinase, \( PNCK \), is temporally and spatially regulated in the murine mammary gland during postnatal development and that \( PNCK \) expression is restricted to a subset of mammary epithelial cells both in vivo and in vitro. Furthermore, our findings that \( PNCK \) is up-regulated in serum-starved and confluent cells suggest that the up-regulation of \( PNCK \) expression in the mammary gland late in pregnancy may be related to the decreased proliferation of mammary epithelial cells during this stage of development. We have shown that \( PNCK \) is expressed in an oncogene-associated manner in murine mammary tumor cell lines with defined genetic initiating events, and that \( PNCK \) expression is restricted to a subset of human breast tumor cell lines. Finally, we have demonstrated that \( PNCK \) is overexpressed in human primary breast cancers compared with benign breast tissue and that this overexpression is restricted to a subset of human breast tumors. In aggregate, our findings are consistent with the hypothesis that \( PNCK \) expression is restricted to a subset of ductal carcinomas in humans and suggest a role for \( PNCK \), or a cell type that expresses \( PNCK \), in mammary carcinogenesis. Our findings represent the first data implicating a CaM kinase in mammary development or carcinogenesis.

Both calmodulin and CaM-dependent kinases have been reported previously to be involved in cell cycle progression (21–26). Our data demonstrate that \( PNCK \) expression in vitro is inversely correlated with cellular proliferation. Specifically, decreasing the proliferative status of mammary epithelial cells in vitro resulted in increased \( PNCK \) expression. Interestingly, both the up-regulation of \( PNCK \) observed in confluent cells and the down-regulation of \( PNCK \) observed as serum-starved cells reenter the cell cycle are consistent with \( PNCK \) expression patterns in the mammary gland during late pregnancy. Although the up-regulation of \( PNCK \) observed during late pregnancy could simply be an effect of decreased epithelial proliferation, \( PNCK \) up-regulation could also be directly involved in inhibiting cellular proliferation or contributing to the exit of epithelial cells from the cell cycle prior to their terminal differentiation. Nevertheless, although a role for \( PNCK \) in cell cycle regulation is plausible, further work will be required to establish this relationship.

The markedly heterogeneous spatial expression pattern that we have observed for \( PNCK \) in the mammary gland is unusual compared with other genes that we have investigated (7). Moreover, the observation that \( PNCK \) expression peaks late in pregnancy and remains heterogeneous throughout pregnancy and lactation distinguishes \( PNCK \) from milk protein genes and other markers of mammary epithelial differentiation (27). Although the expression patterns of milk protein genes such as \( \beta \)-casein, WAP, and \( \alpha \)-lactalbumin are spatially heterogeneous during the developmental stages at which they are initially induced, each of these genes is expressed homogeneously throughout the mammary epithelium when their expression peaks during lactation. These data suggest that \( PNCK \) expression is not simply a marker for terminally differentiated mammary epithelial cells. Indeed, the down-regulation of \( PNCK \) expression in the mammary gland during lactation is consistent with a model in which this kinase plays a role in the process of differentiation but not in the maintenance of the differentiated state per se.

At least two hypotheses could account for the heterogeneous pattern of \( PNCK \) expression in mammary epithelial cells in vivo and in vitro: (a) only a small percentage of mammary epithelial cells may express \( PNCK \) at any given time, but all cells may express \( PNCK \) at some time. Such a model is consistent with genes whose expression is cell cycle regulated but is inconsistent with our finding that multiple mammary epithelial cell lines do not express \( PNCK \); (b) alternatively, we favor the hypothesis that \( PNCK \) expression may identify an as yet undefined mammary epithelial cell type. This hypothesis is consistent with our findings that \( PNCK \) expression is detected within only a subset of cells in the mammary epithelium in vivo, as well as within a subset of murine breast cancer cell lines, human breast cancer cell lines, and primary human breast cancers. Nevertheless, this hypothesis does not rule out the possibility that \( PNCK \) expression may be modulated within expressing cell types or that \( PNCK \)-expressing cell types may only express \( PNCK \) during certain physiological states. In aggregate, the expression patterns for \( PNCK \) described in this report suggest that a \( PNCK \)-expressing cell type exists that may have unique properties with respect to mammary development and mammary epithelial transformation.

Potentially related to the expression of \( PNCK \) in a mammary epithelial cell subtype, \( PNCK \) expression was found to be restricted to cell lines derived from murine mammary tumors initiated by the oncogenes c-myc or int-2/Fg/3 as compared with those initiated by an activated form of neu or by \( H-Ras \). Although such oncogene-associated patterns of expression are unusual, we and others have reported genes whose patterns of expression are the inverse of that observed for \( PNCK \) (7, 17, 28). Previous reports have demonstrated that murine mammary tumors induced by the expression of \( H-Ras \), c-myc, \( neu \), or int-2/Fg/3 each have histological patterns that are highly specific for
Fig. 6. PNCK is overexpressed in a subset of human primary breast tumors. RNA was isolated from 12 benign breast tissue samples and from 23 primary breast tumors obtained after surgery as indicated. A. RNase protection analysis was performed using 10 μg of total RNA hybridized with a 32P-labeled antisense riboprobe specific for PNCK or for β-actin as indicated. Northern hybridization analysis was performed on the same RNA samples using 3 μg of total RNA hybridized with a 32P-labeled cDNA probe specific for cytokeratin 18 (CK18). The 28S rRNA band is shown as a control for equal RNA loading. PNCK, β-actin, and CK18 expression levels were quantitated by phosphorimager analysis. PNCK expression levels normalized to CK18 are shown for each sample. B, PNCK expression levels in breast tumors compared with benign tissue. PNCK expression levels for the samples shown in A were normalized either to β-actin or to CK18, as indicated. Normalized PNCK expression levels in benign tissues was set equal to 1.0. The means of each distribution are shown. Bars, SE. *, P = 0.01 for PNCK/β-actin expression in tumors compared with benign tissue. P = 0.039 for PNCK/CK18 expression in tumors compared with benign tissue. C, histogram of individual PNCK expression levels normalized to CK18 for primary breast tumors and benign breast tissue samples shown in A. PNCK and cytokeratin 18 expression levels were quantitated by phosphorimager analysis. PNCK expression for each sample was normalized to CK18 expression and the average expression in benign samples was set equal to 1.0. Values represent fold changes relative to the mean PNCK/CK18 expression level observed for benign breast tissue. Bin sizes are 0.5 unit. Note that the mode for both the tumor and the benign samples is the same.

the inducing oncogene (29, 30). These morphological differences have been hypothesized to result either from the activation of unique downstream pathways or from the preferential transformation of different epithelial cell types by these oncogenes (17). Although c-myc or int-2/Fgf3 could directly up-regulate Pnck expression, the lack of correlation between Pnck expression and c-myc expression in mammary tumor cell lines, along with the punctate expression of Pnck in vivo, raises the possibility that the oncogene-associated expression of Pnck may be more likely to result from the preferential transformation of a Pnck-expressing cell type by c-myc. Experiments are currently under way to directly address these and other potential explanations.
Superficially, our finding that one-third of human primary breast tumors overexpress Pnck compared with benign tissue seems inconsistent given the data presented in this report demonstrating an inverse correlation between Pnck expression and cellular proliferation. However, because negative regulators of the cell cycle are commonly up-regulated in tumors, it is possible that the observed up-regulation of Pnck in human tumors is a consequence of intact cell cycle checkpoints functioning to retard tumor growth. That is, if Pnck plays a negative role in cell cycle progression, the up-regulation of Pnck in breast tumors may be a result of the transformation process rather than an indication that Pnck plays a causal role in tumorigenesis.

We have hypothesized that Pnck expression is restricted to a mammary epithelial cell type that is transformed in a subset of breast cancers. This hypothesis is consistent with our findings that expression of the human homologue of Pnck is restricted to a subset of human breast tumor cell lines and is highly overexpressed in a subset of human breast tumors since these results could reflect the selection and enrichment of a particular epithelial cell type. Alternately, it is possible that Pnck expression in these cell lines and primary tumors does not correlate with a particular epithelial cell type or with a particular initiating genetic event. However, given the restricted pattern of Pnck expression in the mammary epithelium in vivo, along with the oncogene-associated pattern of Pnck expression in murine mammary tumor cell lines, we favor the hypothesis that selective expression of Pnck in human tumors is not random but rather reflects differences in the events that led to their transformation. Because tailoring specific therapeutic regimens to individual cancers bearing distinct molecular profiles may enhance the efficacy of breast cancer treatments, it will be important to evaluate the biological significance of the differential expression of Pnck in human breast cancers. For instance, it is possible that Pnck-overexpressing tumors may behave differently than other breast tumors and may thereby be associated with a different prognosis. Ultimately, the identification of either additional genes involved in breast carcinogenesis or genetic markers that identify different molecular subtypes of breast cancers will be invaluable both in improving our understanding of the pathogenesis of breast cancer and in promoting more effective treatments.

ACKNOWLEDGMENTS
We thank Keith Mintzer and Douglas Stairs for assistance with cell culture experiments and members of the Chodosh laboratory for helpful discussions and critical reading of the manuscript.

REFERENCES
MEMORANDUM FOR Administrator, Defense Technical Information Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir, VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has reexamined the need for the limitation assigned to technical reports written for this Command. Request the limited distribution statement for the enclosed accession numbers be changed to "Approved for public release; distribution unlimited." These reports should be released to the National Technical Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl

PHYLIS M. RINEHART
Deputy Chief of Staff for Information Management
<table>
<thead>
<tr>
<th>ADB263458</th>
<th>ADB282838</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADB282174</td>
<td>ADB233092</td>
</tr>
<tr>
<td>ADB270704</td>
<td>ADB263929</td>
</tr>
<tr>
<td>ADB282196</td>
<td>ADB282182</td>
</tr>
<tr>
<td>ADB264903</td>
<td>ADB257136</td>
</tr>
<tr>
<td>ADB268484</td>
<td>ADB282227</td>
</tr>
<tr>
<td>ADB282253</td>
<td>ADB282177</td>
</tr>
<tr>
<td>ADB282115</td>
<td>ADB263548</td>
</tr>
<tr>
<td>ADB263413</td>
<td>ADB246535</td>
</tr>
<tr>
<td>ADB269109</td>
<td>ADB282826</td>
</tr>
<tr>
<td>ADB282106</td>
<td>ADB282127</td>
</tr>
<tr>
<td>ADB262514</td>
<td>ADB271165</td>
</tr>
<tr>
<td>ADB282264</td>
<td>ADB282112</td>
</tr>
<tr>
<td>ADB256789</td>
<td>ADB255775</td>
</tr>
<tr>
<td>ADB251569</td>
<td>ADB265599</td>
</tr>
<tr>
<td>ADB258878</td>
<td>ADB282098</td>
</tr>
<tr>
<td>ADB282275</td>
<td>ADB232738</td>
</tr>
<tr>
<td>ADB270822</td>
<td>ADB243196</td>
</tr>
<tr>
<td>ADB282207</td>
<td>ADB257445</td>
</tr>
<tr>
<td>ADB257105</td>
<td>ADB267547</td>
</tr>
<tr>
<td>ADB281673</td>
<td>ADB277556</td>
</tr>
<tr>
<td>ADB254429</td>
<td>ADB239320</td>
</tr>
<tr>
<td>ADB282110</td>
<td>ADB253648</td>
</tr>
<tr>
<td>ADB262549</td>
<td>ADB282171</td>
</tr>
<tr>
<td>ADB268358</td>
<td>ADB233883</td>
</tr>
<tr>
<td>ADB257359</td>
<td>ADB257696</td>
</tr>
<tr>
<td>ADB265810</td>
<td>ADB232089</td>
</tr>
<tr>
<td>ADB282111</td>
<td>ADB240398</td>
</tr>
<tr>
<td>ADB273020</td>
<td>ADB261087</td>
</tr>
<tr>
<td>ADB282185</td>
<td>ADB249593</td>
</tr>
<tr>
<td>ADB266340</td>
<td>ADB264542</td>
</tr>
<tr>
<td>ADB262490</td>
<td>ADB282216</td>
</tr>
<tr>
<td>ADB266385</td>
<td>ADB261617</td>
</tr>
<tr>
<td>ADB282181</td>
<td>ADB269116</td>
</tr>
<tr>
<td>ADB262451</td>
<td>ADB266306</td>
</tr>
<tr>
<td>ADB260298</td>
<td>ADB269253</td>
</tr>
<tr>
<td>ADB282119</td>
<td>ADB261755</td>
</tr>
<tr>
<td>ADB257398</td>
<td>ADB267683</td>
</tr>
<tr>
<td>ADB267683</td>
<td>ADB282231</td>
</tr>
<tr>
<td>ADB234475</td>
<td>ADB247704</td>
</tr>
<tr>
<td>ADB258112</td>
<td>ADB267627</td>
</tr>
</tbody>
</table>